DE69333807T2
(de)
|
1992-02-06 |
2006-02-02 |
Chiron Corp., Emeryville |
Marker für krebs und biosynthetisches bindeprotein dafür
|
US6329507B1
(en)
*
|
1992-08-21 |
2001-12-11 |
The Dow Chemical Company |
Dimer and multimer forms of single chain polypeptides
|
EP0672068A4
(de)
*
|
1992-09-25 |
1997-02-26 |
Commw Scient Ind Res Org |
Zielmoleküle-bindende polypeptide.
|
US6652863B1
(en)
|
1992-11-16 |
2003-11-25 |
Centocor, Inc. |
Method of reducing the immunogenicity of compounds
|
AU5670194A
(en)
*
|
1992-11-20 |
1994-06-22 |
Enzon, Inc. |
Linker for linked fusion polypeptides
|
AU690528B2
(en)
*
|
1992-12-04 |
1998-04-30 |
Medical Research Council |
Multivalent and multispecific binding proteins, their manufacture and use
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
DE69327229T2
(de)
*
|
1992-12-11 |
2000-03-30 |
Dow Chemical Co |
Multivalente einkettige Antikörper
|
GB9412166D0
(en)
*
|
1993-09-22 |
1994-08-10 |
Medical Res Council |
Retargetting antibodies
|
AU680685B2
(en)
|
1993-09-22 |
1997-08-07 |
Medical Research Council |
Retargeting antibodies
|
WO1995009917A1
(en)
*
|
1993-10-07 |
1995-04-13 |
The Regents Of The University Of California |
Genetically engineered bispecific tetravalent antibodies
|
US5837544A
(en)
*
|
1995-02-02 |
1998-11-17 |
Cell Genesys, Inc. |
Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
|
US6103521A
(en)
*
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
US7368111B2
(en)
|
1995-10-06 |
2008-05-06 |
Cambridge Antibody Technology Limited |
Human antibodies specific for TGFβ2
|
CN1173878A
(zh)
*
|
1995-10-16 |
1998-02-18 |
尤尼利弗公司 |
双功能或双价抗体片段类似物
|
DK0894135T3
(da)
*
|
1996-04-04 |
2004-12-06 |
Unilever Nv |
Multivalent og multispecifikt antigenbindingsprotein
|
GB9610967D0
(en)
|
1996-05-24 |
1996-07-31 |
Cambridge Antibody Tech |
Specific binding members,materials and methods
|
IT1286663B1
(it)
*
|
1996-06-27 |
1998-07-15 |
Ministero Uni Ricerca Scient E |
Proteina capace di inibire l'attivita' ribosomiale,sua preparazione ed uso come immunoconiugato chimico o ricombinante e sequenza di cdna
|
GB9712818D0
(en)
|
1996-07-08 |
1997-08-20 |
Cambridge Antibody Tech |
Labelling and selection of specific binding molecules
|
US5922845A
(en)
|
1996-07-11 |
1999-07-13 |
Medarex, Inc. |
Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
|
TR199903123T2
(xx)
|
1997-04-07 |
2000-05-22 |
Genentech, Inc. |
Anti-Vegf antikorlar�.
|
AU740738B2
(en)
|
1997-04-07 |
2001-11-15 |
Genentech Inc. |
Humanized antibodies and methods for forming humanized antibodies
|
CA2288994C
(en)
|
1997-04-30 |
2011-07-05 |
Enzon, Inc. |
Polyalkylene oxide-modified single chain polypeptides
|
GB9710154D0
(en)
*
|
1997-05-16 |
1997-07-09 |
Medical Res Council |
Detection of retroviruses
|
AU735883C
(en)
|
1997-06-13 |
2002-02-07 |
Genentech Inc. |
Protein recovery by chromatography followed by filtration upon a charged layer
|
US5994511A
(en)
|
1997-07-02 |
1999-11-30 |
Genentech, Inc. |
Anti-IgE antibodies and methods of improving polypeptides
|
US6172213B1
(en)
|
1997-07-02 |
2001-01-09 |
Genentech, Inc. |
Anti-IgE antibodies and method of improving polypeptides
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
ATE461282T1
(de)
|
1997-10-27 |
2010-04-15 |
Bac Ip Bv |
Multivalente antigenbindende proteine
|
US8088386B2
(en)
|
1998-03-20 |
2012-01-03 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
DE69840105D1
(de)
|
1997-11-21 |
2008-11-20 |
Genentech Inc |
Plättchen-spezifische antigene und deren pharmazeutische verwendung
|
EP1947119A3
(de)
|
1997-12-12 |
2012-12-19 |
Genentech, Inc. |
Krebsbehandlung mit Antikörpern gegen ERBB2 und einem chemotherapeutischen Mittel
|
WO1999040434A1
(en)
|
1998-02-04 |
1999-08-12 |
Invitrogen Corporation |
Microarrays and uses therefor
|
EP2050762A3
(de)
|
1998-03-10 |
2009-07-08 |
Genentech, Inc. |
Neue Polypeptide und für diese kodierende Nukleinsäuren
|
EP1941905A1
(de)
|
1998-03-27 |
2008-07-09 |
Genentech, Inc. |
APO-2 Liganden-Anti-HER-2-Antikörper-Synergismus
|
CZ121599A3
(cs)
|
1998-04-09 |
1999-10-13 |
Aventis Pharma Deutschland Gmbh |
Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
|
ES2292242T5
(es)
|
1998-05-15 |
2011-05-04 |
Genentech, Inc. |
Utilizaciones terapéuticas de polipéptidos homólogos de il-17.
|
EP3112468A1
(de)
|
1998-05-15 |
2017-01-04 |
Genentech, Inc. |
Il-17-homologe polypeptide und therapeutische verwendung davon
|
US20020172678A1
(en)
|
2000-06-23 |
2002-11-21 |
Napoleone Ferrara |
EG-VEGF nucleic acids and polypeptides and methods of use
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
SI1135498T1
(sl)
|
1998-11-18 |
2008-06-30 |
Genentech Inc |
Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
|
US20030035798A1
(en)
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
US6492497B1
(en)
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
AU5152700A
(en)
|
1999-06-15 |
2001-01-02 |
Genentech Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
CN100340575C
(zh)
|
1999-06-25 |
2007-10-03 |
杰南技术公司 |
人源化抗ErbB2抗体及其在制备药物中的应用
|
ATE269976T1
(de)
*
|
1999-08-11 |
2004-07-15 |
Unilever Nv |
Immunoassay und test-vorrichtung mit integrierter referenz
|
DK1210115T3
(da)
|
1999-08-27 |
2009-11-30 |
Genentech Inc |
Doseringer til behandling med anti-ErB2-antistoffer
|
US20040214783A1
(en)
|
2002-05-08 |
2004-10-28 |
Terman David S. |
Compositions and methods for treatment of neoplastic disease
|
US7947496B2
(en)
|
1999-10-08 |
2011-05-24 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
KR20080068767A
(ko)
|
1999-10-20 |
2008-07-23 |
제넨테크, 인크. |
T 헬퍼 세포 매개 질환의 치료를 위한 t 세포 분화의조절
|
CA2496312A1
(en)
|
1999-12-01 |
2001-06-07 |
Kevin P. Baker |
Colon tumour marker pro4799 polypeptides and nucleic acids encoding the same
|
DK1897945T3
(da)
|
1999-12-23 |
2012-05-07 |
Genentech Inc |
IL-17 homologe polypeptider og terapeutiske anvendelser deraf.
|
AU785055B2
(en)
|
2000-01-13 |
2006-09-07 |
Genentech Inc. |
Novel stra6 polypeptides
|
CA2400622A1
(en)
|
2000-02-24 |
2001-08-30 |
Eidgenossische Technische Hochschule Zurich |
Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US6740520B2
(en)
|
2000-03-21 |
2004-05-25 |
Genentech, Inc. |
Cytokine receptor and nucleic acids encoding the same
|
LT2857516T
(lt)
|
2000-04-11 |
2017-09-11 |
Genentech, Inc. |
Multivalentiniai antikūnai ir jų panaudojimas
|
DE10021678A1
(de)
*
|
2000-05-05 |
2002-04-18 |
Stefan Duebel |
Antikörperkonstrukte mit variablen Regionen
|
CA2411102A1
(en)
|
2000-06-20 |
2001-12-27 |
Idec Pharmaceutical Corporation |
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
CA2648048A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
EP2275549A1
(de)
|
2000-06-23 |
2011-01-19 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
|
EP2014298A3
(de)
|
2000-08-24 |
2009-10-07 |
Genentech, Inc. |
Interleukin-22-Polypeptide, Nukleinsäuren zu deren Codierung und Verfahren zur Behandlung von Bauchspeicheldrüsenerkrankungen
|
EP1944317A3
(de)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
|
EP1324776B2
(de)
|
2000-10-12 |
2018-03-21 |
Genentech, Inc. |
Niederviskose konzentrierte proteinformulierungen
|
US7534429B2
(en)
|
2000-11-29 |
2009-05-19 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
AU2002316855B2
(en)
|
2001-04-24 |
2008-03-13 |
Merck Patent Gmbh |
Combination therapy using anti-angiogenic agents and TNFalpha
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
GB0111628D0
(en)
|
2001-05-11 |
2001-07-04 |
Scancell Ltd |
Binding member
|
EP2335728A1
(de)
|
2001-05-11 |
2011-06-22 |
Ludwig Institute for Cancer Research Ltd. |
Spezifische Bindeproteine und deren Verwendungen
|
AU2002308722B2
(en)
|
2001-05-30 |
2007-05-17 |
Genentech, Inc. |
Anti-NGF antibodies for the treatment of various disorders
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
MXPA03011985A
(es)
|
2001-06-20 |
2004-03-26 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores.
|
NZ530852A
(en)
|
2001-08-27 |
2006-11-30 |
Genentech Inc |
Methods and compositions for recombinantly producing functional antibodies or antibody fragments in prokaryotic and eukaryotic host cells
|
WO2003020892A2
(en)
|
2001-08-29 |
2003-03-13 |
Genentech, Inc. |
Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY
|
ES2390531T3
(es)
|
2001-09-18 |
2012-11-13 |
Genentech, Inc. |
Composiciones y procedimientos para el diagnósitco y tratamiento de tumor
|
CA2462883A1
(en)
|
2001-10-12 |
2003-04-17 |
Schering Corporation |
Use of bispecific antibodies to regulate immune responses
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
CA2467363A1
(en)
*
|
2001-11-16 |
2003-06-12 |
Idec Pharmaceuticals Corporation |
Polycistronic expression of antibodies
|
GB0130543D0
(en)
|
2001-12-20 |
2002-02-06 |
Univ Cambridge Tech |
Human antibodies and their use
|
EP3960855A1
(de)
|
2001-12-28 |
2022-03-02 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur stabilisierung von proteinen
|
EP2067472A1
(de)
|
2002-01-02 |
2009-06-10 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
CA2472937C
(en)
|
2002-01-11 |
2014-06-17 |
Biomarin Pharmaceutical, Inc. |
Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
|
EP1575480A4
(de)
|
2002-02-22 |
2008-08-06 |
Genentech Inc |
Zusammensetzungen und verfahren zur behandlung von immunbedingten erkrankungen
|
EP2277522B1
(de)
|
2002-03-01 |
2012-11-21 |
UCB Manufacturing, Inc. |
Verfahren zur Erhöhung oder Verminderung der Knochendichte und zur Identifizierung von Molekulen
|
AU2003228505B2
(en)
|
2002-04-12 |
2009-01-08 |
Colorado School Of Mines |
Method for detecting low concentrations of a target bacterium that uses phages to infect target bacterial cells
|
NZ535925A
(en)
|
2002-04-16 |
2008-06-30 |
Genentech Inc |
An isolated antibody that binds to a particular polypeptide
|
EP2305710A3
(de)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetische Antikörperphagenbibliotheken
|
AU2003239966B9
(en)
|
2002-06-03 |
2010-08-26 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US7585501B2
(en)
|
2002-06-14 |
2009-09-08 |
Stowers Institute For Medical Research |
Compositions and methods for treating kidney disease
|
WO2004004649A2
(en)
|
2002-07-08 |
2004-01-15 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
JP5069843B2
(ja)
|
2002-07-15 |
2012-11-07 |
ジェネンテック, インコーポレイテッド |
抗ErbB2抗体を用いる処置に応答性である腫瘍を同定するための方法
|
DK2283868T3
(en)
|
2002-07-15 |
2016-04-25 |
Univ Texas |
PEPTIDES BINDING TO PHOSPHATIDYLETHANOLAMINE AND ITS USE IN TREATING VIRUS INFECTIONS AND CANCER
|
EP1527346B1
(de)
|
2002-08-07 |
2011-06-08 |
Ablynx N.V. |
Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
EP1539228B1
(de)
|
2002-09-11 |
2010-12-29 |
Genentech, Inc. |
Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
|
CA2496060C
(en)
|
2002-09-11 |
2015-08-04 |
Genentech, Inc. |
Protein purification by ion exchange chromatography
|
AU2003276874B2
(en)
|
2002-09-11 |
2009-09-03 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
US20070010434A1
(en)
|
2002-09-16 |
2007-01-11 |
Genetech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
EP2500438A3
(de)
|
2002-09-25 |
2012-11-28 |
Genentech, Inc. |
Neue Zusammensetzungen und Verfahren zur Behandlung von Psoriasis
|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
US7622270B2
(en)
|
2002-10-22 |
2009-11-24 |
Eisai R&D Management Co., Ltd. |
Methods of isolating dopaminergic neuron precursor cells
|
EP2322201A3
(de)
|
2002-10-29 |
2011-07-27 |
Genentech, Inc. |
Gestaltungen und Methoden für die behandlung von Immune verwandte Krankheiten
|
CA2503748A1
(en)
|
2002-11-08 |
2004-05-27 |
Genentech, Inc. |
Compositions and methods for the treatment of natural killer cell related diseases
|
ITMI20022411A1
(it)
*
|
2002-11-14 |
2004-05-15 |
Bracco Imaging Spa |
Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
|
EP1572106B1
(de)
|
2002-11-15 |
2010-05-05 |
Novartis Vaccines and Diagnostics, Inc. |
Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
|
ATE481422T1
(de)
|
2002-11-21 |
2010-10-15 |
Celltech R & D Inc |
Modulieren von immunantworten
|
JP2011516026A
(ja)
|
2002-11-26 |
2011-05-26 |
ジェネンテック・インコーポレーテッド |
免疫関連疾患の治療のための組成物と方法
|
AU2004204262B2
(en)
|
2003-01-10 |
2010-11-04 |
Ablynx N.V. |
Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
|
US7488475B2
(en)
|
2003-01-21 |
2009-02-10 |
Arius Research, Inc. |
Antibody therapy of tumors
|
CA2514125A1
(en)
|
2003-01-24 |
2004-08-12 |
Elan Pharmaceuticals, Inc. |
Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
|
EP1594956A4
(de)
|
2003-02-03 |
2007-08-01 |
Fraunhofer Usa Inc |
System zur expression von genen in pflanzen
|
MXPA05009743A
(es)
|
2003-03-12 |
2006-03-09 |
Genentech Inc |
Composiciones con actividad hematopoyetica e inmune.
|
ES2349779T5
(es)
|
2003-04-04 |
2013-11-26 |
Genentech, Inc. |
Formulaciones de anticuerpos y de proteínas a concentración elevada
|
UA99933C2
(ru)
|
2003-04-09 |
2012-10-25 |
Дженентек, Инк. |
Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
|
CA2897608C
(en)
|
2003-05-09 |
2018-07-31 |
Duke University |
Cd20-specific antibodies and methods employing same
|
AU2004272972A1
(en)
|
2003-05-22 |
2005-03-24 |
Fraunhofer Usa, Inc. |
Recombinant carrier molecule for expression, delivery and purification of target polypeptides
|
AU2004248138B2
(en)
|
2003-05-29 |
2009-09-03 |
The Scripps Research Institute |
Targeted delivery to legumain-expressing cells
|
RU2005136988A
(ru)
|
2003-05-30 |
2006-06-10 |
Дженентек, Инк. (Us) |
Лечение антителами против vegf
|
EP2228445A1
(de)
|
2003-06-18 |
2010-09-15 |
Chugai Seiyaku Kabushiki Kaisha |
Fucose Transporter
|
KR100835786B1
(ko)
|
2003-07-08 |
2008-06-09 |
제넨테크, 인크. |
Il-17a/f 이종 폴리펩티드 및 그의 치료 용도
|
WO2005005482A1
(de)
*
|
2003-07-09 |
2005-01-20 |
Schering Ag |
Emitter-bindende peptide die eine veränderung der spektralen emissionseigenschaften des emitters bewirken
|
DE10331054A1
(de)
*
|
2003-07-09 |
2005-02-03 |
Schering Ag |
Emitter-bindende Peptide die eine Veränderung der spektralen Emissionseigenschaften des Emitters bewirken
|
GB0407315D0
(en)
|
2003-07-15 |
2004-05-05 |
Cambridge Antibody Tech |
Human antibody molecules
|
US7758859B2
(en)
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US8883147B2
(en)
|
2004-10-21 |
2014-11-11 |
Xencor, Inc. |
Immunoglobulins insertions, deletions, and substitutions
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
AU2003271186A1
(en)
|
2003-10-14 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
US7304139B2
(en)
|
2003-10-28 |
2007-12-04 |
University Of Florida Research Foundation, Inc. |
Polynucleotides and polypeptides of Anaplasma phagocytophilum and methods of using the same
|
CA2542886A1
(en)
|
2003-11-05 |
2005-05-19 |
Neelima M. Bhat |
Enhanced b cell cytotoxicity of cdim binding antibody
|
ZA200603619B
(en)
|
2003-11-06 |
2008-10-29 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
AR046833A1
(es)
|
2003-11-10 |
2005-12-28 |
Schering Corp |
Anticuerpos anti-interleuquina-10
|
ES2382942T3
(es)
|
2003-11-13 |
2012-06-14 |
Sutter West Bay Hospitals |
Terapia anti-pecam para la supresión de la metástasis
|
JP4901478B2
(ja)
|
2003-11-17 |
2012-03-21 |
ジェネンテック, インコーポレイテッド |
造血系起源の腫瘍の治療のための組成物と方法
|
JPWO2005056605A1
(ja)
|
2003-12-12 |
2007-12-06 |
中外製薬株式会社 |
3量体以上の受容体を認識する改変抗体
|
PT2311873T
(pt)
|
2004-01-07 |
2018-11-20 |
Novartis Vaccines & Diagnostics Inc |
Anticorpo monoclonal específico para m-csf e respetivos usos
|
DE602005018325D1
(de)
|
2004-02-19 |
2010-01-28 |
Genentech Inc |
Antikörper mit korrigierten cdr
|
US7833731B2
(en)
|
2004-03-31 |
2010-11-16 |
Canon Kabushiki Kaisha |
Gold-binding protein and use thereof
|
MY162179A
(en)
|
2004-04-01 |
2017-05-31 |
Elan Pharm Inc |
Steroid sparing agents and methods of using same
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
JP2007538258A
(ja)
|
2004-05-15 |
2007-12-27 |
ジェネンテック・インコーポレーテッド |
標的分子に結合親和性を有する分子を検出するためのクロススクリーニングシステムと方法
|
EP2583981A3
(de)
|
2004-05-28 |
2013-07-31 |
Agensys, Inc. |
An PSCA-Proteine bindende Antikörper und zugehörige Moleküle
|
KR20120064120A
(ko)
|
2004-06-01 |
2012-06-18 |
제넨테크, 인크. |
항체 약물 접합체 및 방법
|
BRPI0510915A
(pt)
|
2004-06-04 |
2007-11-13 |
Genentech Inc |
método para o tratamento da esclerose múltipla e artigo manufaturado
|
US7604947B2
(en)
|
2004-06-09 |
2009-10-20 |
Cornell Research Foundation, Inc. |
Detection and modulation of cancer stem cells
|
SV2006002143A
(es)
|
2004-06-16 |
2006-01-26 |
Genentech Inc |
Uso de un anticuerpo para el tratamiento del cancer resistente al platino
|
US20060115827A1
(en)
|
2004-07-01 |
2006-06-01 |
University Of Southern California |
Genetic markers for predicting disease and treatment outcome
|
US7973134B2
(en)
|
2004-07-07 |
2011-07-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
|
US8604185B2
(en)
|
2004-07-20 |
2013-12-10 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
EP1771474B1
(de)
|
2004-07-20 |
2010-01-27 |
Genentech, Inc. |
Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung
|
CA2574177C
(en)
|
2004-07-22 |
2019-01-08 |
Eisai Co., Ltd. |
Lrp4/corin dopaminergic neuron progenitor cell markers
|
US7560111B2
(en)
|
2004-07-22 |
2009-07-14 |
Genentech, Inc. |
HER2 antibody composition
|
US8603824B2
(en)
|
2004-07-26 |
2013-12-10 |
Pfenex, Inc. |
Process for improved protein expression by strain engineering
|
CN101014245A
(zh)
|
2004-08-03 |
2007-08-08 |
比奥根艾迪克Ma公司 |
神经元功能中的taj
|
JP5237638B2
(ja)
|
2004-08-06 |
2013-07-17 |
ジェネンテック, インコーポレイテッド |
バイオマーカーを用いたアッセイおよび方法
|
RU2410438C2
(ru)
|
2004-08-06 |
2011-01-27 |
Дженентек, Инк. |
Анализы и способы, использующие биомаркеры
|
NZ580115A
(en)
|
2004-09-23 |
2010-10-29 |
Genentech Inc |
Cysteine engineered antibody light chains and conjugates
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
US7935790B2
(en)
|
2004-10-04 |
2011-05-03 |
Cell Singaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
|
CA2580271A1
(en)
|
2004-10-05 |
2006-04-20 |
Genentech, Inc. |
Method for treating vasculitis
|
AU2005294150B2
(en)
|
2004-10-07 |
2011-06-16 |
Coimmune, Inc. |
Mature dendritic cell compositions and methods for culturing same
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
EP2324848A3
(de)
|
2004-10-21 |
2011-09-14 |
Genentech, Inc. |
Methode zur behandlung von intraokulären neovaskularisations erkrankungen
|
EP1814913B1
(de)
|
2004-11-05 |
2015-08-19 |
IGM Biosciences, Inc. |
Antikörperinduzierte zellmembranverletzung
|
US7807789B2
(en)
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
JPWO2006067847A1
(ja)
|
2004-12-22 |
2008-06-12 |
中外製薬株式会社 |
フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
|
WO2006067210A1
(en)
|
2004-12-23 |
2006-06-29 |
Laboratoires Serono S.A. |
Bcma polypeptides and uses thereof
|
EP2230517A1
(de)
|
2005-01-07 |
2010-09-22 |
Diadexus, Inc. |
OVR110-Antikörperzusammensetzungen und Verwendungsverfahren dafür
|
JP4829897B2
(ja)
|
2005-01-14 |
2011-12-07 |
アブリンクス ナームローゼ フェンノートシャップ |
血小板減少及び/又はフォンビルブラント因子(vWF)と血小板との間の自発的相互作用によって特徴づけられる疾患及び障害の異なる形態を区別する方法及びアッセイ
|
CN102580084B
(zh)
|
2005-01-21 |
2016-11-23 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
KR101289537B1
(ko)
|
2005-02-15 |
2013-07-31 |
듀크 유니버시티 |
항-cd19 항체 및 종양학에서 이의 용도
|
US20060263357A1
(en)
|
2005-05-05 |
2006-11-23 |
Tedder Thomas F |
Anti-CD19 antibody therapy for autoimmune disease
|
CN103251946A
(zh)
|
2005-02-23 |
2013-08-21 |
健泰科生物技术公司 |
使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
|
WO2006105504A1
(en)
|
2005-03-31 |
2006-10-05 |
Microphage Incorporated |
Apparatus and method for detecting microorganisms using flagged bacteriophage
|
AU2006230563B8
(en)
|
2005-03-31 |
2010-06-17 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161P2F10B proteins
|
ES2592271T3
(es)
|
2005-03-31 |
2016-11-29 |
Chugai Seiyaku Kabushiki Kaisha |
Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
|
EP1876236B9
(de)
|
2005-04-08 |
2015-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antikörper als funktioneller ersatz für blutgerinnungsfaktor viii
|
NZ563273A
(en)
|
2005-04-09 |
2010-02-26 |
Fusion Antibodies Ltd |
Cathepsin S antibody
|
CN101203241B
(zh)
|
2005-04-19 |
2012-02-22 |
西雅图基因公司 |
人源化抗-cd70结合物和其应用
|
WO2007143231A2
(en)
|
2006-01-10 |
2007-12-13 |
Zymogenetics, Inc. |
Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
|
CA2606783C
(en)
|
2005-05-10 |
2014-03-25 |
Incyte Corporation |
Modulators of indoleamine 2,3-dioxygenase and methods of using the same
|
US8329652B2
(en)
|
2005-05-10 |
2012-12-11 |
Neoloch Aps |
Neuritogenic peptides
|
RU2433139C2
(ru)
|
2005-05-20 |
2011-11-10 |
Аблинкс Н.В. |
Nanobodies tm для лечения заболеваний, опосредованных агрегацией
|
WO2006132788A2
(en)
|
2005-06-06 |
2006-12-14 |
Genentech, Inc. |
Transgenic models for different genes and their use for gene characterization
|
MX348154B
(es)
|
2005-06-21 |
2017-05-30 |
Xoma (Us) Llc |
Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
|
AU2006269422B2
(en)
|
2005-07-07 |
2012-12-06 |
Seagen Inc. |
Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus
|
LT1912671T
(lt)
|
2005-07-18 |
2017-12-11 |
Seattle Genetics, Inc. |
Vaisto konjugatai, turintys gliukoronido linkerį
|
PL1912675T3
(pl)
*
|
2005-07-25 |
2014-10-31 |
Emergent Product Dev Seattle |
Zmniejszanie liczby komórek B za pomocą cząsteczek wiążących swoistych dla antygenów CD37 i CD20
|
JP5457671B2
(ja)
|
2005-07-28 |
2014-04-02 |
ノバルティス アーゲー |
M−csf特異的モノクローナル抗体およびその使用
|
ES2702650T3
(es)
|
2005-07-29 |
2019-03-04 |
The Government Of The Us Secretary Of Health And Human Services |
Exotoxinas de pseudomonas mutadas con antigenicidad reducida
|
US7456258B2
(en)
|
2005-08-02 |
2008-11-25 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7456259B2
(en)
|
2005-08-02 |
2008-11-25 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7452978B2
(en)
|
2005-08-02 |
2008-11-18 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7411046B2
(en)
|
2005-08-02 |
2008-08-12 |
Arius Research Inc |
Cancerous disease modifying antibodies
|
US7452979B2
(en)
|
2005-08-02 |
2008-11-18 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7494648B2
(en)
|
2005-08-02 |
2009-02-24 |
Hoffmann-La Roche Inc. |
Cancerous disease modifying antibodies
|
BRPI0614475B8
(pt)
|
2005-08-03 |
2021-05-25 |
Fraunhofer Usa Inc |
polipeptídeo, anticorpo, ácido nucleico, vetores, célula hospedeira, composição e processos de produção de anticorpo
|
US20070037224A1
(en)
|
2005-08-11 |
2007-02-15 |
Hamer Peter J |
Quantitative assays for PDGFR-beta in body fluids
|
AU2006280321A1
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
CN101365951B
(zh)
|
2005-08-16 |
2013-09-11 |
健泰科生物技术公司 |
通过检测细胞/组织中galnac-t14的表达判定对apo2l/trail的凋亡敏感性
|
EP1931710B1
(de)
|
2005-08-31 |
2017-01-18 |
Merck Sharp & Dohme Corp. |
Konstruierte anti-il-23-antikörper
|
WO2007027906A2
(en)
|
2005-08-31 |
2007-03-08 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
ATE445415T1
(de)
|
2005-09-01 |
2009-10-15 |
Schering Corp |
Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
|
JP2009508494A
(ja)
|
2005-09-16 |
2009-03-05 |
ラプトール ファーマシューティカル インコーポレイテッド |
Crを含むタンパク質に対して特異的な受容体−結合タンパク質(rap)変異体を含む組成物およびその使用
|
WO2007056227A2
(en)
|
2005-11-04 |
2007-05-18 |
Genentech, Inc. |
Use of complement pathway inhibitors to treat ocular diseases
|
US8679490B2
(en)
|
2005-11-07 |
2014-03-25 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
WO2007059221A2
(en)
|
2005-11-11 |
2007-05-24 |
Vertex Pharmaceuticals, Inc |
Hepatitis c virus variants
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
WO2007056858A1
(en)
|
2005-11-18 |
2007-05-24 |
Glenmark Pharmaceuticals S.A. |
Anti-alpha2 integrin antibodies and their uses
|
AU2006335053A1
(en)
|
2005-11-21 |
2007-07-19 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
EP2567973B1
(de)
|
2005-11-28 |
2014-05-14 |
Zymogenetics, Inc. |
IL-21-Antagonisten
|
ES2388932T3
(es)
|
2005-12-02 |
2012-10-19 |
Genentech, Inc. |
Polipéptidos de unión y usos de los mismos
|
DOP2006000277A
(es)
|
2005-12-12 |
2007-08-31 |
Bayer Pharmaceuticals Corp |
Anticuerpos anti mn y métodos para su utilización
|
DK1973950T3
(en)
|
2006-01-05 |
2014-12-15 |
Genentech Inc |
ANTI-EphB4 ANTIBODIES AND METHODS FOR USING SAME
|
US20090246208A1
(en)
|
2006-01-05 |
2009-10-01 |
Novartis Ag |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
KR20080106433A
(ko)
|
2006-02-13 |
2008-12-05 |
프라운호퍼 유에스에이, 인코포레이티드 |
인플루엔자 항원, 백신 조성물 및 관련 방법
|
EP1989228B1
(de)
|
2006-02-14 |
2015-04-29 |
University Of Tasmania Through The Menzies Research Institute |
Von metallothionein abgeleitete peptidfragmente
|
WO2007114979A2
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
US8021839B2
(en)
|
2006-02-24 |
2011-09-20 |
Investigen, Inc. |
Methods and compositions for detecting polynucleotides
|
EP2540741A1
(de)
|
2006-03-06 |
2013-01-02 |
Aeres Biomedical Limited |
Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
|
AU2007226627B2
(en)
|
2006-03-10 |
2012-09-20 |
Zymogenetics, Inc. |
Antibodies that bind both IL-17A and IL-17F and methods of using the same
|
CA3022097C
(en)
|
2006-03-15 |
2020-10-27 |
Alexion Pharmaceuticals, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
GEP20135917B
(en)
|
2006-03-17 |
2013-09-10 |
Biogen Idec Inc |
Stabilized polypeptide compositions
|
US8278421B2
(en)
|
2006-03-20 |
2012-10-02 |
Xoma Techolology Ltd. |
Human antibodies specific for gastrin materials and methods
|
US20090220504A1
(en)
|
2006-03-21 |
2009-09-03 |
Anan Chuntharapai |
Combinatorial therapy
|
EP2389947A1
(de)
|
2006-03-23 |
2011-11-30 |
Novartis AG |
Antitumorzellenantigen-Antikörper-Therapeutika
|
EP4001409A1
(de)
|
2006-03-31 |
2022-05-25 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur kontrolle der blutkinetik eines antikörpers
|
WO2007114325A1
(ja)
|
2006-03-31 |
2007-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
二重特異性抗体を精製するための抗体改変方法
|
BRPI0710055A2
(pt)
|
2006-04-10 |
2011-08-02 |
Fusion Antibodies Ltd |
métodos de inibir regulação ascendente induzida por quimioterapia de catepsina s, expressão de catepsina s sobre a superfìcie de células de tumor e angiogênese em um grupo de células, um tecido ou um órgão, de tratar doença neoplásica e uma condição associada com atividade de catepsina s em um paciente, de induzir reação citotóxica mediada por célula dependente de anticorpo contra uma célula de tumor, de matar células de tumor, de identificar células de tumor em uma população de células e de avaliar in vitro a resposta de células de tumor de um indivìduo à presença de um agente quimioterápico, usos de um inibidor de catepsina s e um agente quimioterapêutico, de catepsina s, de um anticorpo anti-catepsina s ou um fragmento do mesmo e de uma molécula de anticorpo, composição farmacêutica, kit farmacêutico e molécula de anticorpo ou um ácido nucleico codificando dita molécula de anticorpo
|
US20090288176A1
(en)
|
2006-04-19 |
2009-11-19 |
Genentech, Inc. |
Novel Gene Disruptions, Compositions and Methods Relating Thereto
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
RU2008147398A
(ru)
|
2006-05-02 |
2010-06-10 |
Актогеникс Н.В. (Be) |
Доставка пептидов, связанных с ожирением, через кишечник посредством микроорганизмов
|
CA2652452C
(en)
|
2006-05-15 |
2018-07-31 |
Sea Lane Biotechnologies, Llc |
Neutralizing antibodies to influenza viruses
|
US8796429B2
(en)
|
2006-05-31 |
2014-08-05 |
Lpath, Inc. |
Bioactive lipid derivatives, and methods of making and using same
|
US9274130B2
(en)
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to lysophosphatidic acid
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
US9217749B2
(en)
|
2006-05-31 |
2015-12-22 |
Lpath, Inc. |
Immune-derived moieties reactive against lysophosphatidic acid
|
US9274129B2
(en)
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Methods and reagents for detecting bioactive lipids
|
CL2007001623A1
(es)
|
2006-06-06 |
2008-01-18 |
Genentech Inc |
Anticuerpo anti-dll4; polinucleotido que lo codifica; vector y celula huesped que comprenden dicho polinucleotido; metodo para elaborar el anticuerpo e inmunojugado; metodo de deteccion de dll4 y metodo diagnostico de un trastorno asociado a dll4; composicion que comprende al anticuerpo.
|
MX363905B
(es)
*
|
2006-06-12 |
2019-04-08 |
Aptevo Res & Development Llc |
Proteinas de union multivalentes monocatenarias con funcion efectora.
|
WO2007145227A1
(ja)
|
2006-06-14 |
2007-12-21 |
Chugai Seiyaku Kabushiki Kaisha |
造血幹細胞増加促進剤
|
US8874380B2
(en)
|
2010-12-09 |
2014-10-28 |
Rutgers, The State University Of New Jersey |
Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
|
CA2656620C
(en)
|
2006-07-04 |
2018-03-13 |
Genmab A/S |
Cd20 binding molecules for the treatment of copd
|
PE20081004A1
(es)
|
2006-07-13 |
2008-09-18 |
Chugai Pharmaceutical Co Ltd |
Agentes inductores de muerte celular
|
AU2007275654A1
(en)
|
2006-07-19 |
2008-01-24 |
The Trustees Of The University Of Pennsylvania |
WSX-1/p28 as a target for anti-inflammatory responses
|
CN103524619B
(zh)
|
2006-08-03 |
2016-10-05 |
阿斯利康(瑞典)有限公司 |
针对αVβ6的抗体及其应用
|
US7939636B2
(en)
|
2006-08-11 |
2011-05-10 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in c-Src signaling pathways
|
EP3111955B1
(de)
|
2006-08-14 |
2019-01-23 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnose und behandlung von krebs mittels anti-desmoglein-3 antikörper
|
EP3415532A1
(de)
|
2006-08-18 |
2018-12-19 |
XOMA Technology Ltd. |
Prlr-spezifischer antikörper und verwendungen davon
|
JP4780405B2
(ja)
*
|
2006-08-29 |
2011-09-28 |
アイシン精機株式会社 |
結合親和性を利用する被検物質の測定方法、及び被検物質の測定のための結合親和性解析の制御方法
|
US10118970B2
(en)
|
2006-08-30 |
2018-11-06 |
Genentech, Inc. |
Multispecific antibodies
|
ES2616204T3
(es)
|
2006-09-05 |
2017-06-09 |
Alexion Pharmaceuticals, Inc. |
Métodos y composiciones para el tratamiento de neuropatías mediadas por anticuerpos
|
US7833527B2
(en)
|
2006-10-02 |
2010-11-16 |
Amgen Inc. |
Methods of treating psoriasis using IL-17 Receptor A antibodies
|
MX2009003738A
(es)
|
2006-10-12 |
2009-07-17 |
Forerunner Pharma Res Co Ltd |
Diagnóstico y tratamiento de cáncer usando anticuerpo anti-ereg.
|
CA2666559A1
(en)
|
2006-10-20 |
2008-04-24 |
Forerunner Pharma Research Co., Ltd. |
Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
|
US9023993B2
(en)
|
2006-10-20 |
2015-05-05 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient
|
US7846434B2
(en)
|
2006-10-24 |
2010-12-07 |
Trubion Pharmaceuticals, Inc. |
Materials and methods for improved immunoglycoproteins
|
JP5732182B2
(ja)
|
2006-10-27 |
2015-06-10 |
エルパス・インコーポレイテッドLpath, Inc. |
眼疾患と症状を処置するための組成物および方法
|
AU2007329759B2
(en)
|
2006-10-27 |
2013-05-30 |
Lpath, Inc. |
Compositions and methods for binding sphingosine-1-phosphate
|
CA2668484A1
(en)
|
2006-11-13 |
2008-05-22 |
F. Hoffmann-La Roche Ag |
Cancerous disease modifying antibodies 180706-02
|
EP2121743B1
(de)
|
2006-11-22 |
2015-06-03 |
Bristol-Myers Squibb Company |
Gezielte therapeutika auf der basis von manipulierten proteinen für tyrosinkinaserezeptoren, einschliesslich igf-ir
|
AU2007325283B2
(en)
|
2006-11-27 |
2012-08-30 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
ES2523915T5
(es)
|
2006-12-01 |
2022-05-26 |
Seagen Inc |
Agentes de unión a la diana variantes y usos de los mismos
|
WO2008070780A1
(en)
|
2006-12-07 |
2008-06-12 |
Novartis Ag |
Antagonist antibodies against ephb3
|
WO2008072723A1
(ja)
|
2006-12-14 |
2008-06-19 |
Forerunner Pharma Research Co., Ltd. |
抗Claudin3モノクローナル抗体およびそれを用いる癌の治療および診断
|
CN101605814B
(zh)
|
2006-12-14 |
2014-02-19 |
默沙东公司 |
经工程改造的抗tslp抗体
|
BRPI0720552A2
(pt)
|
2006-12-19 |
2014-01-07 |
Genentech Inc |
Antagonistas específicos de vegf para terapia adjuvante e neoadjuvante e o tratamento de tumores em estágio precoce
|
JP5645409B2
(ja)
|
2006-12-20 |
2014-12-24 |
ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー |
IL−1β関連疾患の治療方法
|
EP2099916A2
(de)
|
2006-12-22 |
2009-09-16 |
Dow AgroSciences LLC |
Aus pflanzen hergestellte west-nil-virus-impfstoffe, vektoren und pflanzencodonoptimierte sequenzen
|
US20100111851A1
(en)
|
2007-01-05 |
2010-05-06 |
The University Of Tokyo |
Diagnosis and treatment of cancer by using anti-prg-3 antibody
|
PL2104682T3
(pl)
|
2007-01-11 |
2017-03-31 |
Michael Bacher |
Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych
|
EP2629094A1
(de)
|
2007-01-24 |
2013-08-21 |
Carnegie Mellon University |
Optische Biosensoren
|
CN104043123B
(zh)
|
2007-01-25 |
2019-08-13 |
达娜-法勃肿瘤研究所公司 |
抗egfr抗体在治疗egfr突变体介导的疾病中的用途
|
JP5507851B2
(ja)
|
2007-02-09 |
2014-05-28 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Gabaニューロン前駆細胞マーカー65b13
|
WO2008103474A1
(en)
|
2007-02-20 |
2008-08-28 |
Anaptysbio, Inc. |
Methods of generating libraries and uses thereof
|
PL2426144T3
(pl)
|
2007-02-23 |
2019-05-31 |
Merck Sharp & Dohme |
Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej
|
US7771947B2
(en)
|
2007-02-23 |
2010-08-10 |
Investigen, Inc. |
Methods and compositions for rapid light-activated isolation and detection of analytes
|
CN103396489A
(zh)
|
2007-02-23 |
2013-11-20 |
默沙东公司 |
工程改造的抗IL-23p19抗体
|
US8192740B2
(en)
|
2007-02-27 |
2012-06-05 |
Forerunner Pharma Research Co., Ltd. |
Pharmaceutical composition comprising anti-GRP78 antibody as active ingredient
|
MX2009009283A
(es)
|
2007-02-28 |
2009-11-18 |
Schering Corp |
Anticuerpos anti-interleuquina -23r de ingenieria.
|
MX2009009167A
(es)
|
2007-02-28 |
2009-09-04 |
Schering Corp |
Terapia de combinacion para el tratamiento de trastornos inmunes.
|
WO2008109440A2
(en)
|
2007-03-02 |
2008-09-12 |
Genentech, Inc. |
Predicting response to a her dimerisation inhibitor based on low her3 expression
|
EP1972639A3
(de)
|
2007-03-07 |
2008-12-03 |
Cell Signaling Technology, Inc. |
Reagenzien zur Erkennung von Proteinphosphorylierung in Karzinom-Signalwegen
|
CL2008000719A1
(es)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
AU2008227123B2
(en)
|
2007-03-15 |
2014-03-27 |
Ludwig Institute For Cancer Research Ltd. |
Treatment method using EGFR antibodies and src inhibitors and related formulations
|
EP1975184A3
(de)
|
2007-03-26 |
2008-11-26 |
Cell Signaling Technology, Inc. |
Serin- oder Threonin-Phosphorylationsorte
|
PL2155248T3
(pl)
|
2007-04-12 |
2015-12-31 |
Brigham & Womens Hospital Inc |
Celowanie w ABCB5 w terapii nowotworowej
|
US7977462B2
(en)
|
2007-04-19 |
2011-07-12 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
EP2145902A3
(de)
|
2007-04-19 |
2010-09-29 |
Peter Hornbeck |
Tyrosinphosphorylations-Stellen und spezifische Antikörper
|
EP1983003A3
(de)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosinphosphorylationsstellen und spezifische Antikörper
|
EP2615172A1
(de)
|
2007-04-27 |
2013-07-17 |
Pfenex Inc. |
Schnellscreeningverfahren für Bakterienwirte zur Identifizierung bestimmter Stämme mit verbessertem Ertrag und/oder verbesserter Qualität bei der Expression heterologer Proteine
|
ES2465223T3
(es)
|
2007-04-27 |
2014-06-05 |
Zymogenetics, Inc. |
Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
CA2685558A1
(en)
|
2007-04-28 |
2008-11-06 |
Fraunhofer Usa, Inc. |
Trypanosoma antigens, vaccine compositions, and related methods
|
US20090053831A1
(en)
|
2007-05-01 |
2009-02-26 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
EP2703011A3
(de)
|
2007-05-07 |
2014-03-26 |
MedImmune, LLC |
Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
|
JP5989299B2
(ja)
|
2007-05-30 |
2016-09-07 |
エルパス・インコーポレイテッドLpath, Inc. |
リゾホスファチジン酸結合のための組成物と方法
|
US9163091B2
(en)
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
WO2008154251A2
(en)
|
2007-06-07 |
2008-12-18 |
Genentech, Inc. |
C3b antibodies and methods for the prevention and treatment of complement- associated disorders
|
ES2583377T3
(es)
|
2007-06-08 |
2016-09-20 |
Genentech, Inc. |
Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
|
PT2170956E
(pt)
|
2007-06-15 |
2015-02-05 |
Medigene Ag |
Tratamento de tumores utilizando um anticorpo anti-l1 específico
|
CA2855098C
(en)
|
2007-06-18 |
2018-02-27 |
Merck Sharp & Dohme B.V. |
Antibodies to human programmed death receptor pd-1
|
AU2008287195A1
(en)
*
|
2007-07-06 |
2009-02-19 |
Emergent Product Development Seattle, Llc |
Binding peptides having a C-terminally disposed specific binding domain
|
UA107557C2
(xx)
|
2007-07-06 |
2015-01-26 |
|
Композиція антитіла офатумумабу
|
CA2692933C
(en)
|
2007-07-11 |
2016-10-18 |
Fraunhofer Usa, Inc. |
Yersinia pestis antigens, vaccine compositions, and related methods
|
US9845355B2
(en)
|
2007-07-16 |
2017-12-19 |
Genentech, Inc. |
Humanized anti-CD79b antibodies and immunoconjugates and methods of use
|
PL2474557T3
(pl)
|
2007-07-16 |
2015-02-27 |
Genentech Inc |
Przeciwciała anty- CD79b i immunokoniugaty i sposoby stosowania
|
US8461303B2
(en)
|
2007-08-02 |
2013-06-11 |
Gilead Biologics, Inc. |
LOX and LOXL2 inhibitors and uses thereof
|
BRPI0815399A2
(pt)
|
2007-08-13 |
2019-09-24 |
Vasgene Therapeutics Inc |
tratamento de câncer usando anticorpos humanizados que se ligam ephb4
|
MX2010001757A
(es)
|
2007-08-14 |
2010-09-14 |
Ludwig Inst Cancer Res |
Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
|
US8916135B2
(en)
|
2007-08-22 |
2014-12-23 |
Colorado School Of Mines |
Lanthanide nanoparticle conjugates and uses thereof
|
ES2642516T3
(es)
|
2007-09-04 |
2017-11-16 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Supresiones en el dominio II de la exotoxina A de Pseudomonas que reducen la toxicidad no específica
|
US7704508B2
(en)
|
2007-09-14 |
2010-04-27 |
New York Blood Center |
Babesia subtilisin
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
MX344415B
(es)
|
2007-09-14 |
2016-12-15 |
Adimab Inc |
Bancos de anticuerpos sinteticos, designados racionalmente y usos para los mismos.
|
EP2192922A4
(de)
|
2007-09-17 |
2010-09-29 |
Univ California |
Auf prostatazellen in situ abzielende internalisierende humane monoklonale antikörper
|
EP2195341B1
(de)
|
2007-09-26 |
2017-03-22 |
UCB Biopharma SPRL |
Fusionsantikörper mit dualer spezifität
|
CN101874042B9
(zh)
|
2007-09-26 |
2019-01-01 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
GB0718843D0
(en)
|
2007-09-26 |
2007-11-07 |
Cancer Rec Tech Ltd |
Materials and methods relating to modifying the binding of antibodies
|
AU2008304111B2
(en)
|
2007-09-27 |
2014-04-24 |
Amgen Inc. |
Pharmaceutical formulations
|
SG185263A1
(en)
|
2007-09-28 |
2012-11-29 |
Portola Pharm Inc |
Antidotes for factor xa inhibitors and methods of using the same
|
US20110014196A1
(en)
*
|
2007-10-03 |
2011-01-20 |
Covalys Biosciences Ag |
Drug Transfer into Living Cells
|
US8470560B2
(en)
|
2007-10-03 |
2013-06-25 |
The United States Of America As Represented By The Secretary Of The Army |
CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines
|
EP2050764A1
(de)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Neues polyvalentes bispezifisches Antikörperformat und Verwendung
|
CN101918579A
(zh)
|
2007-10-22 |
2010-12-15 |
先灵公司 |
完全人抗-vegf抗体和使用方法
|
EP3441402A1
(de)
|
2007-10-30 |
2019-02-13 |
Genentech, Inc. |
Antikörperreinigung durch kationenaustauschchromatographie
|
WO2009061910A1
(en)
|
2007-11-08 |
2009-05-14 |
Genetech, Inc. |
Anti-factor b antibodies and their uses
|
CA2705152C
(en)
|
2007-11-09 |
2016-10-11 |
Peregrine Pharmaceuticals, Inc. |
Anti-vegf antibody compositions and methods
|
MX2010005244A
(es)
|
2007-11-12 |
2010-10-25 |
Theraclone Sciences Inc |
Composiciones y métodos para la terapia y el diagnóstico de influenza.
|
CN104109208A
(zh)
|
2007-11-14 |
2014-10-22 |
中外制药株式会社 |
使用抗gpr49抗体的癌症的诊断和治疗
|
AR069333A1
(es)
|
2007-11-15 |
2010-01-13 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos monoclonales que se unen al receptor tirosin quinasa anexelekto (axl), hibridomas que los producen y sus usos
|
ES2962777T3
(es)
|
2007-11-15 |
2024-03-21 |
Amgen Inc |
Formulación acuosa de anticuerpos estabilizada por antioxidantes para la administración parenteral
|
US7892760B2
(en)
|
2007-11-19 |
2011-02-22 |
Celera Corporation |
Lung cancer markers, and uses thereof
|
US20090203043A1
(en)
|
2007-11-21 |
2009-08-13 |
Peter Hornbeck |
Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
|
CA2706729A1
(en)
|
2007-11-29 |
2009-06-11 |
Genentech, Inc. |
Gene expression markers for inflammatory bowel disease
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗-vegf抗體
|
US20110129459A1
(en)
|
2007-12-05 |
2011-06-02 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-nr10 antibody and use thereof
|
GB0723797D0
(en)
|
2007-12-05 |
2008-01-16 |
Immunosolv Ltd |
Method
|
EP2067787A1
(de)
|
2007-12-06 |
2009-06-10 |
Boehringer Ingelheim International GmbH |
Verfahren zur Kontrolle von Insektenpopulationen
|
AU2008352942B2
(en)
|
2007-12-19 |
2013-09-12 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
|
PL2391650T3
(pl)
|
2007-12-20 |
2015-03-31 |
Xoma Us Llc |
Sposoby leczenia dny
|
US8414893B2
(en)
|
2007-12-21 |
2013-04-09 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
US7914785B2
(en)
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
EP2077281A1
(de)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom
|
SG187457A1
(en)
|
2008-01-11 |
2013-02-28 |
Univ Tokyo |
Anti-cldn6 antibody
|
US8697434B2
(en)
|
2008-01-11 |
2014-04-15 |
Colorado School Of Mines |
Detection of phage amplification by SERS nanoparticles
|
ATE548052T1
(de)
|
2008-01-17 |
2012-03-15 |
Philogen Spa |
Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
|
JP5701064B2
(ja)
|
2008-01-25 |
2015-04-15 |
アムジエン・インコーポレーテツド |
フェロポーチン抗体およびその使用方法
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
RU2553566C2
(ru)
|
2008-01-31 |
2015-06-20 |
Дженентек, Инк. |
АНТИ-CD79b АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
ES2542308T3
(es)
|
2008-03-10 |
2015-08-04 |
Theraclone Sciences, Inc. |
Composiciones y métodos para la terapia y diagnóstico de infecciones por citomegalovirus
|
CA2718942A1
(en)
|
2008-03-18 |
2009-09-24 |
Seattle Genetics, Inc. |
Auristatin drug linker conjugates
|
US9441034B2
(en)
|
2008-03-27 |
2016-09-13 |
Zymogenetics, Inc. |
Compositions and methods for inhibiting PDGFRβ and VEGF-A
|
JP2011516423A
(ja)
|
2008-03-28 |
2011-05-26 |
シー レーン バイオテクノロジーズ, エルエルシー |
ウイルス抗原に対する中和分子
|
US9441204B2
(en)
|
2008-04-03 |
2016-09-13 |
Colorado School Of Mines |
Compositions and methods for detecting Yersinia pestis bacteria
|
WO2009124294A2
(en)
|
2008-04-05 |
2009-10-08 |
Lpath, Inc. |
Pharmaceutical compositions for binding sphingosine-1-phosphate
|
CN104655854A
(zh)
|
2008-04-09 |
2015-05-27 |
健泰科生物技术公司 |
用于免疫相关疾病的治疗的新组合物和方法
|
CA2718975A1
(en)
|
2008-04-10 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting egfr mutations in cancer
|
WO2009126944A1
(en)
*
|
2008-04-11 |
2009-10-15 |
Trubion Pharmaceuticals, Inc. |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
SG190572A1
(en)
|
2008-04-29 |
2013-06-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
US9315577B2
(en)
|
2008-05-01 |
2016-04-19 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
JP5624535B2
(ja)
|
2008-05-02 |
2014-11-12 |
シアトル ジェネティクス,インコーポレーテッド |
低いコアフコシル化を有する抗体及び抗体誘導体を調製するための方法並びに組成物
|
EP2116555A1
(de)
|
2008-05-08 |
2009-11-11 |
Bayer Schering Pharma Aktiengesellschaft |
Verwendung eines spezifisch an ED-B Fibronectin bindenden radioaktiv markierten Moleküls bei einem Verfahren zur Behandlung von Hodgkin-Lymphom
|
EP2281057B1
(de)
|
2008-05-09 |
2013-12-25 |
Akonni Biosystems |
Mikroarray-system
|
US8680025B2
(en)
|
2008-05-09 |
2014-03-25 |
Akonni Biosystems, Inc. |
Microarray system
|
US8093018B2
(en)
|
2008-05-20 |
2012-01-10 |
Otsuka Pharmaceutical Co., Ltd. |
Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
|
EP2799448A1
(de)
|
2008-05-22 |
2014-11-05 |
Bristol-Myers Squibb Company |
Polyvalente Proteine mit Fibronectin-Gerüstdomänen
|
US9109026B2
(en)
|
2008-06-03 |
2015-08-18 |
Abbvie, Inc. |
Dual variable domain immunoglobulins and uses thereof
|
RU2010153580A
(ru)
|
2008-06-03 |
2012-07-20 |
Эбботт Лэборетриз (Us) |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
US8575314B2
(en)
|
2008-06-20 |
2013-11-05 |
National University Corporation Okayama University |
Antibody against oxidized LDL/β2GPI complex and use of the same
|
DK2732823T3
(da)
|
2008-06-25 |
2019-09-16 |
H Lundbeck As |
Modulering af TrpV : Vps10p-domæne-receptorsystemet til behandlingen af smerte
|
MX2010014574A
(es)
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
PT2824100T
(pt)
|
2008-07-08 |
2018-05-10 |
Incyte Holdings Corp |
1,2,5-oxadiazoles como inibidores da indoleamina 2,3-dioxigenase
|
EP2322610B1
(de)
|
2008-07-16 |
2016-12-14 |
Medical and Biological Laboratories Co., Ltd. |
Anti-human-clcp1-antikörper und seine anwendung
|
US8148088B2
(en)
|
2008-07-18 |
2012-04-03 |
Abgent |
Regulation of autophagy pathway phosphorylation and uses thereof
|
EP2633864A1
(de)
|
2008-07-25 |
2013-09-04 |
The Regents of the University of Colorado |
Clip-Hemmer und Verfahren zur Modulation der Immunfunktion
|
DK3604324T3
(da)
|
2008-08-14 |
2024-04-08 |
Genentech Inc |
Fremgangsmåder til at fjerne en kontaminant under anvendelse af ionbytningskromatografi med forskydning af iboende proteiner
|
WO2010096464A1
(en)
|
2009-02-18 |
2010-08-26 |
Boyes Stephen G |
Gold/lanthanide nanoparticle conjugates and uses thereof
|
US8790642B2
(en)
|
2008-08-29 |
2014-07-29 |
Genentech, Inc. |
Cross-reactive and bispecific anti-IL-17A/F antibodies
|
PE20110593A1
(es)
|
2008-09-03 |
2011-09-10 |
Genentech Inc |
Anticuerpos multiespecificos
|
AR073295A1
(es)
|
2008-09-16 |
2010-10-28 |
Genentech Inc |
Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
|
WO2010032060A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune Llc |
Antibodies directed to dll4 and uses thereof
|
PT2334705T
(pt)
|
2008-09-26 |
2017-03-22 |
Ucb Biopharma Sprl |
Produtos biológicos
|
WO2010037046A1
(en)
|
2008-09-28 |
2010-04-01 |
Fraunhofer Usa, Inc. |
Humanized neuraminidase antibody and methods of use thereof
|
CN102271724B
(zh)
|
2008-10-09 |
2015-10-14 |
塔夫茨大学信托人 |
含有甘油的改性丝膜
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
AU2009312532B2
(en)
|
2008-11-06 |
2013-05-16 |
Ichnos Sciences SA |
Treatment with anti-alpha2 integrin antibodies
|
WO2010054264A1
(en)
|
2008-11-07 |
2010-05-14 |
Triact Therapeutics, Inc. |
Use of catecholic butane derivatives in cancer therapy
|
US8298533B2
(en)
|
2008-11-07 |
2012-10-30 |
Medimmune Limited |
Antibodies to IL-1R1
|
US20110293605A1
(en)
|
2008-11-12 |
2011-12-01 |
Hasige Sathish |
Antibody formulation
|
EP2346529B1
(de)
|
2008-11-12 |
2016-02-10 |
Theraclone Sciences, Inc. |
Humane m2e-peptid-immunogene
|
CA2742871C
(en)
|
2008-11-13 |
2018-10-23 |
Herb Lin |
Methods and compositions for regulating iron homeostasis by modulation of bmp-6
|
KR20110112301A
(ko)
|
2008-11-18 |
2011-10-12 |
메리맥 파마슈티컬즈, 인크. |
인간 혈청 알부민 링커 및 그 콘쥬게이트
|
EP2189539B2
(de)
|
2008-11-21 |
2018-06-13 |
Chimera Biotec GmbH |
Konjugatkomplexe zum Analytnachweis
|
HUE032693T2
(en)
|
2008-11-22 |
2017-10-30 |
Hoffmann La Roche |
Use of anti-vegf antibody in combination with chemotherapy to treat breast cancer
|
CA2746511C
(en)
|
2008-12-04 |
2019-06-18 |
Lankenau Institute For Medical Research |
Compositions and methods for the treatment and prevention of lens fibrotic diseases
|
SG10201708690SA
(en)
|
2008-12-09 |
2017-12-28 |
Genentech Inc |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
JP2012512261A
(ja)
|
2008-12-17 |
2012-05-31 |
ジェネンテック, インコーポレイテッド |
C型肝炎ウイルス併用療法
|
US20110250644A1
(en)
|
2008-12-19 |
2011-10-13 |
Schering Corporation |
Feed supplement for mammalian cell culture and methods of use
|
WO2010074049A1
(ja)
|
2008-12-22 |
2010-07-01 |
株式会社 未来創薬研究所 |
抗hs6st2抗体及びその用途
|
WO2010073972A1
(ja)
|
2008-12-22 |
2010-07-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Neph3を用いた膵臓前駆細胞の取得方法
|
JP2012513194A
(ja)
|
2008-12-23 |
2012-06-14 |
アストラゼネカ アクチボラグ |
α5β1に向けられた標的結合剤およびその使用
|
WO2010073694A1
(ja)
|
2008-12-25 |
2010-07-01 |
国立大学法人東京大学 |
抗tm4sf20抗体を用いた癌の診断と治療
|
SG172427A1
(en)
|
2008-12-26 |
2011-07-28 |
Univ Tokyo |
Diagnosis and treatment of cancer using anti-lgr7 antibody
|
GB0902916D0
(en)
|
2009-02-20 |
2009-04-08 |
Fusion Antibodies Ltd |
Antibody therapy
|
GB0903168D0
(en)
|
2009-02-25 |
2009-04-08 |
Fusion Antibodies Ltd |
Diagnostic method and kit
|
DK3103476T3
(da)
|
2009-03-02 |
2022-10-17 |
Aduro Biotech Holdings Europe B V |
Antistoffer mod en prolifererende inducerende ligand (april)
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
EP2230515B1
(de)
|
2009-03-16 |
2014-12-17 |
Agilent Technologies, Inc. |
Passivierung von Oberflächen nach Ligandenkupplung
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
MA33198B1
(fr)
|
2009-03-20 |
2012-04-02 |
Genentech Inc |
Anticorps anti-her di-spécifiques
|
JP2012521197A
(ja)
|
2009-03-20 |
2012-09-13 |
アムジエン・インコーポレーテツド |
担体免疫グロブリンおよびその使用
|
US8124740B2
(en)
|
2009-03-25 |
2012-02-28 |
Genentech, Inc. |
Anti- α5 β1 antibodies and uses thereof
|
CN102378767B
(zh)
|
2009-03-25 |
2015-01-14 |
健泰科生物技术公司 |
抗-fgfr3抗体及其使用方法
|
EP2233496A1
(de)
|
2009-03-26 |
2010-09-29 |
Ruhr-Universität Bochum |
Fluoreszenzproteine
|
WO2010117729A1
(en)
|
2009-03-30 |
2010-10-14 |
Portola Pharmaceuticals, Inc. |
Antidotes for factor xa inhibitors and methods of using the same
|
NZ595574A
(en)
|
2009-04-01 |
2013-11-29 |
Genentech Inc |
Anti-fcrh5 antibodies and immunoconjugates and methods of use
|
CA2752908A1
(en)
|
2009-04-01 |
2010-10-07 |
Genentech, Inc. |
Treatment of insulin-resistant disorders
|
AU2010230563A1
(en)
|
2009-04-02 |
2011-09-22 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain Fab fragments
|
WO2010112034A2
(en)
|
2009-04-02 |
2010-10-07 |
Aarhus Universitet |
Compositions and methods for treatment and diagnosis of synucleinopathies
|
US20100297127A1
(en)
|
2009-04-08 |
2010-11-25 |
Ghilardi Nico P |
Use of il-27 antagonists to treat lupus
|
JP5746018B2
(ja)
|
2009-04-16 |
2015-07-08 |
国立大学法人 東京大学 |
抗tmprss11e抗体を用いた癌の診断と治療
|
CA2759506A1
(en)
|
2009-04-23 |
2010-10-28 |
Theraclone Sciences, Inc. |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
UY32560A
(es)
|
2009-04-29 |
2010-11-30 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
KR20120024763A
(ko)
|
2009-05-15 |
2012-03-14 |
추가이 세이야쿠 가부시키가이샤 |
항axl 항체
|
US20120128673A1
(en)
|
2009-05-20 |
2012-05-24 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
EP2432803A2
(de)
|
2009-05-20 |
2012-03-28 |
Theraclone Sciences, Inc. |
Zusammensetzungen und verfahren zur therapie und diagnose von grippe
|
ES2545792T5
(es)
|
2009-05-20 |
2018-09-14 |
Novimmune Sa |
Bancos de polipéptidos sintéticos y métodos para generar variantes de polipéptidos diversificados de forma natural
|
JP5808052B2
(ja)
|
2009-05-29 |
2015-11-10 |
中外製薬株式会社 |
Egfファミリーリガンドのアンタゴニストを成分とする医薬組成物
|
GB0909906D0
(en)
|
2009-06-09 |
2009-07-22 |
Affitech As |
Antibodies
|
GB0909904D0
(en)
|
2009-06-09 |
2009-07-22 |
Affitech As |
Product
|
CA2766152A1
(en)
|
2009-06-24 |
2011-01-13 |
Lpath, Inc. |
Methods of increasing neuronal differentiation using antibodies to lysophosphatidic acid
|
WO2011004899A1
(en)
|
2009-07-06 |
2011-01-13 |
Takeda Pharmaceutical Company Limited |
Cancerous disease modifying antibodies
|
CN102471381A
(zh)
|
2009-07-07 |
2012-05-23 |
霍夫曼-拉罗奇有限公司 |
自身免疫性脱髓鞘疾病的诊断和治疗
|
EP2453910B1
(de)
|
2009-07-15 |
2016-08-31 |
Portola Pharmaceuticals, Inc. |
Einzeldosisformulierung von antidoten für faktor-xa-hemmer zur prävention von blutung
|
US20110033486A1
(en)
|
2009-07-20 |
2011-02-10 |
Abbas Alexander R |
Gene expression markers for crohn's disease
|
CN106591104B
(zh)
|
2009-07-24 |
2020-05-22 |
阿科尼生物系统公司 |
流通池装置
|
SG177689A1
(en)
|
2009-07-31 |
2012-02-28 |
Organon Nv |
Fully human antibodies to btla
|
SG178177A1
(en)
|
2009-07-31 |
2012-03-29 |
Genentech Inc |
Inhibition of tumor metastasis using bv8- or g-csf-antagonists
|
SI2462158T1
(en)
|
2009-08-06 |
2018-04-30 |
F. Hoffmann-La Roche Ag |
A method for improving the removal of the virus in the cleansing of proteins
|
LT2464725T
(lt)
|
2009-08-11 |
2020-06-10 |
F. Hoffmann-La Roche Ag |
Baltymų gamyba ląstelių mitybinėje terpėje, kurioje nėra glutamino
|
TW201431558A
(zh)
|
2009-08-15 |
2014-08-16 |
建南德克公司 |
用於治療先前治療過之乳癌之抗-血管新生療法
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
WO2011021381A1
(ja)
|
2009-08-17 |
2011-02-24 |
株式会社未来創薬研究所 |
抗hb-egf抗体を有効成分として含む医薬組成物
|
KR101553740B1
(ko)
|
2009-08-17 |
2015-09-17 |
트라콘 파마수티칼즈, 인코포레이티드 |
항엔도글린 항체 및 항vegf 제제를 사용한 암 치료를 위한 병용 요법
|
RU2570554C2
(ru)
|
2009-08-31 |
2015-12-10 |
Роше Гликарт Аг |
Гуманизированные моноклональные антитела к сеа с созревшей аффинностью
|
WO2011028811A2
(en)
|
2009-09-01 |
2011-03-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
LT3023438T
(lt)
|
2009-09-03 |
2020-05-11 |
Merck Sharp & Dohme Corp. |
Anti-gitr antikūnai
|
ES2544805T3
(es)
|
2009-09-11 |
2015-09-04 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Exotoxina A de Pseudomonas mejorada con inmunogenicidad reducida
|
NZ701769A
(en)
|
2009-09-16 |
2016-06-24 |
Genentech Inc |
Coiled coil and/or tether containing protein complexes and uses thereof
|
ES2530732T3
(es)
|
2009-09-17 |
2015-03-05 |
Hoffmann La Roche |
Procedimientos de diagnóstico para el cáncer de pulmón
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
EP2480888B1
(de)
|
2009-09-25 |
2016-11-30 |
XOMA Technology Ltd. |
Screening-verfahren
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
WO2011041391A1
(en)
|
2009-09-29 |
2011-04-07 |
Fraunhofer Usa, Inc. |
Influenza hemagglutinin antibodies, compositions, and related methods
|
CN102656266B
(zh)
|
2009-10-15 |
2016-08-03 |
霍夫曼-拉罗奇有限公司 |
具有改变的受体特异性的嵌合成纤维细胞生长因子
|
CN102666875A
(zh)
|
2009-10-15 |
2012-09-12 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
GB0918383D0
(en)
|
2009-10-20 |
2009-12-02 |
Cancer Rec Tech Ltd |
Prognostic,screening and treatment methods and agents for treatment of metastasis and inflammation
|
KR20120105447A
(ko)
|
2009-10-22 |
2012-09-25 |
제넨테크, 인크. |
항-헵신 항체 및 그의 사용 방법
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
EP2322149A1
(de)
|
2009-11-03 |
2011-05-18 |
Universidad del Pais Vasco |
Verfahren und Zusammensetzung zur Behandlung von Ischämie
|
CN102782149B
(zh)
|
2009-11-04 |
2014-11-12 |
默沙东公司 |
经工程改造的抗-tslp抗体
|
US20110165648A1
(en)
|
2009-11-04 |
2011-07-07 |
Menno Van Lookeren Campagne |
Co-crystal structure of factor D and anti-factor D antibody
|
ES2636971T3
(es)
|
2009-11-05 |
2017-10-10 |
F. Hoffmann-La Roche Ag |
Procedimientos y composición para la secreción de polipéptidos heterógenos
|
JP5888728B2
(ja)
|
2009-11-05 |
2016-03-22 |
国立大学法人大阪大学 |
自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
|
RU2012124093A
(ru)
|
2009-11-12 |
2013-12-20 |
Дженентек, Инк. |
Способ увеличения плотности дендритных шипиков
|
CA2781532A1
(en)
|
2009-11-20 |
2011-05-26 |
Amgen Inc. |
Anti-orai1 antigen binding protein that binds the second extracellular loop of orai1
|
NZ628923A
(en)
|
2009-11-24 |
2016-02-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
PE20121584A1
(es)
|
2009-11-30 |
2012-11-29 |
Genentech Inc |
Composiciones y metodos para el diagnostico y el tratamiento de tumores
|
EP2507381A4
(de)
|
2009-12-04 |
2016-07-20 |
Hoffmann La Roche |
Multispezifische antikörper, antikörperanaloge, zusammensetzungen und verfahren
|
US8691227B2
(en)
|
2009-12-17 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
|
PL2516465T3
(pl)
|
2009-12-23 |
2016-11-30 |
|
Przeciwciała anty-bv8 i ich zastosowania
|
EA201270662A1
(ru)
|
2009-12-23 |
2013-01-30 |
4-Антибоди Аг |
Связывающие элементы для человеческого цитамегаловируса
|
GB0922553D0
(en)
|
2009-12-23 |
2010-02-10 |
Fusion Antibodies Ltd |
Prognostic marker
|
EP2338492A1
(de)
|
2009-12-24 |
2011-06-29 |
Universidad del Pais Vasco |
Verfahren und Zusammensetzung zur Behandlung von Alzheimer
|
US20110159588A1
(en)
|
2009-12-30 |
2011-06-30 |
Kui Lin |
Methods for Modulating a PDGF-AA Mediated Biological Response
|
EP3295957B1
(de)
|
2010-01-15 |
2019-08-07 |
Kirin-Amgen, Inc. |
Anti il-17ra-antikörperformulierung und therapeutische regimen zur behandlung von psoriasis
|
US8685524B2
(en)
|
2010-01-29 |
2014-04-01 |
Toray Industries, Inc. |
Polylactic acid-based resin sheet
|
PL3342786T3
(pl)
|
2010-01-29 |
2021-12-20 |
Chugai Seiyaku Kabushiki Kaisha |
Przeciwciało przeciwko dll3
|
RU2573994C2
(ru)
|
2010-02-10 |
2016-01-27 |
Иммьюноджен, Инк |
Антитела против cd20 и их применение
|
GB201002238D0
(en)
|
2010-02-10 |
2010-03-31 |
Affitech As |
Antibodies
|
KR20130004579A
(ko)
|
2010-02-23 |
2013-01-11 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 조성물 및 방법
|
KR20180028561A
(ko)
|
2010-02-23 |
2018-03-16 |
제넨테크, 인크. |
난소암의 치료를 위한 항혈관신생 요법
|
US20120321557A1
(en)
|
2010-02-26 |
2012-12-20 |
Forerunner Pharma Research Co., Ltd. |
Anti-icam3 antibody and use thereof
|
US20130004516A1
(en)
|
2010-03-04 |
2013-01-03 |
Dainippon Sumitomo Pharma Co., Ltd. |
Drug for inflammatory bowel disease
|
KR20180000342A
(ko)
|
2010-03-22 |
2018-01-02 |
제넨테크, 인크. |
단백질-함유 제제의 안정화에 유용한 조성물 및 방법
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
TWI586806B
(zh)
|
2010-04-23 |
2017-06-11 |
建南德克公司 |
異多聚體蛋白質之製造
|
CN107090045A
(zh)
|
2010-05-03 |
2017-08-25 |
霍夫曼-拉罗奇有限公司 |
用于肿瘤诊断和治疗的组合物和方法
|
MX2012012743A
(es)
|
2010-05-03 |
2012-11-23 |
Genentech Inc |
Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
|
ME02819B
(de)
|
2010-05-14 |
2018-01-20 |
Amgen Inc |
Hochkonzentrierte antikörperformulierungen
|
MY161534A
(en)
|
2010-05-25 |
2017-04-28 |
Genentech Inc |
Methods of purifying polypeptides
|
US9995679B2
(en)
|
2010-05-25 |
2018-06-12 |
Carnegie Mellon University |
Targeted probes of cellular physiology
|
PL2575881T3
(pl)
|
2010-05-28 |
2018-06-29 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Przeciwciała swoiste wobec CD160 do leczenia zaburzeń oczu związanych z angiogenezą
|
WO2011152503A1
(ja)
|
2010-06-02 |
2011-12-08 |
大日本住友製薬株式会社 |
自己免疫疾患またはアレルギー疾患の治療剤
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
CN103201290B
(zh)
|
2010-06-14 |
2016-09-28 |
莱克拉生物医学股份公司 |
S100a4抗体及其治疗用途
|
MY161390A
(en)
|
2010-06-24 |
2017-04-14 |
Genentech Inc |
Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
|
CN103080135B
(zh)
|
2010-06-30 |
2017-06-13 |
诺沃—诺迪斯克有限公司 |
能够特异性结合组织因子途径抑制剂的抗体
|
WO2012004367A1
(en)
|
2010-07-09 |
2012-01-12 |
N.V. Organon |
Agonistic antibody to cd27
|
NZ605449A
(en)
|
2010-07-09 |
2015-03-27 |
Genentech Inc |
Anti-neuropilin antibodies and methods of use
|
JP2013538191A
(ja)
|
2010-07-23 |
2013-10-10 |
トラスティーズ オブ ボストン ユニバーシティ |
病的血管新生および腫瘍細胞侵襲性の阻害のための治療法としてならびに分子イメージングおよび標的化送達のための抗DEsupR阻害剤
|
PE20131412A1
(es)
|
2010-08-03 |
2014-01-19 |
Abbvie Inc |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
WO2012021648A1
(en)
|
2010-08-10 |
2012-02-16 |
Amgen Inc. |
Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
|
AU2011289275A1
(en)
|
2010-08-12 |
2013-02-21 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
CN103109190B
(zh)
|
2010-08-19 |
2015-07-22 |
霍夫曼-拉罗奇有限公司 |
用于测量结合治疗性单克隆抗体的抗体的测定法
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
WO2012027440A1
(en)
|
2010-08-24 |
2012-03-01 |
Abbott Laboratories |
Hiv core protein specific antibodies and uses thereof
|
TW201211252A
(en)
|
2010-08-26 |
2012-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
WO2012027721A2
(en)
|
2010-08-27 |
2012-03-01 |
Gilead Biologics, Inc |
Antibodies to matrix metalloproteinase 9
|
ES2774369T3
(es)
|
2010-08-31 |
2020-07-20 |
Theraclone Science Int |
Anticuerpo de neutralización del virus de la inmunodeficiencia humana
|
WO2012028683A1
(en)
|
2010-09-02 |
2012-03-08 |
Novartis Ag |
Antibody gel system for sustained drug delivery
|
WO2012032043A1
(en)
|
2010-09-07 |
2012-03-15 |
Areva Med Llc |
212 pb imaging
|
CN103328511B
(zh)
|
2010-09-10 |
2016-01-20 |
埃派斯进有限公司 |
抗-IL-1β抗体及其使用方法
|
US20130263294A1
(en)
|
2010-09-20 |
2013-10-03 |
Bioiberica, S.A. |
Markers for joint displasia, osteoarthritis and conditions secondary thereto
|
US8993727B2
(en)
|
2010-09-22 |
2015-03-31 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
KR101886890B1
(ko)
|
2010-09-28 |
2018-08-08 |
세키스이가가쿠 고교가부시키가이샤 |
항인간 ccr7 항체, 하이브리도마, 핵산, 벡터, 세포, 의약 조성물 및 항체 고정화 담체
|
KR20130130709A
(ko)
|
2010-09-29 |
2013-12-02 |
어젠시스 인코포레이티드 |
191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(adc)
|
AU2011317107B2
(en)
|
2010-10-19 |
2016-02-25 |
Trustees Of Tufts College |
Silk fibroin-based microneedles and methods of making the same
|
AU2011323784A1
(en)
|
2010-10-25 |
2013-05-30 |
Regents Of The University Of Minnesota |
Therapeutic composition for treatment of glioblastoma
|
EP3214442A1
(de)
|
2010-10-25 |
2017-09-06 |
F. Hoffmann-La Roche AG |
Behandlung von gastrointestinalen entzündungen und psoriasis und asthmaentzündung und psoriasis a
|
SG189547A1
(en)
|
2010-10-27 |
2013-05-31 |
Univ New York State Res Found |
Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
|
CA2816805A1
(en)
|
2010-11-01 |
2012-05-10 |
Genentech, Inc. |
Predicting progression to advanced age-related macular degeneration using a polygenic score
|
CA2817418A1
(en)
|
2010-11-10 |
2012-05-18 |
Laboratorios Del Dr. Esteve, S.A. |
Highly immunogenic hiv p24 sequences
|
EP2640831A1
(de)
|
2010-11-17 |
2013-09-25 |
Sea Lane Biotechnologies,llc. |
Die bindungsstelle eines influenzaneutralisierenden antikörpers nachahmende influenzavirusneutralisierungsmittel
|
PT2644698T
(pt)
|
2010-11-17 |
2018-01-31 |
Chugai Pharmaceutical Co Ltd |
Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue
|
EP2643353A1
(de)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispezifische moleküle
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
GB201020738D0
(en)
|
2010-12-07 |
2011-01-19 |
Affitech Res As |
Antibodies
|
EP2655413B1
(de)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
WO2012095412A1
(en)
|
2011-01-10 |
2012-07-19 |
Ct Atlantic Ltd. |
Combination therapy including tumor associated antigen binding antibodies
|
EP2663857B1
(de)
|
2011-01-11 |
2018-12-12 |
The Governing Council Of The University Of Toronto |
Proteinnachweisverfahren
|
WO2012098124A1
(en)
|
2011-01-17 |
2012-07-26 |
Lykera Biomed Sa |
Antibodies against the s100p protein for the treatment and diagnosis of cancer
|
WO2012100835A1
(en)
|
2011-01-28 |
2012-08-02 |
Laboratorios Del Dr. Esteve, S.A. |
Methods and compositions for the treatment of aids
|
BR112013019499B1
(pt)
|
2011-02-04 |
2023-01-10 |
Genentech, Inc. |
Proteína heteromultimérica variante ou anticorpo igg modificado, método para produzir uma proteína heteromultimérica variante ou anticorpo igg modificado, composição, método para preparar uma proteína heteromultimérica e proteína heteromultimérica variante
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
EP2673301A2
(de)
|
2011-02-09 |
2013-12-18 |
Cancer Research Technology Limited |
Frmd4a-antagonisten und ihre verwendung
|
US20120213781A1
(en)
|
2011-02-11 |
2012-08-23 |
Zyngenia, Inc. |
Monovalent and Multivalent Multispecific Complexes and Uses Thereof
|
EP2675478A4
(de)
|
2011-02-14 |
2015-06-10 |
Theraclone Sciences Inc |
Zusammensetzungen und verfahren zur therapie und diagnose von grippe
|
CN103429256B
(zh)
|
2011-03-02 |
2022-09-13 |
诺和诺德保健股份有限公司 |
凝血因子向活化的血小板上的tlt-1的靶向
|
WO2012119999A1
(en)
|
2011-03-07 |
2012-09-13 |
F. Hoffmann-La Roche Ag |
Means and methods for in vivo testing of therapeutic antibodies
|
JP6385060B2
(ja)
|
2011-03-07 |
2018-09-05 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
治療的に活性な抗体のインビボにおける選択
|
JP5832559B2
(ja)
|
2011-03-10 |
2015-12-16 |
オメロス コーポレーション |
exvivoにおける加速された抗体進化による抗FN14モノクローナル抗体の生成
|
SG193402A1
(en)
|
2011-03-15 |
2013-10-30 |
Theraclone Sciences Inc |
Compositions and methods for the therapy and diagnosis of influenza
|
PE20140593A1
(es)
|
2011-03-16 |
2014-05-10 |
Amgen Inc |
Inhibidores potentes y selectivos de nav1.3 y nav1.7
|
AR085911A1
(es)
|
2011-03-16 |
2013-11-06 |
Sanofi Sa |
Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
|
EP2500073A1
(de)
|
2011-03-17 |
2012-09-19 |
ChromaCon AG |
Verfahren zur Identifizierung und Reinigung von mehrfach spezifischen Polypeptiden
|
SI2697369T1
(sl)
|
2011-03-25 |
2018-10-30 |
F. Hoffmann-La Roche Ag |
Novi postopki čiščenja beljakovin
|
TWI743461B
(zh)
|
2011-03-28 |
2021-10-21 |
法商賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
EP3398612A1
(de)
|
2011-03-31 |
2018-11-07 |
Merck Sharp & Dohme Corp. |
Stabile formulierungen aus antikörpern gegen den menschlichen pd (programmed death)-1-rezeptor und behandlungen damit
|
CA2831732C
(en)
|
2011-03-31 |
2019-12-31 |
Genentech, Inc. |
Use of a monoclonal anti-beta7 antibody for treating gastrointestinal inflammatory disorders
|
CA2834734A1
(en)
|
2011-04-04 |
2012-10-11 |
University Of Iowa Research Foundation |
Methods of improving vaccine immunogenicity
|
EP2694554A1
(de)
|
2011-04-08 |
2014-02-12 |
Gilead Biologics, Inc. |
Verfahren und zusammensetzungen zur normalisierung einer tumorvaskulatur mittels loxl2-hemmung
|
JP6104794B2
(ja)
|
2011-04-18 |
2017-03-29 |
国立大学法人 東京大学 |
抗itm2a抗体を用いる癌の診断および治療
|
US10335519B2
(en)
|
2011-04-20 |
2019-07-02 |
Trustees Of Tufts College |
Dynamic silk coatings for implantable devices
|
AU2012245198B2
(en)
|
2011-04-21 |
2017-07-13 |
Trustees Of Tufts College |
Compositions and methods for stabilization of active agents
|
CN107998388B
(zh)
|
2011-05-02 |
2023-07-14 |
千禧制药公司 |
抗α4β7抗体的制剂
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
WO2012151317A1
(en)
|
2011-05-03 |
2012-11-08 |
Genentech, Inc. |
Vascular disruption agents and uses thereof
|
EP2704739B1
(de)
|
2011-05-06 |
2017-07-12 |
The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services |
Gegen mesothelin gerichtetes rekombinantes immuntoxin
|
EP2707388B1
(de)
|
2011-05-09 |
2019-06-12 |
Duke University |
Gerichtete evolution von durch kristallstrukturen und tiefensequenzierung erkannten hiv-1-neutralisierenden antikörpern
|
JP6323718B2
(ja)
|
2011-05-17 |
2018-05-16 |
ザ ロックフェラー ユニバーシティー |
ヒト免疫不全ウイルスを無毒化する抗体、およびその使用方法。
|
US20140093514A1
(en)
|
2011-06-03 |
2014-04-03 |
University Of Zurich |
Magea3 binding antibodies
|
SG10201902706VA
(en)
|
2011-06-03 |
2019-04-29 |
Xoma Technology Ltd |
Antibodies specific for tgf-beta
|
EP2714743A1
(de)
|
2011-06-03 |
2014-04-09 |
CT Atlantic Ltd. |
Magea3-bindende antikörper
|
ES2635416T3
(es)
|
2011-06-09 |
2017-10-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Exotoxina A de pseudomonas con epítopos de linfocitos T y/o linfocitos B menos inmunogénicos
|
GB201109966D0
(en)
|
2011-06-10 |
2011-07-27 |
Cancer Res Inst Royal |
Materials and methods for treating pten mutated or deficient cancer
|
GB201109965D0
(en)
|
2011-06-10 |
2011-07-27 |
Cancer Res Inst Royal |
Materials and methods for treating estrogen receptor alpher(ER) positive cancer
|
JP6334395B2
(ja)
|
2011-06-17 |
2018-05-30 |
ノヴォ ノルディスク アー/エス |
侵食細胞の選択的排除
|
CN107988156B
(zh)
|
2011-06-30 |
2022-01-04 |
建新公司 |
T细胞活化的抑制剂
|
AR086823A1
(es)
|
2011-06-30 |
2014-01-22 |
Genentech Inc |
Formulaciones de anticuerpo anti-c-met, metodos
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
EP3088005B1
(de)
|
2011-07-05 |
2019-01-02 |
biOasis Technologies Inc |
P97-antikörperkonjugate
|
WO2013011063A1
(en)
|
2011-07-18 |
2013-01-24 |
Novo Nordisk A/S |
Antagonistic antibodies against oscar
|
WO2013011062A2
(en)
|
2011-07-18 |
2013-01-24 |
Novo Nordisk A/S |
Oscar antagonists
|
WO2013011059A1
(en)
|
2011-07-18 |
2013-01-24 |
Novo Nordisk A/S |
Antagonist antibodies against oscar
|
WO2013011061A1
(en)
|
2011-07-18 |
2013-01-24 |
Novo Nordisk A/S |
Antagonistic antibodies against oscar
|
WO2013010749A1
(en)
|
2011-07-19 |
2013-01-24 |
Philogen S.P.A |
Sequential anti - ctla4 and targeted il-2 therapy
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
PE20190262A1
(es)
|
2011-08-01 |
2019-02-25 |
Genentech Inc |
Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
|
CA2842492A1
(en)
|
2011-08-05 |
2013-02-14 |
Bioasis Technologies, Inc. |
P97 fragments with transfer activity
|
CA2845259A1
(en)
|
2011-08-15 |
2013-02-21 |
The University Of Chicago |
Compositions and methods related to antibodies to staphylococcal protein a
|
RU2014109985A
(ru)
|
2011-08-17 |
2015-09-27 |
Дженентек, Инк. |
Ингибирование ангиогенеза в рефрактерных опухолях
|
WO2013025936A1
(en)
|
2011-08-18 |
2013-02-21 |
Cornell University |
Detection and treatment of metastatic disease
|
WO2013027802A1
(ja)
|
2011-08-23 |
2013-02-28 |
中外製薬株式会社 |
抗腫瘍活性を有する新規な抗ddr1抗体
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
GB201212550D0
(en)
|
2012-07-13 |
2012-08-29 |
Novartis Ag |
B cell assay
|
EP2749641B1
(de)
|
2011-09-07 |
2021-06-02 |
Chugai Seiyaku Kabushiki Kaisha |
Krebsstammzellenisolierung
|
WO2013035345A2
(en)
|
2011-09-09 |
2013-03-14 |
Osaka University |
Dengue-virus serotype neutralizing antibodies
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
EP3301110A1
(de)
|
2011-09-16 |
2018-04-04 |
The USA, as represented by The Secretary, Department of Health and Human Services |
Pseudomonas exotoxin a mit weniger immunogenen b-zellepitopen
|
CA3186007A1
(en)
|
2011-09-30 |
2013-04-04 |
Chugai Seiyaku Kabushiki Kaisha |
Ion concentration-dependent binding molecule library
|
US9575073B2
(en)
|
2011-10-10 |
2017-02-21 |
Rutgers, The State University Of New Jersey |
Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
|
PL3418306T3
(pl)
|
2011-10-11 |
2024-04-15 |
F. Hoffmann-La Roche Ag |
Ulepszone składanie przeciwciał dwuswoistych
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
EP2581388A1
(de)
|
2011-10-14 |
2013-04-17 |
Centre National de la Recherche Scientifique (CNRS) |
Antikörper gegen sPLA2-V und Gebrauch davon
|
EP2772268B8
(de)
|
2011-10-28 |
2020-01-08 |
Chugai Seiyaku Kabushiki Kaisha |
Krebsstammzellenspezifisches molekül
|
EP2784080B1
(de)
*
|
2011-10-31 |
2019-12-18 |
Shimadzu Corporation |
Peptidscharnierfreies flexibles antikörperähnliches molekül
|
SI3257564T1
(sl)
|
2011-11-02 |
2019-04-30 |
F. Hoffmann-La Roche Ag |
Izpiralna kromatografija s preobremenitvijo
|
WO2013067639A1
(en)
|
2011-11-07 |
2013-05-16 |
UNIVERSITé LAVAL |
Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging
|
WO2013070907A1
(en)
|
2011-11-08 |
2013-05-16 |
Tufts University |
A silk-based scaffold platform for engineering tissue constructs
|
MX2014005702A
(es)
|
2011-11-09 |
2015-02-17 |
Tufts College |
Particulas de fibroina de seda inyectables y sus usos.
|
US9492504B2
(en)
|
2011-11-09 |
2016-11-15 |
Trustees Of Tufts College |
Injectable silk fibroin foams and uses thereof
|
ES2657014T3
(es)
|
2011-11-17 |
2018-03-01 |
Pfizer Inc. |
Péptidos citotóxicos y conjugados de fármaco anticuerpo de los mismos
|
RU2014124842A
(ru)
|
2011-11-21 |
2015-12-27 |
Дженентек, Инк. |
Очистка анти-с-мет антител
|
RU2014124530A
(ru)
|
2011-11-23 |
2015-12-27 |
Идженика, Инк. |
Антитела к cd98 и способы их применения
|
SG11201402603WA
(en)
|
2011-11-28 |
2014-06-27 |
Merck Patent Gmbh |
Anti-pd-l1 antibodies and uses thereof
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
EP2602265A1
(de)
|
2011-12-07 |
2013-06-12 |
Centre National de la Recherche Scientifique (CNRS) |
Antikörper gegen Anti-sPLA2-X und Verwendungen damit
|
EP2791175A2
(de)
|
2011-12-14 |
2014-10-22 |
Abbvie Deutschland GmbH & Co. KG |
Zusammensetzung und verfahren zur diagnose und behandlung von durch eisenmangel bedingten erkrankungen
|
EP2791173B1
(de)
|
2011-12-14 |
2020-07-29 |
AbbVie Deutschland GmbH & Co. KG |
Zusammensetzung und verfahren zur diagnose und behandlung von durch eisenmangel bedingten erkrankungen
|
CN104144946A
(zh)
|
2011-12-19 |
2014-11-12 |
爱克索马美国有限责任公司 |
治疗痤疮的方法
|
ES2953308T3
(es)
|
2011-12-22 |
2023-11-10 |
Harvard College |
Composiciones y métodos para la detección de analitos
|
WO2013091903A1
(en)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anti-crac channel antibodies
|
RU2648999C2
(ru)
|
2011-12-22 |
2018-03-29 |
Дженентек, Инк. |
Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии
|
US9988439B2
(en)
|
2011-12-23 |
2018-06-05 |
Nicholas B. Lydon |
Immunoglobulins and variants directed against pathogenic microbes
|
EP2793944A4
(de)
|
2011-12-23 |
2015-09-02 |
Nicholas B Lydon |
Immunoglobuline und varianten gegen pathogene mikroben
|
KR101963230B1
(ko)
|
2011-12-26 |
2019-03-29 |
삼성전자주식회사 |
복수개의 단일 항체를 포함하는 단백질 복합체
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
US20150010630A1
(en)
|
2011-12-29 |
2015-01-08 |
Trustees Of Tufts College |
Functionalization of biomaterials to control regeneration and inflammation responses
|
TW201333035A
(zh)
|
2011-12-30 |
2013-08-16 |
Abbvie Inc |
針對il-13及/或il-17之雙特異性結合蛋白
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
CN104411717A
(zh)
|
2012-01-09 |
2015-03-11 |
斯克利普斯研究所 |
具有超长cdr3s的人源化抗体
|
AU2013208003B2
(en)
|
2012-01-09 |
2017-12-14 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
CA2862999A1
(en)
|
2012-01-11 |
2013-07-18 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University |
Bispecific antibody fragments for neurological disease proteins and methods of use
|
KR102129234B1
(ko)
|
2012-01-27 |
2020-07-02 |
아비에 도이치란트 게엠베하 운트 콤파니 카게 |
신경돌기 변성과 연관된 질환의 진단 및 치료를 위한 조성물 및 방법
|
TW201334789A
(zh)
|
2012-01-31 |
2013-09-01 |
Genentech Inc |
抗ige抗體及其使用方法
|
CN104254544B
(zh)
|
2012-02-08 |
2017-04-26 |
Igm生物科学有限公司 |
Cdim结合蛋白及其用途
|
MX2014009565A
(es)
|
2012-02-10 |
2014-11-10 |
Genentech Inc |
Anticuerpos monocatenarios y otros heteromultimeros.
|
KR20140130724A
(ko)
|
2012-02-29 |
2014-11-11 |
길리아드 바이오로직스, 인크. |
매트릭스 메탈로프로테이나제 9에 대한 항체
|
MD20140108A2
(ro)
|
2012-02-29 |
2015-03-31 |
Gilead Biologics, Inc. |
Anticorpi împotriva metaloproteinazei 9 matriciale
|
CA2866881A1
(en)
|
2012-03-09 |
2013-09-12 |
Lankenau Institute For Medical Research |
Compositions and methods for treating cancer
|
US9677070B2
(en)
|
2012-03-15 |
2017-06-13 |
Omeros Corporation |
Composition and method for diversification of target sequences
|
AU2013234046B2
(en)
|
2012-03-16 |
2017-09-07 |
University Health Network |
Methods and compositions for modulating Toso activity
|
CA2867464A1
(en)
|
2012-03-20 |
2013-09-26 |
Trustees Of Tufts College |
Silk reservoirs for drug delivery
|
EP2641916A1
(de)
|
2012-03-23 |
2013-09-25 |
Centre National de la Recherche Scientifique (C.N.R.S) |
Neue Antikörper gegen Anti-sPLA2-IIA und Verwendungen damit
|
AU2013240261A1
(en)
|
2012-03-27 |
2014-09-18 |
Genentech, Inc. |
Diagnosis and treatments relating to HER3 inhibitors
|
ES2702278T3
(es)
|
2012-04-01 |
2019-02-28 |
Technion Res & Dev Foundation |
Péptidos de inductor de metaloproteinasa de matriz extracelular (emmprin) y anticuerpos de unión
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
US9493744B2
(en)
|
2012-06-20 |
2016-11-15 |
Genentech, Inc. |
Methods for viral inactivation and other adventitious agents
|
AU2013245785A1
(en)
|
2012-04-13 |
2014-10-23 |
Trustees Of Tufts College |
Methods and compositions for preparing a silk microsphere
|
US20130281355A1
(en)
|
2012-04-24 |
2013-10-24 |
Genentech, Inc. |
Cell culture compositions and methods for polypeptide production
|
EP2841108A4
(de)
|
2012-04-25 |
2015-11-25 |
Tufts College |
Seidenmikrokügelchen sowie verfahren zur oberflächenschmierung
|
DK2857420T3
(da)
|
2012-05-30 |
2020-11-23 |
Chugai Pharmaceutical Co Ltd |
Målvævsspecifikt antigenbindende molekyle
|
SG11201407859YA
(en)
|
2012-05-31 |
2014-12-30 |
Genentech Inc |
Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
|
WO2013188855A1
(en)
|
2012-06-15 |
2013-12-19 |
Genentech, Inc. |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
RU2015100656A
(ru)
|
2012-06-27 |
2016-08-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
|
KR20150023889A
(ko)
|
2012-06-27 |
2015-03-05 |
에프. 호프만-라 로슈 아게 |
2 개 이상의 상이한 결합 단위를 함유하는 맞춤-제작된 고도로 선별적이고 다중-특이적인 표적화 단위의 선별 및 제조 방법 및 이의 용도
|
RU2015105588A
(ru)
|
2012-07-19 |
2016-09-10 |
Редвуд Байосайнс, Инк. |
Антитело, специфическое к cd22, и способы его применения
|
WO2014022515A1
(en)
|
2012-07-31 |
2014-02-06 |
Bioasis Technologies, Inc. |
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
US10513540B2
(en)
|
2012-07-31 |
2019-12-24 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
FR2994390B1
(fr)
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
MX359817B
(es)
|
2012-08-16 |
2018-10-11 |
Ipierian Inc |
Anticuerpos que se enlazan a tau.
|
KR102355959B1
(ko)
|
2012-08-23 |
2022-01-27 |
어젠시스 인코포레이티드 |
158p1d7 단백질에 결합하는 항체 약물 컨쥬게이트(adc)
|
US20150202287A1
(en)
|
2012-08-30 |
2015-07-23 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
US10689705B2
(en)
|
2012-09-27 |
2020-06-23 |
Chugai Seiyaku Kabushiki Kaisha |
FGFR3 fusion gene and pharmaceutical drug targeting same
|
AU2013326974B2
(en)
|
2012-10-03 |
2019-01-03 |
Zymeworks Bc Inc. |
Methods of quantitating heavy and light chain polypeptide pairs
|
HUE044927T2
(hu)
|
2012-10-03 |
2019-11-28 |
Philogen Spa |
Ellenanyag-konjugátum, gyulladásos bélbetegség kezelésében történõ alkalmazásra
|
ES2738305T3
(es)
|
2012-10-05 |
2020-01-21 |
Hoffmann La Roche |
Procedimientos para diagnosticar y tratar enfermedades inflamatorias intestinales
|
CA2887129A1
(en)
|
2012-10-09 |
2014-04-17 |
Igenica, Inc. |
Anti-c16orf54 antibodies and methods of use thereof
|
BR112015008635B1
(pt)
|
2012-10-18 |
2023-10-31 |
The Rockefeller University |
Anticorpos anti-hiv amplamente neutralizantes
|
CN110818798A
(zh)
|
2012-10-25 |
2020-02-21 |
美国比奥维拉迪维股份有限公司 |
抗补体C1s抗体和其用途
|
SG10201703240RA
(en)
|
2012-10-30 |
2017-06-29 |
Gilead Sciences Inc |
Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2)
|
KR101911438B1
(ko)
|
2012-10-31 |
2018-10-24 |
삼성전자주식회사 |
이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
|
KR20190107184A
(ko)
|
2012-11-01 |
2019-09-18 |
애브비 인코포레이티드 |
항-vegf/dll4 이원 가변 도메인 면역글로불린 및 이의 용도
|
LT2914291T
(lt)
|
2012-11-02 |
2022-06-10 |
Bioverativ Usa Inc. |
Antikūnai prieš komplemento c1s ir jų panaudojimo būdai
|
ES2656298T3
(es)
|
2012-11-05 |
2018-02-26 |
Pfizer Inc. |
Análogos de ayustoestatina
|
KR20150082548A
(ko)
|
2012-11-07 |
2015-07-15 |
화이자 인코포레이티드 |
항-notch3 항체 및 항체-약물 접합체
|
AU2013342163B2
(en)
|
2012-11-08 |
2018-08-16 |
F. Hoffmann-La Roche Ltd |
IL-6 antagonists and uses thereof
|
KR20150084046A
(ko)
|
2012-11-15 |
2015-07-21 |
제넨테크, 인크. |
이온 강도-매개 pH 구배 이온 교환 크로마토그래피
|
EP2922870B1
(de)
|
2012-11-21 |
2019-08-07 |
The Governors of the University of Alberta |
Immunmodulatorische peptide und verfahren zur verwendung davon
|
EP3686218A1
(de)
|
2012-12-10 |
2020-07-29 |
Biogen MA Inc. |
Antigen-2-antikörper gegen dendritische zellen und verwendungen davon
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
GB201223172D0
(en)
|
2012-12-21 |
2013-02-06 |
Immunocore Ltd |
Method
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
EP2767549A1
(de)
|
2013-02-19 |
2014-08-20 |
Adienne S.A. |
Anti-CD26-Antikörper und Verwendungen davon
|
AR094873A1
(es)
|
2013-02-25 |
2015-09-02 |
Genentech Inc |
Métodos y composiciones para detectar y tratar mutantes de akt resistentes a fármacos
|
WO2014134202A1
(en)
|
2013-02-26 |
2014-09-04 |
Triact Therapeutics, Inc. |
Cancer therapy
|
US10344060B2
(en)
|
2013-03-12 |
2019-07-09 |
Amgen Inc. |
Potent and selective inhibitors of Nav1.7
|
CA2906057A1
(en)
|
2013-03-13 |
2014-10-02 |
Genentech, Inc. |
Antibody formulations
|
EP2970433B1
(de)
|
2013-03-13 |
2019-09-18 |
Bioasis Technologies Inc. |
Fragmente von p97 und verwendungen davon
|
EP2968550B1
(de)
|
2013-03-14 |
2018-11-14 |
Ffe Therapeutics LLC |
Zusammensetzungen und verfahren zur behandlung von angiogenesebedingten erkrankungen
|
WO2014151680A1
(en)
|
2013-03-15 |
2014-09-25 |
Biogen Idec Ma Inc. |
Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
|
US10035859B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
US20140363433A1
(en)
|
2013-03-15 |
2014-12-11 |
Omeros Corporation |
Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
|
US10119134B2
(en)
|
2013-03-15 |
2018-11-06 |
Abvitro Llc |
Single cell bar-coding for antibody discovery
|
WO2014143739A2
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Anti-alpha v beta 6 antibodies and uses thereof
|
BR112015023797A2
(pt)
|
2013-03-15 |
2017-10-24 |
Abbvie Inc |
proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
|
CN105263514B
(zh)
|
2013-03-15 |
2019-04-26 |
本质生命科学有限公司 |
抗铁调素抗体及其用途
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
WO2014144911A2
(en)
|
2013-03-15 |
2014-09-18 |
Capon Daniel J |
Hybrid immunoglobulin containing non-peptidyl linkage
|
JP6586016B2
(ja)
|
2013-03-15 |
2019-10-02 |
ノヴォ ノルディスク アー/エス |
組織因子系凝固インヒビター上の2つのエピトープに特異的に結合することが可能な抗体
|
EP2976362B1
(de)
|
2013-03-19 |
2019-10-23 |
Beijing Shenogen Pharma Group Ltd. |
Antikörper und verfahren zur behandlung von östrogenrezeptor-assoziierten erkrankungen
|
CA2904095A1
(en)
|
2013-03-27 |
2014-10-02 |
Genentech, Inc. |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
US20160053023A1
(en)
|
2013-04-09 |
2016-02-25 |
Annexon, Inc. |
Methods of treatment for neuromyelitis optica
|
US9914768B2
(en)
|
2013-04-09 |
2018-03-13 |
Lykera Biomed, S.A. |
Anti-S100A7 antibodies for the treatment and diagnosis of cancer
|
LT2981822T
(lt)
|
2013-05-06 |
2020-12-28 |
Scholar Rock, Inc. |
Kompozicijos ir būdai, skirti augimo faktoriaus moduliacijai
|
US20160115231A1
(en)
|
2013-05-21 |
2016-04-28 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Treatment of mast cell related pathologies
|
EP3006042A4
(de)
|
2013-05-30 |
2017-03-01 |
National University Corporation Chiba University |
Zusammensetzung zur behandlung von entzündungskrankheiten mit anti-myosin-regulatorischem leichtketten-polypeptidantikörper
|
ES2753419T3
(es)
|
2013-06-07 |
2020-04-08 |
Univ Duke |
Inhibidores del factor H del complemento
|
CA2914768A1
(en)
|
2013-06-10 |
2014-12-18 |
Ipierian, Inc. |
Methods of treating a tauopathy
|
WO2014200767A1
(en)
|
2013-06-12 |
2014-12-18 |
The General Hospital Corporation |
Methods, kits, and systems for multiplexed detection of target molecules and uses thereof
|
US9890369B2
(en)
|
2013-06-20 |
2018-02-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor
|
EP3015115A4
(de)
|
2013-06-24 |
2017-02-22 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutikum mit humanisiertem anti-epiregulin-antikörper als wirkstoff für nicht-kleinzelliges bronchialkarzinom ohne adenokarzinom
|
WO2015001082A1
(en)
|
2013-07-05 |
2015-01-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
|
MX2015017341A
(es)
|
2013-07-09 |
2016-07-06 |
Anexxon Inc |
Anticuerpos anti-factor del complemento c1q y uso de los mismos.
|
SG11201600221YA
(en)
|
2013-07-12 |
2016-02-26 |
Genentech Inc |
Elucidation of ion exchange chromatography input optimization
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
KR20230118704A
(ko)
|
2013-07-16 |
2023-08-11 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을치료하는 방법
|
EP3022224A2
(de)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antikörper mit ultralangen komplementaritätsbestimmenden regionen
|
AU2014290361B2
(en)
|
2013-07-18 |
2019-04-18 |
Taurus Biosciences, Llc |
Humanized antibodies with ultralong complementarity determining regions
|
SG11201600741SA
(en)
|
2013-08-01 |
2016-02-26 |
Univ Catholique Louvain |
Anti-garp protein and uses thereof
|
RU2679657C2
(ru)
|
2013-08-01 |
2019-02-12 |
Эдженсис, Инк. |
Конъюгаты антител с лекарственными средствами, связывающиеся с белками cd37
|
KR20160037989A
(ko)
|
2013-08-02 |
2016-04-06 |
아두로 바이오테크 홀딩스, 유럽 비.브이. |
면역 자극을 위한 cd27 효능제와 면역 체크포인트 억제의 조합
|
EA201690213A1
(ru)
|
2013-08-12 |
2016-07-29 |
Дженентек, Инк. |
Композиции и способ лечения связанных с комплементом состояний
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
CA2922439A1
(en)
|
2013-08-29 |
2015-03-05 |
University Of Copenhagen |
Anti-adam12 antibodies for the treatment of cancer
|
JP2016531920A
(ja)
|
2013-09-05 |
2016-10-13 |
アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップAduro Biotech Holdings, Europe B.V. |
Cd70結合ペプチドおよびそれに関連する方法、プロセスおよび用途
|
KR20160050062A
(ko)
|
2013-09-05 |
2016-05-10 |
제넨테크, 인크. |
크로마토그래피 재사용 방법
|
CA2920896A1
(en)
|
2013-09-06 |
2015-03-12 |
Theranos, Inc. |
Systems and methods for detecting infectious diseases
|
NL2011406C2
(en)
|
2013-09-06 |
2015-03-10 |
Bionovion Holding B V |
Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
|
US9381246B2
(en)
|
2013-09-09 |
2016-07-05 |
Triact Therapeutics, Inc. |
Cancer therapy
|
RU2016107435A
(ru)
|
2013-09-13 |
2017-10-18 |
Дженентек, Инк. |
Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
|
SG11201601823TA
(en)
|
2013-09-13 |
2016-04-28 |
Genentech Inc |
Methods and compositions comprising purified recombinant polypeptides
|
GB201317207D0
(en)
|
2013-09-27 |
2013-11-13 |
Univ Glasgow |
Materials and methods for modulating disc1 turnover
|
SG11201602261VA
(en)
|
2013-09-27 |
2016-04-28 |
Chugai Pharmaceutical Co Ltd |
Method for producing polypeptide heteromultimer
|
WO2015046554A1
(ja)
|
2013-09-30 |
2015-04-02 |
中外製薬株式会社 |
改変されたヘルパーファージを用いて抗原結合分子を作製する方法
|
US9243294B2
(en)
|
2013-09-30 |
2016-01-26 |
Hadasit Medical Research Services And Development Ltd. |
Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
|
EP3038641B1
(de)
|
2013-10-06 |
2019-04-17 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Modifiziertes pseudomonas-exotoxin a
|
WO2015057939A1
(en)
|
2013-10-18 |
2015-04-23 |
Biogen Idec Ma Inc. |
Anti-s1p4 antibodies and uses thereof
|
EP3733868A3
(de)
|
2013-10-28 |
2021-01-13 |
DOTS Technology Corp. |
Allergennachweis
|
WO2015067755A2
(en)
|
2013-11-07 |
2015-05-14 |
Novo Nordisk A/S |
Novel methods and antibodies for treating coagulapathy
|
CA2929044A1
(en)
|
2013-11-11 |
2015-05-14 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified antibody variable region
|
CN105722523B
(zh)
|
2013-11-15 |
2022-06-14 |
豪夫迈·罗氏有限公司 |
使用环保洗涤剂的病毒灭活方法
|
EP3072527B1
(de)
|
2013-11-20 |
2022-03-09 |
National University Corporation Hokkaido University |
Immunsuppressiionsmittel
|
EP3074035B1
(de)
|
2013-11-25 |
2020-05-13 |
FameWave Ltd. |
Zusammensetzungen mit anti-ceacam-1- und anti-pd-antikörper zur krebsbehandlung
|
EP2876114A1
(de)
|
2013-11-25 |
2015-05-27 |
Consejo Superior De Investigaciones Científicas |
Antikörper gegen CCR9 und Anwendungen davon
|
EP3074039A4
(de)
|
2013-11-26 |
2017-10-11 |
The Brigham and Women's Hospital, Inc. |
Zusammensetzungen und verfahren zur modulierung einer immunreaktion
|
MX2016006356A
(es)
|
2013-11-27 |
2016-10-28 |
Ipierian Inc |
Metodos de tratamiento de una tauopatia.
|
SG10201906981TA
(en)
|
2013-12-03 |
2019-09-27 |
Harvard College |
Methods and reagents for the assessment of gestational diabetes
|
MX2016007312A
(es)
|
2013-12-04 |
2017-01-13 |
Chugai Pharmaceutical Co Ltd |
Moleculas de union al antigeno, cuya actividad de union al antigeno varia de acuerdo con la concentracion de los compuestos y bibliotecas de dichas moleculas.
|
US20160333063A1
(en)
|
2013-12-13 |
2016-11-17 |
The General Hospital Corporation |
Soluble high molecular weight (hmw) tau species and applications thereof
|
US20150210772A1
(en)
|
2013-12-17 |
2015-07-30 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
EP3083685A2
(de)
|
2013-12-20 |
2016-10-26 |
Intervet International B.V. |
Hundeantikörper mit modifizierten ch2-ch3-sequenzen
|
RU2732032C2
(ru)
|
2013-12-20 |
2020-09-10 |
Дженентек, Инк. |
Антитела с двойной специфичностью
|
ES2756175T3
(es)
|
2013-12-27 |
2020-04-27 |
Chugai Pharmaceutical Co Ltd |
Genes mutantes guardián de fgfr y fármacos que se dirigen a los mismos
|
JP2017502672A
(ja)
|
2013-12-30 |
2017-01-26 |
メディシナル バイオコンバージェンス リサーチ センター |
抗krsモノクロナル抗体及びこれの用途
|
EP2896400A1
(de)
|
2014-01-17 |
2015-07-22 |
Université Catholique De Louvain |
Verfahren zur Erhöhung der Bioverfügbarkeit von inhaliertem Verbindungen
|
WO2015110923A2
(en)
|
2014-01-21 |
2015-07-30 |
Acerta Pharma B.V. |
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
|
DK3097122T3
(da)
|
2014-01-24 |
2020-08-10 |
Ngm Biopharmaceuticals Inc |
Antistoffer, der binder beta-klotho-domæne 2, og fremgangsmåder til anvendelse deraf
|
SG11201605437YA
(en)
|
2014-01-27 |
2016-08-30 |
Pfizer |
Bifunctional cytotoxic agents
|
WO2015117121A1
(en)
|
2014-02-03 |
2015-08-06 |
Bioasis Technologies, Inc. |
P97 fusion proteins
|
EP3105252B1
(de)
|
2014-02-12 |
2019-07-24 |
Michael Uhlin |
Bispezifische antikörper zur verwendung in der stammzelltransplantation
|
WO2015126729A1
(en)
|
2014-02-19 |
2015-08-27 |
Bioasis Technologies, Inc. |
P97-ids fusion proteins
|
JP2017507949A
(ja)
|
2014-02-27 |
2017-03-23 |
ギリアード サイエンシーズ, インコーポレイテッド |
マトリックスメタロプロテイナーゼ9に対する抗体およびその使用の方法
|
CA2941697A1
(en)
|
2014-03-07 |
2015-09-11 |
University Health Network |
Methods and compositions for modifying the immune response
|
LT3701971T
(lt)
|
2014-03-14 |
2023-01-10 |
Biomolecular Holdings Llc |
Junginiai, naudingi hibridinio imunoglobulino, turinčio nepeptidilo ryšį, gamyboje
|
WO2015140351A1
(en)
|
2014-03-21 |
2015-09-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing myelination
|
EP3119913B1
(de)
|
2014-03-21 |
2021-01-06 |
The Brigham and Women's Hospital, Inc. |
Verfahren und zusammensetzungen zur behandlung von immunbedingten erkrankungen oder störungen und/oder therapieüberwachung
|
WO2015145449A2
(en)
|
2014-03-27 |
2015-10-01 |
Yeda Research And Development Co. Ltd. |
T-cell receptor cdr3 peptides and antibodies
|
AU2015235986B2
(en)
|
2014-03-27 |
2020-12-03 |
Genentech, Inc. |
Methods for diagnosing and treating inflammatory bowel disease
|
US10882919B2
(en)
|
2014-03-31 |
2021-01-05 |
Rallybio Ipa, Llc |
Antibodies against HPA-1a
|
CA2943405A1
(en)
|
2014-03-31 |
2015-10-08 |
Debiopharm International Sa |
Fgfr fusions
|
WO2015152908A1
(en)
|
2014-04-02 |
2015-10-08 |
U.S. Army Medical Research Institute Of Infectious Diseases |
Rapid dual direct fluorescent antibody assay for the identification of bacillus anthracis
|
EP3134733B1
(de)
|
2014-04-25 |
2020-10-14 |
The Brigham and Women's Hospital, Inc. |
Test und verfahren zur behandlung von patienten mit immunvermittelten erkrankungen
|
EP3804745A1
(de)
|
2014-04-25 |
2021-04-14 |
The Brigham and Women's Hospital, Inc. |
Verfahren zur manipulation von alpha-fetoprotein (afp)
|
CA2946262C
(en)
|
2014-04-27 |
2022-07-26 |
Ccam Biotherapeutics Ltd. |
Humanized antibodies against ceacam1
|
US11427647B2
(en)
|
2014-04-27 |
2022-08-30 |
Famewave Ltd. |
Polynucleotides encoding humanized antibodies against CEACAM1
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
CN106471117A
(zh)
|
2014-05-06 |
2017-03-01 |
豪夫迈·罗氏有限公司 |
使用哺乳动物细胞产生异多聚体蛋白
|
ES2905777T3
(es)
|
2014-05-30 |
2022-04-12 |
Shanghai Henlius Biotech Inc |
Anticuerpos anti-receptor del factor de crecimiento epidérmico (EGFR)
|
CN106604743A
(zh)
|
2014-06-09 |
2017-04-26 |
奥特吉尼克斯制药公司 |
用于最佳骨形成的血清磷酸盐的有效和高效控制
|
EA201692202A1
(ru)
|
2014-06-11 |
2017-06-30 |
Джилид Сайэнс, Инк. |
Способы лечения сердечно-сосудистых заболеваний
|
BR112016029076B1
(pt)
|
2014-06-12 |
2024-02-15 |
Ra Pharmaceuticals, Inc |
Polipeptídeo e composição compreendendo o mesmo para inibir a clivagem de c5 em um sistema celular
|
WO2016007919A2
(en)
|
2014-07-11 |
2016-01-14 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
CN116617401A
(zh)
|
2014-07-15 |
2023-08-22 |
豪夫迈·罗氏有限公司 |
使用pd-1轴结合拮抗剂和mek抑制剂治疗癌症的组合物
|
US20170240631A1
(en)
|
2014-08-08 |
2017-08-24 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
TW201609099A
(zh)
|
2014-08-11 |
2016-03-16 |
艾森塔製藥公司 |
使用布魯頓(Bruton)氏酪胺酸激酶(BTK)抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
|
HRP20220738T1
(hr)
|
2014-08-11 |
2022-08-19 |
Acerta Pharma B.V. |
Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1
|
UA122395C2
(uk)
|
2014-08-19 |
2020-11-10 |
Мерк Шарп Енд Доум Корп. |
Антитіло проти tigit
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
WO2016026143A1
(en)
|
2014-08-22 |
2016-02-25 |
Huiru Wang |
Saccharide-based biomarkers and therapeutics
|
MX2017003247A
(es)
|
2014-09-15 |
2017-11-30 |
Amgen Inc |
Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
|
EP3193932B1
(de)
|
2014-09-15 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Antikörperformulierungen
|
ES2727656T3
(es)
|
2014-09-15 |
2019-10-17 |
Abvitro Llc |
Secuenciación de alto rendimiento de banco de nucleótidos
|
PL3110447T3
(pl)
|
2014-09-16 |
2020-10-19 |
Synermore Biologics Co., Ltd. |
Przeciwciało anty-EGFR i jego zastosowania
|
NZ730186A
(en)
|
2014-09-22 |
2020-04-24 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
TWI701435B
(zh)
|
2014-09-26 |
2020-08-11 |
日商中外製藥股份有限公司 |
測定fviii的反應性之方法
|
TWI700300B
(zh)
|
2014-09-26 |
2020-08-01 |
日商中外製藥股份有限公司 |
中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
GB201419108D0
(en)
|
2014-10-27 |
2014-12-10 |
Glythera Ltd |
Materials and methods relating to linkers for use in antibody drug conjugates
|
KR102626877B1
(ko)
|
2014-11-05 |
2024-01-19 |
애넥슨, 인코포레이티드 |
인간화 항-보체 인자 c1q 항체 및 이의 용도
|
BR112017008666A2
(pt)
|
2014-11-05 |
2018-01-30 |
Genentech, Inc. |
anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
|
SG11201703376QA
(en)
|
2014-11-06 |
2017-05-30 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
EP3632931A1
(de)
|
2014-11-07 |
2020-04-08 |
Sesen Bio, Inc. |
Verbesserte il-6-antikörper
|
WO2016073894A1
(en)
|
2014-11-07 |
2016-05-12 |
Eleven Biotherapeutics, Inc. |
Therapeutic agents with increased ocular retention
|
CN107172879B
(zh)
|
2014-11-10 |
2021-11-05 |
豪夫迈·罗氏有限公司 |
抗白细胞介素-33抗体及其用途
|
CN107105632A
(zh)
|
2014-11-10 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
肾病动物模型及其治疗剂
|
HUE061672T2
(hu)
|
2014-11-12 |
2023-08-28 |
Seagen Inc |
Glikán-interakcióban lévõ vegyületek és felhasználási módszerek
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
US10155820B2
(en)
|
2014-11-12 |
2018-12-18 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
CN107429075B
(zh)
|
2014-11-17 |
2022-11-01 |
卡内基梅隆大学 |
可激活的双组份光敏剂
|
WO2016079219A1
(en)
|
2014-11-19 |
2016-05-26 |
Koninklijke Philips N.V. |
Diagnostic method employing hnl
|
EP3221445B1
(de)
|
2014-11-20 |
2021-07-14 |
The Regents of The University of California |
Zusammensetzungen und verfahren in zusammenhang mit hämatologischer erholung
|
EP3581585A1
(de)
|
2014-11-26 |
2019-12-18 |
Millennium Pharmaceuticals, Inc. |
Vedolizumab zur behandlung von fistelbildendem morbus crohn
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
CN107206088A
(zh)
|
2014-12-05 |
2017-09-26 |
豪夫迈·罗氏有限公司 |
使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物
|
JP2017538412A
(ja)
|
2014-12-11 |
2017-12-28 |
インバイオモーション エセ.エレ. |
ヒトc−mafに対する結合メンバー
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
JP6827928B2
(ja)
|
2014-12-19 |
2021-02-10 |
ユニヴェルシテ・ドゥ・ナント |
抗il−34抗体
|
ES2881484T3
(es)
|
2014-12-22 |
2021-11-29 |
Pd 1 Acquisition Group Llc |
Anticuerpos anti-PD-1
|
EP3236994A1
(de)
|
2014-12-23 |
2017-11-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Alpha-zellenwiedererzeugung kombiniert mit umwandlung in beta-zellen
|
NL2014108B1
(en)
|
2015-01-09 |
2016-09-30 |
Aduro Biotech Holdings Europe B V |
Altered april binding antibodies.
|
SG10201906471PA
(en)
|
2015-01-14 |
2019-09-27 |
Brigham & Womens Hospital Inc |
Treatment of cancer with anti-lap monoclonal antibodies
|
JP2018506275A
(ja)
|
2015-01-28 |
2018-03-08 |
ジェネンテック, インコーポレイテッド |
多発性硬化症の遺伝子発現マーカー及び治療
|
SI3250230T1
(sl)
|
2015-01-28 |
2022-01-31 |
Ra Pharmaceuticals, Inc. |
Modulatorji aktivnosti komplementa
|
EP3253796A1
(de)
|
2015-02-03 |
2017-12-13 |
Université Catholique de Louvain |
Anti-garp-protein und verwendungen davon
|
MA41451A
(fr)
|
2015-02-04 |
2017-12-12 |
Univ Washington |
Constructions anti-tau
|
CN114773469A
(zh)
|
2015-02-05 |
2022-07-22 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
|
CN114891816A
(zh)
|
2015-02-06 |
2022-08-12 |
新加坡国立大学 |
核酸、包含其的工程免疫细胞及其制备方法和用途
|
WO2016128912A1
(en)
|
2015-02-12 |
2016-08-18 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
|
AU2016222928B2
(en)
|
2015-02-26 |
2021-05-13 |
Merck Patent Gmbh |
PD-1 / PD-L1 inhibitors for the treatment of cancer
|
CN113209289A
(zh)
|
2015-02-26 |
2021-08-06 |
豪夫迈·罗氏有限公司 |
治疗Crohn病的整联蛋白β7拮抗剂和方法
|
US10711067B2
(en)
|
2015-03-03 |
2020-07-14 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
MX2017011189A
(es)
|
2015-03-06 |
2018-01-23 |
Genentech Inc |
Dsba y dsbc ultrapurificado y métodos para elaborarlos y utilizarlos.
|
MA41636A
(fr)
|
2015-03-06 |
2018-01-09 |
Millennium Pharm Inc |
Méthode de traitement de la cholangite sclérosante primitive
|
WO2016146134A1
(en)
|
2015-03-16 |
2016-09-22 |
Aarhus Universitet |
Antibodies towards an extracellular region of nbcn1
|
WO2016145536A1
(en)
|
2015-03-18 |
2016-09-22 |
Immunobiochem Corporation |
Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
|
BR112017020091A2
(pt)
|
2015-03-20 |
2018-11-06 |
Aarhus Universitet |
inibidores de pcsk9 para tratamento de distúrbios do metabolismo de lipoproteínas
|
RU2682645C1
(ru)
|
2015-03-20 |
2019-03-20 |
Пфайзер Инк. |
Бифункциональные цитотоксические агенты, содержащие CTI фармакофор
|
WO2016159213A1
(ja)
|
2015-04-01 |
2016-10-06 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
US20180111989A1
(en)
|
2015-04-01 |
2018-04-26 |
Hadasit Medical Research Services And Development Ltd. |
Inhibitors of neuroligin 4 - neurexin 1-beta protein-protein interaction for treatment of liver disorders
|
CA3232651A1
(en)
|
2015-04-02 |
2016-10-06 |
Intervet International B.V. |
Antibodies to canine interleukin-4 receptor alpha
|
US11279768B1
(en)
|
2015-04-03 |
2022-03-22 |
Precision Biologics, Inc. |
Anti-cancer antibodies, combination therapies, and uses thereof
|
CN114456272A
(zh)
|
2015-04-03 |
2022-05-10 |
优瑞科生物技术公司 |
靶向afp肽/mhc复合体的构建体及其用途
|
US10167334B2
(en)
|
2015-04-03 |
2019-01-01 |
Xoma Technology Ltd. |
Treatment of cancer using anti-TGF-BETA and PD-1 antibodies
|
ES2901273T3
(es)
|
2015-04-06 |
2022-03-21 |
Subdomain Llc |
Polipéptidos que contienen dominios de unión de novo y usos de los mismos
|
BR112017021289A2
(pt)
|
2015-04-06 |
2018-06-26 |
Bioverativ Usa Inc |
anticorpos anti-c1s humanizados e métodos de uso dos mesmos
|
ES2899227T3
(es)
|
2015-04-07 |
2022-03-10 |
Alector Llc |
Anticuerpos anti sortilina y métodos de uso de los mismos
|
CN107709364A
(zh)
|
2015-04-07 |
2018-02-16 |
豪夫迈·罗氏有限公司 |
具有激动剂活性的抗原结合复合体及使用方法
|
EP3081575A1
(de)
|
2015-04-12 |
2016-10-19 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti-plasmodium-parasiten-antikörper
|
MX2017010734A
(es)
|
2015-04-17 |
2017-12-04 |
Hoffmann La Roche |
Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos.
|
JP7044553B2
(ja)
|
2015-04-24 |
2022-03-30 |
ジェネンテック, インコーポレイテッド |
結合ポリペプチドを含む細菌を特定する方法
|
CN116196414A
(zh)
|
2015-05-11 |
2023-06-02 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
WO2016184987A1
(en)
|
2015-05-19 |
2016-11-24 |
Yaya Diagnostics Gmbh |
Means and methods for the enrichment of nucleic acids
|
EP3718569B1
(de)
|
2015-05-22 |
2023-05-03 |
Translational Drug Development, LLC |
Benzamid- und aktivverbindungszusammensetzungen und verwendungsmethoden
|
WO2016189091A1
(en)
|
2015-05-26 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas
|
WO2016189118A1
(en)
|
2015-05-28 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
|
ES2823033T3
(es)
|
2015-05-28 |
2021-05-05 |
Genentech Inc |
Ensayo basado en células para detectar homodímeros anti-CD3
|
EP3303619B1
(de)
|
2015-05-29 |
2020-06-10 |
H. Hoffnabb-La Roche Ag |
Pd-l1-promotormethylierung bei krebs
|
AU2016273214B2
(en)
|
2015-06-01 |
2018-10-18 |
Medigene Immunotherapies Gmbh |
Method for generating antibodies against T cell receptor
|
EP3303389A1
(de)
|
2015-06-01 |
2018-04-11 |
Medigene Immunotherapies GmbH |
T-zell-rezeptor-spezifische antikörper
|
NZ737400A
(en)
|
2015-06-01 |
2019-09-27 |
Medigene Immunotherapies Gmbh |
T cell receptor library
|
WO2016197367A1
(en)
|
2015-06-11 |
2016-12-15 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
US11174313B2
(en)
|
2015-06-12 |
2021-11-16 |
Alector Llc |
Anti-CD33 antibodies and methods of use thereof
|
CA2988982A1
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
EP3310810A1
(de)
|
2015-06-16 |
2018-04-25 |
Merck Patent GmbH |
Kombinationsbehandlungen mit pd-l1-antagonisten
|
CN108473573A
(zh)
|
2015-06-29 |
2018-08-31 |
豪夫迈·罗氏有限公司 |
Ii型抗cd20抗体用于器官移植中
|
KR101750411B1
(ko)
|
2015-07-10 |
2017-06-27 |
한국생명공학연구원 |
엑소좀 단백질 eif3a 특이반응 오토항체검출용 항원 조성물 및 이를 이용한 간암진단법
|
US10287338B2
(en)
|
2015-07-10 |
2019-05-14 |
Miran NERSISSIAN |
Factor VIII protein compositions and methods of treating of hemophilia A
|
US10940204B2
(en)
|
2015-07-31 |
2021-03-09 |
Research Institute At Nationwide Children's Hospital |
Peptides and antibodies for the removal of biofilms
|
US11273167B2
(en)
|
2015-08-03 |
2022-03-15 |
The Regents Of The University Of California |
Compositions and methods for modulating ABHD2 activity
|
CA2994629A1
(en)
|
2015-08-05 |
2017-02-09 |
Acticor Biotech |
Novel anti-human gpvi antibodies and uses thereof
|
EP3152570A1
(de)
|
2015-08-06 |
2017-04-12 |
Yaya Diagnostics GmbH |
Vorrichtung und verfahren zur erkennung von zielen
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
KR102055396B1
(ko)
|
2015-08-11 |
2019-12-12 |
우시 바이올로직스 (케이만) 인코포레이티드 |
신규한 항-pd-1 항체
|
WO2017033113A1
(en)
|
2015-08-21 |
2017-03-02 |
Acerta Pharma B.V. |
Therapeutic combinations of a mek inhibitor and a btk inhibitor
|
EP3341411A1
(de)
|
2015-08-28 |
2018-07-04 |
Alector LLC |
Anti-siglec-7-antikörper und verfahren zur verwendung davon
|
WO2017037707A1
(en)
|
2015-09-02 |
2017-03-09 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
|
KR20180042412A
(ko)
|
2015-09-02 |
2018-04-25 |
이뮤텝 에스.에이.에스. |
항-lag-3 항체
|
EP3344657A1
(de)
|
2015-09-02 |
2018-07-11 |
The Regents of the University of Colorado, A Body Corporate |
Zusammensetzungen und verfahren zur modulation einer t-zell-vermittelten immunreaktion
|
AU2016323440B2
(en)
|
2015-09-15 |
2023-07-13 |
Amgen Inc. |
Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
|
US20190022092A1
(en)
|
2015-09-15 |
2019-01-24 |
Acerta Pharma B.V. |
Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
CA2993423C
(en)
|
2015-09-18 |
2024-03-12 |
Chugai Seiyaku Kabushiki Kaisha |
Il-8-binding antibodies and uses thereof
|
WO2017046335A1
(en)
|
2015-09-18 |
2017-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
T cell receptors (tcr) and uses thereof for the diagnosis and treatment of diabetes
|
JP7002446B2
(ja)
|
2015-09-21 |
2022-03-04 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
Cd3結合ポリペプチド
|
ES2940360T3
(es)
|
2015-09-22 |
2023-05-05 |
Inst Nat Sante Rech Med |
Polipéptidos capaces de inhibir la unión entre leptina y neuropilina-1
|
AU2016326666B2
(en)
|
2015-09-23 |
2023-06-15 |
Genentech, Inc. |
Optimized variants of anti-VEGF antibodies
|
WO2017050955A1
(en)
|
2015-09-24 |
2017-03-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Agents capable of inhibiting the binding between leptin and vegf165
|
CN108289954B
(zh)
|
2015-09-24 |
2022-05-31 |
阿布维特罗有限责任公司 |
Hiv抗体组合物和使用方法
|
KR20180085717A
(ko)
|
2015-09-24 |
2018-07-27 |
에이비비트로, 엘엘씨 |
친화성-올리고뉴클레오타이드 콘쥬게이트 및 그것의 사용
|
WO2018057051A1
(en)
|
2016-09-24 |
2018-03-29 |
Abvitro Llc |
Affinity-oligonucleotide conjugates and uses thereof
|
CN113774495A
(zh)
|
2015-09-25 |
2021-12-10 |
阿布维特罗有限责任公司 |
用于对天然配对t细胞受体序列进行t细胞受体靶向鉴别的高通量方法
|
WO2017058859A1
(en)
|
2015-09-29 |
2017-04-06 |
Celgene Corporation |
Pd-1 binding proteins and methods of use thereof
|
EP3356551B1
(de)
|
2015-09-29 |
2020-09-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur bestimmung der stoffwechsellage von b-lymphomen
|
WO2017058944A1
(en)
|
2015-09-29 |
2017-04-06 |
Amgen Inc. |
Asgr inhibitors
|
CA3000386A1
(en)
|
2015-09-30 |
2017-04-06 |
Merck Patent Gmbh |
Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
|
JP2018529747A
(ja)
|
2015-10-06 |
2018-10-11 |
ジェネンテック, インコーポレイテッド |
多発性硬化症を治療するための方法
|
AU2016334051B2
(en)
|
2015-10-06 |
2023-10-26 |
Alector Llc |
Anti-TREM2 antibodies and methods of use thereof
|
US10556953B2
(en)
|
2015-10-12 |
2020-02-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Agent capable of depleting CD8 T cells for the treatment of myocardial infarction or acute myocardial infarction
|
US11161912B2
(en)
|
2015-10-13 |
2021-11-02 |
Technion Research & Development Foundation Limited |
Heparanase-neutralizing monoclonal antibodies
|
EP3365027B1
(de)
|
2015-10-14 |
2022-03-30 |
Research Institute at Nationwide Children's Hospital |
Hu-spezifische antikörper und deren verwendeng zur hemmung von biofilm
|
WO2017067944A1
(en)
|
2015-10-19 |
2017-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from triple negative breast cancer
|
CN116003596A
(zh)
|
2015-10-29 |
2023-04-25 |
艾利妥 |
抗siglec-9抗体及其使用方法
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
KR102440160B1
(ko)
|
2015-10-30 |
2022-09-02 |
제넨테크, 인크. |
항-HtrA1 항체 및 이의 사용 방법
|
EP3370763B1
(de)
|
2015-11-03 |
2024-04-10 |
Regents of the University of Minnesota |
Cd200-hemmer und verfahren zur verwendung
|
CN116217729A
(zh)
|
2015-11-12 |
2023-06-06 |
思进公司 |
聚糖相互作用化合物及使用方法
|
JP6925278B2
(ja)
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
|
WO2017095823A1
(en)
|
2015-11-30 |
2017-06-08 |
The Regents Of The University Of California |
Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
|
US10954301B2
(en)
|
2015-12-14 |
2021-03-23 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
EP3390447A1
(de)
|
2015-12-15 |
2018-10-24 |
Amgen Inc. |
Pacap-antikörper und verwendungen davon
|
EP3390441B1
(de)
|
2015-12-15 |
2021-08-25 |
Gilead Sciences, Inc. |
Antikörper zur neutralisierung des humanen immundefizienzvirus
|
AU2016370210A1
(en)
|
2015-12-16 |
2018-06-21 |
Ra Pharmaceuticals, Inc. |
Modulators of complement activity
|
WO2017106129A1
(en)
|
2015-12-16 |
2017-06-22 |
Merck Sharp & Dohme Corp. |
Anti-lag3 antibodies and antigen-binding fragments
|
US20170174788A1
(en)
|
2015-12-17 |
2017-06-22 |
Gilead Sciences, Inc. |
Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
|
CN109152811A
(zh)
|
2015-12-18 |
2019-01-04 |
阿吉尔瓦克斯公司 |
与xCT肽相关的组合物和方法
|
US20190002516A1
(en)
|
2015-12-21 |
2019-01-03 |
Hefei Lifeon Pharmaceutical Co., Ltd. |
Drug Design Method, Obtained Drug and Application Thereof
|
KR20200100858A
(ko)
|
2015-12-23 |
2020-08-26 |
메디진 이뮤노테라피스 게엠바하 |
수지상 세포 조성물
|
CA3004288A1
(en)
|
2015-12-28 |
2017-07-06 |
Nobuyuki Tanaka |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
EP3400443B1
(de)
|
2016-01-04 |
2020-09-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verwendung von pd-1 und tim-3 zur messung von cd8+ zellen zur vorhersage und behandlung von nierenzellkarzinom
|
CA3010827A1
(en)
|
2016-01-07 |
2017-07-13 |
The Schepens Eye Research Institute, Inc. |
Therapeutics for ocular immunoinflammatory diseases
|
RU2766000C2
(ru)
|
2016-01-08 |
2022-02-07 |
АльтруБио Инк. |
Четырехвалентные антитела к psgl-1 и их применения
|
EP3402503B1
(de)
|
2016-01-13 |
2020-10-21 |
Acerta Pharma B.V. |
Therapeutische kombinationen aus einem antifolat und einem btk-hemmer
|
WO2017125897A1
(en)
|
2016-01-21 |
2017-07-27 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
RU2021129189A
(ru)
|
2016-01-22 |
2021-11-15 |
Мерк Шарп И Доум Корп. |
Антитела против фактора свертывания xi
|
WO2017129558A1
(en)
|
2016-01-25 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis
|
US11513127B2
(en)
|
2016-01-25 |
2022-11-29 |
Genentech, Inc. |
Methods for assaying T-cell dependent bispecific antibodies
|
US11028410B2
(en)
|
2016-01-27 |
2021-06-08 |
Just-Evotec Biologics, Inc. |
Hybrid promoter and uses thereof
|
EP4035681A1
(de)
|
2016-01-28 |
2022-08-03 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren und pharmazeutische zusammensetzung zur behandlung von krebs
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
ES2924741T3
(es)
|
2016-01-28 |
2022-10-10 |
Inst Nat Sante Rech Med |
Métodos para incrementar la potencia de los inhibidores del punto de control inmunitario
|
JP2019507126A
(ja)
|
2016-02-01 |
2019-03-14 |
ファイザー・インク |
ツブリシン類似体およびこれらの調製のための方法
|
WO2017139975A1
(en)
|
2016-02-19 |
2017-08-24 |
Huiru Wang |
Antibodies against n-acetylglucosamine and n-acetyl-galactosamine
|
US11066456B2
(en)
|
2016-02-25 |
2021-07-20 |
Washington University |
Compositions comprising TREM2 and methods of use thereof
|
MX2018010445A
(es)
|
2016-03-01 |
2019-10-17 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
Anticuerpos especificos del receptor de poliovirus humano (rvp).
|
WO2017152102A2
(en)
|
2016-03-04 |
2017-09-08 |
Alector Llc |
Anti-trem1 antibodies and methods of use thereof
|
US11340219B2
(en)
|
2016-03-17 |
2022-05-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-pY1235-MET immunological binding reagent
|
WO2017161976A1
(en)
|
2016-03-23 |
2017-09-28 |
Mabspace Biosciences (Suzhou) Co., Ltd |
Novel anti-pd-l1 antibodies
|
CN109843919A
(zh)
|
2016-03-25 |
2019-06-04 |
西雅图基因公司 |
用于制备聚乙二醇化的药物-接头及其中间体的方法
|
KR20230111268A
(ko)
|
2016-03-28 |
2023-07-25 |
인사이트 코포레이션 |
Tam 억제제로서 피롤로트리아진 화합물
|
EP3436070A4
(de)
|
2016-03-29 |
2019-11-27 |
University of Southern California |
Gegen krebs gerichtet chimäre antigenrezeptoren
|
US10883108B2
(en)
|
2016-03-31 |
2021-01-05 |
The Schepens Eye Research Institute, Inc. |
Endomucin inhibitor as an anti-angiogenic agent
|
WO2017173403A1
(en)
|
2016-03-31 |
2017-10-05 |
University Of Southern California |
A highly sensitive and specific luciferase based reporter assay for antigen detection
|
CN109563158B
(zh)
|
2016-04-04 |
2022-08-09 |
比奥贝拉蒂美国公司 |
抗补体因子bb抗体以及其用途
|
EP3439659A1
(de)
|
2016-04-06 |
2019-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von altersbedingten kardiometabolischen erkrankungen
|
JP2019513737A
(ja)
|
2016-04-08 |
2019-05-30 |
ギリアード サイエンシーズ, インコーポレイテッド |
がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法
|
US10954287B2
(en)
|
2016-04-15 |
2021-03-23 |
Ra Pharmaceuticals, Inc. |
Ras binding peptides and methods of use
|
US20190125826A1
(en)
|
2016-04-22 |
2019-05-02 |
Inserm (Institut National De La Santé Et De La Médicale) |
Methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency
|
WO2017189483A1
(en)
|
2016-04-25 |
2017-11-02 |
The Johns Hopkins University |
Znt8 assays for drug development and pharmaceutical compositions
|
US10875919B2
(en)
|
2016-04-26 |
2020-12-29 |
Alector Llc |
Chimeric receptors and methods of use thereof
|
WO2017191300A1
(en)
|
2016-05-06 |
2017-11-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (aml)
|
EP3454884B1
(de)
|
2016-05-10 |
2023-07-12 |
Sorbonne Université |
Wirkstoffe zur aktivierung von cd47 zur verwendung bei der behandlung von entzündungen
|
WO2017194554A1
(en)
|
2016-05-10 |
2017-11-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations therapies for the treatment of cancer
|
KR20190007026A
(ko)
|
2016-05-17 |
2019-01-21 |
제넨테크, 인크. |
면역요법에서의 진단 및 사용을 위한 기질 유전자 특질
|
US20190292259A1
(en)
|
2016-05-24 |
2019-09-26 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
|
BR112018073920A2
(pt)
|
2016-05-26 |
2019-02-26 |
Merck Patent Gmbh |
inibidores de pd-1/pd-l1 para tratamento de câncer".
|
WO2017202890A1
(en)
|
2016-05-27 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating myeloma
|
WO2017218371A1
(en)
|
2016-06-14 |
2017-12-21 |
Merck Sharp & Dohme Corp. |
Anti-coagulation factor xi antibodies
|
CN109563124A
(zh)
|
2016-06-17 |
2019-04-02 |
豪夫迈·罗氏有限公司 |
多特异性抗体的纯化
|
DK3264087T3
(da)
|
2016-06-27 |
2020-07-20 |
Chimera Biotec Gmbh |
Fremgangsmåde og indretning til kvantificering af målmolekyler
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
WO2018022479A1
(en)
|
2016-07-25 |
2018-02-01 |
Biogen Ma Inc. |
Anti-hspa5 (grp78) antibodies and uses thereof
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
JP7148493B2
(ja)
|
2016-08-01 |
2022-10-05 |
ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー |
副甲状腺ホルモン受容体1(pth1r)抗体およびその使用
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
WO2018025168A1
(en)
|
2016-08-03 |
2018-02-08 |
Pfizer Inc. |
Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
|
WO2018027124A1
(en)
|
2016-08-05 |
2018-02-08 |
Medimmune, Llc |
Anti-o2 antibodies and uses thereof
|
JP2019530434A
(ja)
|
2016-08-05 |
2019-10-24 |
ジェネンテック, インコーポレイテッド |
アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
|
CN115598231A
(zh)
|
2016-08-15 |
2023-01-13 |
豪夫迈·罗氏有限公司(Ch) |
定量包含非离子表面活性剂和多肽的组合物中非离子表面活性剂的层析方法
|
KR20200136503A
(ko)
|
2016-08-15 |
2020-12-07 |
노파르티스 아게 |
오파투무맙을 사용한 다발성 경화증의 치료 요법 및 방법
|
WO2018041989A1
(en)
|
2016-09-02 |
2018-03-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating refractory celiac disease type 2
|
MA46200A
(fr)
|
2016-09-06 |
2019-07-17 |
Chugai Pharmaceutical Co Ltd |
Procédés d'utilisation d'un anticorps bispécifique qui reconnaît le facteur de coagulation ix et/ou le facteur de coagulation ix activé et le facteur de coagulation x et/ou le facteur de coagulation x activé
|
EP3510046A4
(de)
|
2016-09-07 |
2020-05-06 |
The Regents of the University of California |
Antikörper gegen oxidationsspezifische epitope
|
EP3510398A1
(de)
|
2016-09-12 |
2019-07-17 |
Isoplexis Corporation |
System und verfahren zur multiplex-analyse von zellularen und anderen immunotherapeutika
|
HUE054571T2
(hu)
|
2016-09-14 |
2021-09-28 |
Merck Patent Gmbh |
Hatékony tumorgátlásra szolgáló C-MET elleni ellenanyagok és ellenanyag-drog konjugátumaik
|
DK3512878T3
(da)
|
2016-09-15 |
2020-12-21 |
Novimmune Sa |
Bispecifik antistoffremvisning på fagoverflade
|
BR112019005129A2
(pt)
|
2016-09-16 |
2019-06-04 |
Shanghai Henlius Biotech Inc |
anticorpos anti-pd-1
|
SG11201901950TA
(en)
|
2016-09-19 |
2019-04-29 |
Celgene Corp |
Methods of treating immune disorders using pd-1 binding proteins
|
JP2019534859A
(ja)
|
2016-09-19 |
2019-12-05 |
セルジーン コーポレイション |
Pd−1結合タンパク質を使用して白斑を治療する方法
|
KR20190049866A
(ko)
|
2016-09-20 |
2019-05-09 |
우시 바이올로직스 아일랜드 리미티드 |
신규한 항-pcsk9 항체
|
EP3515455B1
(de)
|
2016-09-20 |
2021-04-14 |
Aarhus Universitet |
Verbindungen zur behandlung von störungen des lipoproteinstoffwechsels
|
WO2018055031A1
(en)
|
2016-09-21 |
2018-03-29 |
Aarhus Universitet |
Acid-base transport inhibitors
|
EP3516071B1
(de)
|
2016-09-22 |
2021-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von lungenkrebs
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
MX2019003543A
(es)
|
2016-09-28 |
2019-06-17 |
Xoma Us Llc |
Anticuerpos que se fijan al interleucina-2 y sus usos.
|
GB201616699D0
(en)
|
2016-09-30 |
2016-11-16 |
Mab Designs Ltd |
Antibodies
|
CA3036714A1
(en)
|
2016-10-03 |
2018-04-12 |
Abbott Laboratories |
Improved methods of assessing uch-l1 status in patient samples
|
WO2018067754A1
(en)
|
2016-10-04 |
2018-04-12 |
Fairbanks Pharmaceuticals, Inc. |
Anti-fstl3 antibodies and uses thereof
|
CN109843324A
(zh)
|
2016-10-06 |
2019-06-04 |
辉瑞公司 |
用于治疗癌症的avelumab用药方案
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
KR20190064636A
(ko)
|
2016-10-19 |
2019-06-10 |
메디뮨 엘엘씨 |
항-o1 항체 및 이의 용도
|
US11186635B2
(en)
|
2016-10-25 |
2021-11-30 |
Institut National De La Santé Et De La Recherché Médical (Inserm) |
Monoclonal antibodies binding to the CD160 transmembrane isoform
|
JP7100030B2
(ja)
|
2016-10-28 |
2022-07-12 |
アスチュート メディカル,インコーポレイテッド |
腎機能の改善のためのtimp-2に対する抗体の使用
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
WO2018081815A2
(en)
|
2016-10-31 |
2018-05-03 |
Sofregen Medical, Inc. |
Compositions comprising silk fibroin particles and uses thereof
|
DK3538891T3
(da)
|
2016-11-11 |
2022-03-28 |
Isoplexis Corp |
Sammensætninger og fremgangsmåder til samtidig genomisk, transkriptomisk og proteomisk analyse af enkeltceller
|
US11229662B2
(en)
|
2016-11-15 |
2022-01-25 |
The Schepens Eye Research Institute, Inc. |
Compositions and methods for the treatment of aberrant angiogenesis
|
US11401330B2
(en)
|
2016-11-17 |
2022-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
CN116327963A
(zh)
|
2016-11-21 |
2023-06-27 |
济世-伊沃泰克生物制品有限公司 |
一种眼科制剂及其用途
|
EP3544601B1
(de)
|
2016-11-23 |
2024-03-20 |
Translational Drug Development, LLC |
Eine zusammensetzung, die ein benzamid und einen tnfrsf-agonisten umfasst, der an 4-1bb oder gitr bindet, und die verwendung derselben bei der behandlung von krebs.
|
US10759855B2
(en)
|
2016-12-02 |
2020-09-01 |
Rigel Pharmaceuticals, Inc. |
Antigen binding molecules to TIGIT
|
EP3548894B1
(de)
|
2016-12-02 |
2021-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und zusammensetzungen zur diagnose eines nierenzellkarzinoms
|
CN110087668A
(zh)
|
2016-12-07 |
2019-08-02 |
Ra制药公司 |
补体活性的调节剂
|
JP2020506716A
(ja)
|
2016-12-22 |
2020-03-05 |
ウニヴェルシタ・デリ・ストゥディ・マニャ・グレチア・カタンツァーロ |
Cd43の固有のシアログリコシル化がん関連エピトープを標的化するモノクローナル抗体
|
WO2018122245A1
(en)
|
2016-12-28 |
2018-07-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
|
WO2018122249A1
(en)
|
2016-12-28 |
2018-07-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
|
US20180230218A1
(en)
|
2017-01-04 |
2018-08-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
US11564982B2
(en)
|
2017-01-04 |
2023-01-31 |
Research Institute At Nationwide Children's Hospital |
DNABII vaccines and antibodies with enhanced activity
|
MX2019007963A
(es)
|
2017-01-06 |
2019-10-21 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumor (til) con agonistas de la superfamilia de recptor de factor de necrosis tumoral (tnfrsf) y combinaciones terapeuticas de til- y agonistas de tnfrsf.
|
JP2020503351A
(ja)
|
2017-01-06 |
2020-01-30 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
カリウムチャネルアゴニストによる腫瘍浸潤リンパ球の増殖及びその治療的使用
|
CA3049435A1
(en)
|
2017-01-09 |
2018-07-12 |
Scott Grindrod |
Selective histone deacetylase inhibitors for the treatment of human disease
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
WO2018132597A1
(en)
|
2017-01-12 |
2018-07-19 |
Eureka Therapeutics, Inc. |
Constructs targeting histone h3 peptide/mhc complexes and uses thereof
|
CN110461860A
(zh)
|
2017-01-24 |
2019-11-15 |
辉瑞公司 |
卡奇霉素衍生物及其抗体药物缀合物
|
WO2018141909A1
(en)
|
2017-02-03 |
2018-08-09 |
Acticor Biotech |
Inhibition of platelet aggregation using anti-human gpvi antibodies
|
JP6995127B2
(ja)
|
2017-02-10 |
2022-02-04 |
ジェネンテック, インコーポレイテッド |
抗トリプターゼ抗体、その組成物、及びその使用
|
WO2018146253A1
(en)
|
2017-02-10 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
EP3589319A4
(de)
|
2017-03-03 |
2021-07-14 |
Seagen Inc. |
Glycaninteragierende verbindungen und verfahren zur verwendung
|
CR20190468A
(es)
|
2017-03-14 |
2019-12-17 |
Bioverativ Usa Inc |
Métodos para tratar enfermedades y trastornos mediados por completo
|
CN111010875B
(zh)
|
2017-03-15 |
2024-04-05 |
库尔生物制药有限公司 |
用于调节免疫应答的方法
|
US10941203B2
(en)
|
2017-03-15 |
2021-03-09 |
Tsinghua University |
Anti-TrkB agonist antibodies binding to D5 domain of TrkB and methods of promoting neuronal survival in motor neuron injury, stroke or glaucoma
|
WO2018170178A1
(en)
|
2017-03-15 |
2018-09-20 |
Research Institute At Nationwide Children's Hospital |
Composition and methods for disruption of bacterial biofilms without accompanying inflammation
|
AR111190A1
(es)
|
2017-03-22 |
2019-06-12 |
Genentech Inc |
Composiciones en hidrogel de prodrogas entrecruzadas de ácido hialurónico y métodos relacionados
|
JP7227151B2
(ja)
|
2017-03-22 |
2023-02-21 |
ジェネンテック, インコーポレイテッド |
眼障害の治療のために最適化された抗体組成物
|
CA3052513A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
MX2019010769A
(es)
|
2017-03-24 |
2019-12-11 |
Seattle Genetics Inc |
Proceso para la preparacion de enlazadores de farmacos de glucuronidos y compuestos intermediarios de los mismos.
|
WO2018172508A1
(en)
|
2017-03-24 |
2018-09-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2018178029A1
(en)
|
2017-03-27 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
|
WO2018178030A1
(en)
|
2017-03-27 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
|
JP7166278B2
(ja)
|
2017-03-30 |
2022-11-07 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
がんの治療のための抗pd-l1抗体およびdna-pkインヒビターの併用
|
WO2018178237A1
(en)
|
2017-03-30 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of mitochondrial genetic diseases
|
US20190048055A1
(en)
|
2017-03-31 |
2019-02-14 |
Altor Bioscience Corporation |
Alt-803 in combination with anti-cd38 antibody for cancer therapies
|
EP3606518A4
(de)
|
2017-04-01 |
2021-04-07 |
The Broad Institute, Inc. |
Verfahren und zusammensetzungen zur detektion und zur modulation einer immuntherapieresistenzgensignatur in krebs
|
EP3609922A2
(de)
|
2017-04-13 |
2020-02-19 |
Aduro Biotech Holdings, Europe B.V. |
Anti-sirp-alpha-antikörper
|
JP7289420B6
(ja)
|
2017-04-14 |
2023-06-30 |
エクセリクシス, インク. |
肺癌を予防又は処置する為のamhrii結合性化合物
|
CA3058282A1
(en)
|
2017-04-14 |
2018-10-18 |
Gamamabs Pharma |
Amhrii-binding compounds for preventing or treating cancers
|
JP7344797B2
(ja)
|
2017-04-15 |
2023-09-14 |
アボット・ラボラトリーズ |
早期バイオマーカーを使用する、ヒト対象における外傷性脳損傷の、超急性の診断及び決定の一助となるための方法
|
EP3612625A4
(de)
|
2017-04-21 |
2021-08-18 |
Mellitus, LLC |
Verfahren und antikörper für mit diabetes assoziierte anwendungen
|
EP3615569A1
(de)
|
2017-04-25 |
2020-03-04 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antikörper und verfahren zur diagnose und behandlung von epstein-barr-virus-infektionen
|
SG11201909728XA
(en)
|
2017-04-26 |
2019-11-28 |
Eureka Therapeutics Inc |
Constructs specifically recognizing glypican 3 and uses thereof
|
JP2020517695A
(ja)
|
2017-04-27 |
2020-06-18 |
テサロ, インコーポレイテッド |
リンパ球活性化遺伝子−3(lag−3)に対する抗体薬およびそれらの使用
|
JP7080899B2
(ja)
|
2017-04-28 |
2022-06-06 |
アボット・ラボラトリーズ |
同じヒト対象に由来する少なくとも2つの試料に対して早期バイオマーカーを使用する、外傷性脳損傷の超急性の診断及び決定の一助となるための方法
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
WO2018209115A1
(en)
|
2017-05-10 |
2018-11-15 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
WO2019103857A1
(en)
|
2017-11-22 |
2019-05-31 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
GB201707561D0
(en)
|
2017-05-11 |
2017-06-28 |
Argenx Bvba |
GARP-TGF-beta antibodies
|
WO2018213316A1
(en)
|
2017-05-16 |
2018-11-22 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
AU2018272054A1
(en)
|
2017-05-25 |
2019-09-26 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
WO2018218222A1
(en)
|
2017-05-26 |
2018-11-29 |
Goldfless Stephen Jacob |
High-throughput polynucleotide library sequencing and transcriptome analysis
|
BR112019025313A2
(pt)
|
2017-05-30 |
2020-06-23 |
Abbott Laboratories |
Métodos para auxílio no diagnóstico e avaliação de uma lesão cerebral traumática leve em um indivíduo humano usando troponina cardíaca i
|
EP3638218A4
(de)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
Zusammensetzungen und verfahren zum targeting von komplementierender komponente 3 zur hemmung des tumorwachstums
|
US11325957B2
(en)
|
2017-06-19 |
2022-05-10 |
Cell Design Labs, Inc. |
Methods and compositions for reducing the immunogenicity of chimeric notch receptors
|
WO2018234843A1
(en)
|
2017-06-22 |
2018-12-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS WITH AGENTS CAPABLE OF INHIBITING THE ACTIVATION OF MOSES-ASSOCIATED INVARIANT T CELLS (MAIT)
|
CA3065954A1
(en)
|
2017-06-27 |
2019-01-03 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identifying and treating resistance to ctla4 antagonists in leukemia
|
WO2019002548A1
(en)
|
2017-06-29 |
2019-01-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
TREATMENT OF MIGRAINE WITH TREK1, TREK2 AGONIZATION OR HETEROMERS COMPRISING SAME
|
EP3649474A1
(de)
|
2017-07-03 |
2020-05-13 |
Abbott Laboratories |
Verbesserte verfahren zur messung von ubiquitin-carboxy-terminalen hydrolase-l1-konzentrationen in blut
|
CN111050808A
(zh)
|
2017-07-06 |
2020-04-21 |
纪念斯隆-凯特林癌症中心 |
用于抗dota/抗肿瘤抗原双特异性抗体预靶向放射免疫治疗的dota-半抗原组合物
|
US11892457B2
(en)
|
2017-07-12 |
2024-02-06 |
The Johns Hopkins University |
Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
|
CN111094334A
(zh)
|
2017-07-19 |
2020-05-01 |
美国卫生与公众服务部 |
用于诊断和治疗乙肝病毒感染的抗体和方法
|
WO2019018729A1
(en)
|
2017-07-20 |
2019-01-24 |
Dana-Farber Cancer Institute, Inc. |
COMPOSITIONS AND METHODS FOR IDENTIFICATION AND TREATMENT OF NEUROENDOCRINE METASTATIC TUMORS OF INTESTINAL HAIL
|
WO2019016310A1
(en)
|
2017-07-20 |
2019-01-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND COMPOSITIONS FOR TREATING CANCERS
|
EP3658173A1
(de)
|
2017-07-25 |
2020-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzungen zur modulation von monozytopoese
|
WO2019023525A1
(en)
|
2017-07-28 |
2019-01-31 |
Dana-Farber Cancer Institute, Inc. |
ENHANCED IMMUNOTHERAPY OF CANCER USING TARGETED TRANSCRIPTION MODULATORS
|
WO2019020807A1
(en)
|
2017-07-28 |
2019-01-31 |
Gene Signal International Sa |
CD9P-1 TARGETING ANTIBODIES AND USES THEREOF
|
JP2020533948A
(ja)
|
2017-08-03 |
2020-11-26 |
アレクトル エルエルシー |
抗trem2抗体及びその使用方法
|
KR20200033798A
(ko)
|
2017-08-03 |
2020-03-30 |
알렉터 엘엘씨 |
항-cd33 항체 및 이의 이용 방법
|
US11085929B2
(en)
|
2017-08-31 |
2021-08-10 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Nanoshell-structured material as co-matrix for peptide characterization in mass spectrometry
|
JP7317023B2
(ja)
|
2017-09-20 |
2023-07-28 |
ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア |
新規抗hla-a2抗体、およびその使用
|
WO2019057742A1
(en)
|
2017-09-20 |
2019-03-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF AUTOPHAGIA
|
US11897917B2
(en)
|
2017-09-27 |
2024-02-13 |
The University Of York |
Bioconjugation of polypeptides
|
EP3690050A4
(de)
|
2017-09-29 |
2021-06-16 |
Chugai Seiyaku Kabushiki Kaisha |
Multispezifisches antigenbindendes molekül mit blutgerinnungsfaktor viii (fviii)-cofaktorfunktionssubstituierender aktivität und pharmazeutische formulierung mit diesem molekül als wirkstoff
|
CN117430699A
(zh)
|
2017-09-30 |
2024-01-23 |
合肥立方制药股份有限公司 |
结合至纤维连接蛋白b结构域的蛋白
|
EP3691656A1
(de)
|
2017-10-06 |
2020-08-12 |
Camp4 Therapeutics Corporation |
Verfahren und zusammensetzungen zur behandlung von harnstoffzyklusstörungen, insbesondere von otc-mangel
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
WO2019075270A1
(en)
|
2017-10-12 |
2019-04-18 |
Amesino Llc |
VEGFR ANTIBODY LIGHT CHAIN FUSION PROTEIN
|
WO2019079362A1
(en)
|
2017-10-16 |
2019-04-25 |
Massachusetts Institute Of Technology |
HOST-PATHOGENIC INTERACTION OF MYCOBACTERIUM TUBERCULOSIS
|
WO2019084460A1
(en)
|
2017-10-26 |
2019-05-02 |
The Regents Of The University Of California |
INHIBITION OF OXIDATION-SPECIFIC EPITOPES TO TREAT ISCHEMIC REPERFUSION INJURY
|
GB201717966D0
(en)
|
2017-10-31 |
2017-12-13 |
Xenikos Bv |
Immunotoxins, formulations thereof and their use in medicine
|
CA3082365A1
(en)
|
2017-11-09 |
2019-05-16 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
CA3082643A1
(en)
|
2017-11-14 |
2019-05-23 |
The Schepens Eye Research Institute, Inc. |
Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
|
AU2018369639A1
(en)
|
2017-11-14 |
2020-04-23 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
AR113696A1
(es)
|
2017-11-17 |
2020-06-03 |
Merck Sharp & Dohme |
Anticuerpos específicos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos
|
JP7183268B2
(ja)
|
2017-11-20 |
2022-12-05 |
ジャスト-エヴォテック バイオロジックス、インコーポレイテッド |
等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
|
WO2019101995A1
(en)
|
2017-11-27 |
2019-05-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for cardiac regeneration
|
WO2019102456A1
(en)
|
2017-11-27 |
2019-05-31 |
University Of Rijeka Faculty Of Medicine |
Immunotoxins for treating cancer
|
US11332736B2
(en)
|
2017-12-07 |
2022-05-17 |
The Broad Institute, Inc. |
Methods and compositions for multiplexing single cell and single nuclei sequencing
|
BR112020010085A2
(pt)
|
2017-12-09 |
2020-10-13 |
Abbott Laboratories |
métodos para auxiliar no diagnóstico e avaliar uma lesão cerebral traumática em um indivíduo humano usando uma combinação de gfap e uch-l1
|
CA3067057A1
(en)
|
2017-12-09 |
2019-06-13 |
Abbott Laboratories |
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
|
RU2020122822A
(ru)
|
2017-12-12 |
2022-01-13 |
Макродженикс, Инк. |
Биспецифичные связывающие cd16 молекулы и их применение при лечении заболеваний
|
WO2019118873A2
(en)
|
2017-12-15 |
2019-06-20 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
EP3498293A1
(de)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Behandlung monogener erkrankungen mit einem anti-cd45rc-antikörper
|
MX2020006372A
(es)
|
2017-12-19 |
2020-09-03 |
Univ Rockefeller |
Variantes de dominio de fc de igg humana con funcion efectora mejorada.
|
US11905327B2
(en)
|
2017-12-28 |
2024-02-20 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against TIGIT
|
KR20200104886A
(ko)
|
2017-12-28 |
2020-09-04 |
난징 레전드 바이오테크 씨오., 엘티디. |
Pd-l1에 대한 항체 및 변이체
|
JP7437303B2
(ja)
|
2017-12-29 |
2024-02-22 |
アボット・ラボラトリーズ |
外傷性脳損傷を診断及び査定するための、新規のバイオマーカー及び方法
|
CN108218990B
(zh)
|
2017-12-29 |
2021-03-02 |
南京优迈生物科技有限公司 |
分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
|
US20210072244A1
(en)
|
2018-01-04 |
2021-03-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma resistant
|
SG11202004233UA
(en)
|
2018-01-15 |
2020-06-29 |
Nanjing Legend Biotech Co Ltd |
Single-domain antibodies and variants thereof against pd-1
|
WO2019145413A1
(en)
|
2018-01-25 |
2019-08-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antagonists of il-33 for use in methods for preventing ischemia reperfusion injury in an organ
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
JP7418337B2
(ja)
|
2018-02-09 |
2024-01-19 |
ジェネンテック, インコーポレイテッド |
マスト細胞媒介性炎症性疾患の治療法及び診断法
|
JP2021512962A
(ja)
|
2018-02-13 |
2021-05-20 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
アデノシンa2a受容体アンタゴニストによる腫瘍浸潤性リンパ球(til)の拡大培養並びにtil及びアデノシンa2a受容体アンタゴニストの治療的組み合わせ
|
JP7337079B2
(ja)
|
2018-02-15 |
2023-09-01 |
マクロジェニクス,インコーポレーテッド |
変異型cd3結合ドメイン、及び疾患の治療のための併用療法におけるその使用
|
EP3752134A1
(de)
|
2018-02-16 |
2020-12-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und zusammensetzungen zur behandlung von vitiligo
|
WO2019164979A1
(en)
|
2018-02-21 |
2019-08-29 |
Cell Design Labs, Inc. |
Chimeric transmembrane receptors and uses thereof
|
TW202000702A
(zh)
|
2018-02-26 |
2020-01-01 |
美商建南德克公司 |
用於抗tigit拮抗劑抗體及抗pd-l1拮抗劑抗體治療之投藥
|
JP7474709B2
(ja)
|
2018-02-27 |
2024-04-25 |
インサイト・コーポレイション |
A2a/a2b阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン
|
NL2020520B1
(en)
|
2018-03-02 |
2019-09-12 |
Labo Bio Medical Invest B V |
Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
|
SG11202006674QA
(en)
|
2018-03-30 |
2020-08-28 |
Nanjing Legend Biotech Co Ltd |
Single-domain antibodies against lag-3 and uses thereof
|
WO2019193375A1
(en)
|
2018-04-04 |
2019-10-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of fzd7 inhibitors for the treatment of retinal neovascularization
|
EP3774883A1
(de)
|
2018-04-05 |
2021-02-17 |
Gilead Sciences, Inc. |
Antikörper und fragmente davon, die hepatitis-b-virus-protein x binden
|
US10640576B2
(en)
|
2018-04-10 |
2020-05-05 |
Y-Biologics Inc. |
Cell engaging binding molecules
|
US11648317B2
(en)
|
2018-04-13 |
2023-05-16 |
Genentech, Inc. |
Stable anti-CD79B immunoconjugate formulations
|
BR112020020919A2
(pt)
|
2018-04-13 |
2021-04-06 |
Sangamo Therapeutics France |
Receptor de antígeno quimérico específico para receptor de interleucina-23
|
WO2019207030A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
US20210171610A1
(en)
|
2018-05-02 |
2021-06-10 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
US20210239700A1
(en)
|
2018-05-04 |
2021-08-05 |
Abbott Laboratories |
Hbv diagnostic, prognostic, and therapeutic methods and products
|
EP3787683A1
(de)
|
2018-05-04 |
2021-03-10 |
Merck Patent GmbH |
Kombinierte inhibierung von pd-1/pd-l1, tgfss und dna-pk zur behandlung von krebs
|
US20210386829A1
(en)
|
2018-05-04 |
2021-12-16 |
The Broad Institute, Inc. |
Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
|
CN112088167A
(zh)
|
2018-05-09 |
2020-12-15 |
耶路撒冷希伯来大学伊森姆研究发展有限公司 |
特异性针对人类连接蛋白4的抗体
|
US11168089B2
(en)
|
2018-05-18 |
2021-11-09 |
Incyte Corporation |
Fused pyrimidine derivatives as A2A / A2B inhibitors
|
WO2019224716A2
(en)
|
2018-05-23 |
2019-11-28 |
Pfizer Inc. |
Antibodies specific for gucy2c and uses thereof
|
KR102602329B1
(ko)
|
2018-05-23 |
2023-11-16 |
화이자 인코포레이티드 |
Cd3에 특이적인 항체 및 이의 용도
|
KR102480815B1
(ko)
|
2018-05-31 |
2022-12-26 |
글라이코넥스 인코포레이티드 |
바이안테나리 루이스 b 및 루이스 y 항원에 결합하는 치료 항체
|
GB201808927D0
(en)
|
2018-05-31 |
2018-07-18 |
Institute Of Cancer Res Royal Cancer Hospital |
Materials and methods for monitoring the development of resistance of cancers to treatment
|
EP3802611A2
(de)
|
2018-06-01 |
2021-04-14 |
Novartis AG |
Bindungsmoleküle gegen bcma und deren verwendungen
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
WO2019236965A1
(en)
|
2018-06-08 |
2019-12-12 |
Alector Llc |
Anti-siglec-7 antibodies and methods of use thereof
|
TW202016151A
(zh)
|
2018-06-09 |
2020-05-01 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
EP4349411A2
(de)
|
2018-06-20 |
2024-04-10 |
Incyte Corporation |
Anti-pd-1-antikörper und verwendungen davon
|
AR117600A1
(es)
|
2018-06-29 |
2021-08-18 |
Incyte Corp |
Formulaciones de un inhibidor de axl / mer
|
CR20200653A
(es)
|
2018-07-03 |
2021-02-11 |
Gilead Sciences Inc |
Anticuerpos que se dirigen al gp120 de vih y métodos de uso
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
ES2940311T3
(es)
|
2018-07-13 |
2023-05-05 |
Alector Llc |
Anticuerpos anti-sortilina y métodos de uso de los mismos
|
WO2020021061A1
(en)
|
2018-07-26 |
2020-01-30 |
Pieris Pharmaceuticals Gmbh |
Humanized anti-pd-1 antibodies and uses thereof
|
MX2021000933A
(es)
|
2018-07-27 |
2021-05-27 |
Alector Llc |
Anticuerpos anti-siglec-5 y métodos para su uso.
|
PL3830120T3
(pl)
|
2018-07-31 |
2023-10-09 |
Pieris Pharmaceuticals Gmbh |
NOWE BIAŁKO FUZYJNE SWOISTE WOBEC CD137 i PD-L1
|
CA3109253A1
(en)
|
2018-08-10 |
2020-02-13 |
Sangamo Therapeutics France |
New car constructs comprising tnfr2 domains
|
CN113166241A
(zh)
|
2018-08-16 |
2021-07-23 |
约翰霍普金斯大学 |
人类znt8抗体
|
EP3843849A1
(de)
|
2018-08-27 |
2021-07-07 |
Pieris Pharmaceuticals GmbH |
Kombinationstherapien mit cd137- und her2-bispezifischen mitteln und pd-1-achseninhibitoren und deren verwendungen
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
WO2020048454A1
(zh)
|
2018-09-04 |
2020-03-12 |
南京优迈生物科技有限公司 |
融合蛋白及其在制备用于治疗肿瘤和/或病毒感染的药物中的应用
|
EP3849545A1
(de)
|
2018-09-10 |
2021-07-21 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren zur behandlung von neurofibromatose
|
EP3853251A1
(de)
|
2018-09-19 |
2021-07-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzung zur behandlung von krebserkrankungen mit resistenz gegen immun-checkpoint-therapie
|
KR20210064269A
(ko)
|
2018-09-20 |
2021-06-02 |
이오반스 바이오테라퓨틱스, 인크. |
동결보존된 종양 샘플로부터의 til의 확장
|
EP3626265A1
(de)
|
2018-09-21 |
2020-03-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-human-cd45rc-antikörper und verwendungen davon
|
WO2020064702A1
(en)
|
2018-09-25 |
2020-04-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
|
CN112839957A
(zh)
|
2018-09-28 |
2021-05-25 |
协和麒麟株式会社 |
Il-36抗体及其用途
|
WO2020070062A1
(en)
|
2018-10-01 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
|
EP3861022A1
(de)
|
2018-10-04 |
2021-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzung zur behandlung von autoimmun-augenkrankheiten
|
CN112771074A
(zh)
|
2018-10-05 |
2021-05-07 |
国家儿童医院研究所 |
用于酶促破坏细菌生物膜的组合物和方法
|
JP2022512648A
(ja)
|
2018-10-09 |
2022-02-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
心筋線維化の処置のためのαV-インテグリン(CD51)阻害剤の使用
|
WO2020076969A2
(en)
|
2018-10-10 |
2020-04-16 |
Tilos Therapeutics, Inc. |
Anti-lap antibody variants and uses thereof
|
US20220411783A1
(en)
|
2018-10-12 |
2022-12-29 |
The Broad Institute, Inc. |
Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
US20210386788A1
(en)
|
2018-10-24 |
2021-12-16 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
US20210395751A1
(en)
|
2018-10-31 |
2021-12-23 |
The University Of Sydney |
Compositions and methods for treating viral infections
|
CA3118453A1
(en)
|
2018-11-02 |
2020-05-07 |
The Regents Of The University Of California |
Compositions and methods for treating brain injury
|
TW202039831A
(zh)
|
2018-11-05 |
2020-11-01 |
美商艾歐凡斯生物治療公司 |
對抗pd-1抗體呈現難治性之非小細胞肺癌(nsclc)病患之治療
|
EP3877511A1
(de)
|
2018-11-05 |
2021-09-15 |
Iovance Biotherapeutics, Inc. |
Expansion von tils unter verwendung von akt-signalweg-inhibitoren
|
GB201818622D0
(en)
|
2018-11-15 |
2019-01-02 |
Amlo Biosciences Ltd |
Monoclonal antibodies against loricrin
|
GB201818618D0
(en)
|
2018-11-15 |
2019-01-02 |
Amlo Biosciences Ltd |
Monoclonal antibodies against ambra-1
|
WO2020104479A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
|
WO2020115261A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
AU2019402163A1
(en)
|
2018-12-20 |
2021-07-08 |
Kyowa Kirin Co., Ltd. |
Fn14 antibodies and uses thereof
|
WO2020127885A1
(en)
|
2018-12-21 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions for treating cancers and resistant cancers
|
MX2021008121A
(es)
|
2019-01-03 |
2021-12-10 |
Inst Nat Sante Rech Med |
Metodos y composiciones farmaceuticas para mejorar las respuestas inmunitarias dependientes de celulas t cd8+ en sujetos que sufren de cancer.
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
WO2020146740A1
(en)
|
2019-01-10 |
2020-07-16 |
Iovance Biotherapeutics, Inc. |
System and methods for monitoring adoptive cell therapy clonality and persistence
|
AU2020207664A1
(en)
|
2019-01-13 |
2021-07-22 |
University Of Rijeka Faculty Of Medicine |
Antibodies specific to human Nectin-2
|
US11680105B2
(en)
|
2019-01-17 |
2023-06-20 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
JP2022518796A
(ja)
|
2019-01-28 |
2022-03-16 |
メイプル バイオテック エルエルシー |
肺、腎臓、または肝臓の線維症疾患の処置に使用するためのpsmpアンタゴニスト
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
CN116063520A
(zh)
|
2019-01-30 |
2023-05-05 |
真和制药有限公司 |
抗gal3抗体及其用途
|
WO2020161083A1
(en)
|
2019-02-04 |
2020-08-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating blood-brain barrier
|
KR20210128443A
(ko)
|
2019-02-15 |
2021-10-26 |
인테그럴 몰큘러 인코포레이티드 |
클라우딘 6 항체 및 이의 용도
|
WO2020168315A1
(en)
|
2019-02-15 |
2020-08-20 |
Just-Evotec Biologics, Inc. |
Automated biomanufacturing systems, facilities, and processes
|
WO2020168024A1
(en)
|
2019-02-15 |
2020-08-20 |
Integral Molecular, Inc. |
Antibodies comprising a common light chain and uses thereof
|
CN113454457A
(zh)
|
2019-02-18 |
2021-09-28 |
株式会社Nb健康研究所 |
细胞的筛选方法、核酸的制造方法、重组细胞的制造方法、目标物质的制造方法、药物组合物的制造方法及试剂
|
EP3931209A1
(de)
|
2019-02-26 |
2022-01-05 |
Pieris Pharmaceuticals GmbH |
Neuartige fusionsproteine spezifisch für cd137 und gpc3
|
MX2021010313A
(es)
|
2019-02-27 |
2021-09-23 |
Genentech Inc |
Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
|
BR112021016875A2
(pt)
|
2019-03-01 |
2022-01-04 |
Iovance Biotherapeutics Inc |
Processo para expansão de linfócitos de sangue periférico
|
AU2020231308A1
(en)
|
2019-03-01 |
2021-08-19 |
Allogene Therapeutics, Inc. |
DLL3 targeting chimeric antigen receptors and binding agents
|
EP3935391B1
(de)
|
2019-03-05 |
2024-04-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Biomarker im nierenzellkarzinom
|
WO2020186101A1
(en)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
WO2020186235A1
(en)
|
2019-03-14 |
2020-09-17 |
The Broad Institute, Inc. |
Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells
|
EP3942023A1
(de)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Zusammensetzungen und verfahren zur modulation metabolischer regulatoren der t-zell-pathogenität
|
WO2020191069A1
(en)
|
2019-03-18 |
2020-09-24 |
The Broad Institute, Inc. |
Modulation of type 2 immunity by targeting clec-2 signaling
|
CN113613676A
(zh)
|
2019-03-19 |
2021-11-05 |
中外制药株式会社 |
包含对抗原的结合活性因mta而变化的抗原结合结构域的抗原结合分子及用于获得该抗原结合结构域的文库
|
EP3942026A1
(de)
|
2019-03-22 |
2022-01-26 |
Université de Paris |
Neue inhibitoren der lrrk2/pp1-interaktion
|
WO2020194317A1
(en)
|
2019-03-28 |
2020-10-01 |
Yeda Research And Development Co. Ltd. |
Method of treating lipid-related disorders
|
WO2020201073A1
(en)
|
2019-03-29 |
2020-10-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
|
EP3946417A1
(de)
|
2019-03-29 |
2022-02-09 |
Pieris Pharmaceuticals GmbH |
Inhalierte verabreichung von lipocalin-muteinen
|
JP2022521840A
(ja)
|
2019-04-01 |
2022-04-12 |
ジェネンテック, インコーポレイテッド |
タンパク質含有製剤を安定化するための組成物および方法
|
JP2022527860A
(ja)
|
2019-04-02 |
2022-06-06 |
ケンジョッケティ バイオテクノロジー,インク. |
排出ポンプ-癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法
|
EP3947737A2
(de)
|
2019-04-02 |
2022-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur vorhersage und vorbeugung von krebs bei patienten mit prämalignen läsionen
|
MA55529A
(fr)
|
2019-04-03 |
2022-02-09 |
Genzyme Corp |
Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
|
US20220175815A1
(en)
|
2019-04-03 |
2022-06-09 |
Orega Biotech |
Combination therapies based on pd1 and il-17b inhibitors
|
MX2021012160A
(es)
|
2019-04-08 |
2022-01-06 |
Biogen Ma Inc |
Anticuerpos antiintegrina y usos de los mismos.
|
EP3956664A1
(de)
|
2019-04-18 |
2022-02-23 |
Genentech, Inc. |
Antikörperpotenztest
|
WO2020221796A1
(en)
|
2019-04-30 |
2020-11-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
GB201906302D0
(en)
|
2019-05-03 |
2019-06-19 |
Amlo Biosciences Ltd |
Methods of determining the margin of a tumour
|
EP3962924A1
(de)
|
2019-05-03 |
2022-03-09 |
Genentech, Inc. |
Verfahren zur verminderung der enzymatischen hydrolyseaktivitätsrate in einer aus einer reinigungsplattform erhaltenen zusammensetzung
|
GB201906297D0
(en)
|
2019-05-03 |
2019-06-19 |
Amlo Biosciences Ltd |
Biomarkers for disease progression in squamous cell carcinoma
|
US20240124889A1
(en)
|
2019-05-07 |
2024-04-18 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
KR20220006519A
(ko)
|
2019-05-10 |
2022-01-17 |
다케다 야쿠힌 고교 가부시키가이샤 |
항체 약물 접합체
|
WO2020234399A1
(en)
|
2019-05-20 |
2020-11-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Novel anti-cd25 antibodies
|
JOP20210309A1
(ar)
|
2019-05-21 |
2023-01-30 |
Novartis Ag |
جزيئات ربط بـ cd19 واستخدامتها
|
US20220396631A1
(en)
|
2019-05-21 |
2022-12-15 |
Lu HUANG |
Trispecific binding molecules against bcma and uses thereof
|
TWI762925B
(zh)
|
2019-05-21 |
2022-05-01 |
美商基利科學股份有限公司 |
鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
|
EP3972993A1
(de)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Variante cd58-domänen und deren verwendungen
|
CA3141452A1
(en)
|
2019-05-24 |
2020-12-03 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
JP2022534889A
(ja)
|
2019-05-24 |
2022-08-04 |
ファイザー・インコーポレイテッド |
Cdk阻害剤を使用した組合せ療法
|
WO2020237491A1
(en)
|
2019-05-28 |
2020-12-03 |
Shanghaitech University |
Composition and methods to treat ectodermal dysplasia 2, clouston type
|
MX2021014534A
(es)
|
2019-05-30 |
2022-02-11 |
Amgen Inc |
Modificación por ingeniería genética de la región bisagra para impulsar la dimerización de anticuerpos.
|
US20220243178A1
(en)
|
2019-05-31 |
2022-08-04 |
The Broad Institute, Inc. |
Methods for treating metabolic disorders by targeting adcy5
|
TW202100560A
(zh)
|
2019-06-04 |
2021-01-01 |
大陸商上海吉倍生物技術有限公司 |
一種抗ceacam5 的單殖株抗體及其製備方法和用途
|
AR119264A1
(es)
|
2019-06-05 |
2021-12-09 |
Genentech Inc |
Método para reutilización de cromatografía
|
CN114008713A
(zh)
|
2019-06-07 |
2022-02-01 |
中外制药株式会社 |
信息处理系统、信息处理方法、程序、以及制备抗原结合分子或蛋白质的方法
|
AU2020304671A1
(en)
|
2019-06-28 |
2022-01-20 |
Amgen Inc. |
Anti-CGRP receptor/anti-PAC1 receptor bispecific antigen binding proteins
|
US20220275064A1
(en)
|
2019-07-08 |
2022-09-01 |
Research Institute At Nationwide Children's Hospital |
Antibody compositions for disrupting biofilms
|
JP2022542808A
(ja)
|
2019-07-15 |
2022-10-07 |
インターベット インターナショナル ベー. フェー. |
イヌctla-4に対するイヌ化抗体
|
WO2021009263A1
(en)
|
2019-07-16 |
2021-01-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity for cd38 and uses thereof
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
WO2021022172A1
(en)
|
2019-08-01 |
2021-02-04 |
Incyte Corporation |
A dosing regimen for an ido inhibitor
|
WO2021023644A1
(en)
|
2019-08-02 |
2021-02-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neutralizing granzyme b for providing cardioprotection in a subject who experienced a myocardial infarction
|
GB201911210D0
(en)
|
2019-08-06 |
2019-09-18 |
Amlo Biosciences Ltd |
Clinical management of oropharyngeal squamous cell carcinoma
|
US20220308072A1
(en)
|
2019-08-12 |
2022-09-29 |
Voyager Therapeutics, Inc. |
High-sensitivity immunoassay for the detection of frataxin in biofluids
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
WO2021048292A1
(en)
|
2019-09-11 |
2021-03-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
CN114340675A
(zh)
|
2019-09-12 |
2022-04-12 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
CR20220149A
(es)
|
2019-09-20 |
2022-05-23 |
Genentech Inc |
Dosis para anticuerpos anti-triptasa
|
EP4034561A2
(de)
|
2019-09-27 |
2022-08-03 |
Starkage Therapeutics |
Mit seneszenten zellen assoziierte antigen-bindende domänen, antikörper und chimäre antigenrezeptoren damit sowie deren verwendungen
|
JP2022548978A
(ja)
|
2019-09-27 |
2022-11-22 |
ジェネンテック, インコーポレイテッド |
薬抗tigit及び抗pd-l1アンタゴニスト抗体を用いた処置のための投薬
|
US10975169B1
(en)
|
2019-09-27 |
2021-04-13 |
Memorial Sloan Kettering Cancer Center |
Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
|
WO2021063968A1
(en)
|
2019-09-30 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and composition for diagnosing chronic obstructive pulmonary disease
|
EP4037714A1
(de)
|
2019-10-03 |
2022-08-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und zusammensetzungen zur modulation von makrophagen-polarisation
|
US20220363776A1
(en)
|
2019-10-04 |
2022-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
GB201914399D0
(en)
|
2019-10-04 |
2019-11-20 |
Univ Newcastle |
Biomarkers for assessing explant organ viability
|
US20240058466A1
(en)
|
2019-10-04 |
2024-02-22 |
TAE Life Sciences |
Antibody Compositions Comprising Fc Mutations and Site-Specific Conjugation Properties For Use In Treating Cancer, Immunological Disorders, and Methods Thereof
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
EP3808766A1
(de)
|
2019-10-15 |
2021-04-21 |
Sangamo Therapeutics France |
Interleukin-23-rezeptor-spezifischer chimärer antigen-rezeptor
|
WO2021076798A1
(en)
|
2019-10-15 |
2021-04-22 |
Sofregen Medical, Inc. |
Delivery devices for delivering and methods of delivering compositions
|
EP3812008A1
(de)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-kompetitiver antagonistischer antikörper
|
AU2020379176A1
(en)
|
2019-11-04 |
2022-06-09 |
Pieris Pharmaceuticals Gmbh |
HER2/4-1BB bispecific fusion proteins for the treatment of cancer
|
EP4054722A1
(de)
|
2019-11-05 |
2022-09-14 |
Merck Patent GmbH |
Anti-tigit-antikörper und verwendungen davon
|
IL292458A
(en)
|
2019-11-06 |
2022-06-01 |
Genentech Inc |
Diagnostic and treatment methods for the treatment of hematological cancer
|
MX2022005566A
(es)
|
2019-11-08 |
2022-07-19 |
Amgen Inc |
Genomanipulación de mutaciones de par de carga para el emparejamiento de moléculas hetero-lgg.
|
US20230037414A1
(en)
|
2019-11-22 |
2023-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
|
MX2022006073A
(es)
|
2019-12-05 |
2022-08-04 |
Alector Llc |
Metodos para utilizar anticuerpos anti-trem2.
|
EP4073117A1
(de)
|
2019-12-10 |
2022-10-19 |
Institut Pasteur |
Neuer antikörper, der menschliche fcgriiia und fcgriiib blockiert
|
GB201918103D0
(en)
|
2019-12-10 |
2020-01-22 |
Oblique Therapeutics Ab |
Epitopes and antibodies
|
BR112022011337A2
(pt)
|
2019-12-12 |
2022-08-23 |
Alector Llc |
Método para tratar e/ou retardar a progressão de uma doença ou lesão em um indivíduo
|
AU2020410410A1
(en)
|
2019-12-17 |
2022-06-09 |
Pfizer Inc. |
Antibodies specific for CD47, PD-L1, and uses thereof
|
US11865168B2
(en)
|
2019-12-30 |
2024-01-09 |
Massachusetts Institute Of Technology |
Compositions and methods for treating bacterial infections
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
BR112022013236A2
(pt)
|
2020-01-03 |
2022-09-06 |
Incyte Corp |
Anticorpos anti-cd73 e usos dos mesmos
|
CN115551595A
(zh)
|
2020-01-03 |
2022-12-30 |
因赛特公司 |
Cd73抑制剂和a2a/a2b腺苷受体抑制剂组合疗法
|
WO2021138512A1
(en)
|
2020-01-03 |
2021-07-08 |
Incyte Corporation |
Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors
|
WO2021144426A1
(en)
|
2020-01-17 |
2021-07-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
JP2023511595A
(ja)
|
2020-01-27 |
2023-03-20 |
ジェネンテック, インコーポレイテッド |
抗tigitアンタゴニスト抗体を用いたがんを処置するための方法
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
MX2022009355A
(es)
|
2020-01-29 |
2022-09-02 |
Kenjockety Biotechnology Inc |
Anticuerpo anti-mdr1 y uso del mismo.
|
CA3167693A1
(en)
|
2020-02-21 |
2021-08-26 |
Jean-Claude Twizere |
Depletion of ext1 expression and/or activity improves cellular production of biological entities
|
CN115443153A
(zh)
|
2020-02-24 |
2022-12-06 |
欧比力克治疗公司 |
Kras表位以及抗体
|
CA3167851A1
(en)
|
2020-02-24 |
2021-09-02 |
Francesca CIGNARELLA |
Methods of use of anti-trem2 antibodies
|
EP4110810A1
(de)
|
2020-02-28 |
2023-01-04 |
Orega Biotech |
Kombinationstherapien auf basis von ctla4- und il-17b-inhibitoren
|
JP2023515566A
(ja)
|
2020-02-28 |
2023-04-13 |
タラック セラピューティクス,インク. |
トランスグルタミナーゼ媒介コンジュゲーション
|
IL296065A
(en)
|
2020-03-06 |
2022-10-01 |
Incyte Corp |
Combined treatment including axl/mer and pd-1/pd-l1 inhibitors
|
IL296256A
(en)
|
2020-03-13 |
2022-11-01 |
Genentech Inc |
Antibodies against interleukin-33 and uses thereof
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
US20230147657A1
(en)
|
2020-03-20 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Chimeric antigen receptor specific for human cd45rc and uses thereof
|
CN116249549A
(zh)
|
2020-03-27 |
2023-06-09 |
诺华股份有限公司 |
用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
|
CN113461817A
(zh)
|
2020-03-31 |
2021-10-01 |
苏州泽璟生物制药股份有限公司 |
一种抗人cd47抗体及其抗原结合片段、制备方法和应用
|
MX2022012182A
(es)
|
2020-04-03 |
2022-12-08 |
Alector Llc |
Metodos de uso de anticuerpos anti-trem2.
|
WO2021198511A1
(en)
|
2020-04-03 |
2021-10-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of sars-cov-2 infection
|
CN115768467A
(zh)
|
2020-04-06 |
2023-03-07 |
耶路撒冷希伯来大学伊森姆研究发展有限公司 |
用于治疗癌症和感染的针对NKp46的抗体及其构建体
|
US20230132275A1
(en)
|
2020-04-08 |
2023-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of cdon inhibitors for the treatment of endothelial dysfunction
|
WO2021207449A1
(en)
|
2020-04-09 |
2021-10-14 |
Merck Sharp & Dohme Corp. |
Affinity matured anti-lap antibodies and uses thereof
|
CA3175523A1
(en)
|
2020-04-13 |
2021-10-21 |
Antti Virtanen |
Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
|
CA3180222A1
(en)
|
2020-04-15 |
2021-10-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
JP2023106635A
(ja)
|
2020-04-17 |
2023-08-02 |
中外製薬株式会社 |
二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
|
EP4138803A1
(de)
|
2020-04-21 |
2023-03-01 |
Université catholique de Louvain |
Alpha-2-adrenerge rezeptoragonisten zur behandlung von krebs
|
US20230149360A1
(en)
|
2020-04-21 |
2023-05-18 |
Université Catholique de Louvain |
Alpha-2 adrenergic receptor agonists for the prevention and/or the treatment of spleen disorders
|
US20230159939A1
(en)
|
2020-04-22 |
2023-05-25 |
Fabmid |
Methods for circularizing linear double stranded nucleic acids
|
WO2021222181A2
(en)
|
2020-04-27 |
2021-11-04 |
The Regents Of The University Of California |
Isoform-independent antibodies to lipoprotein(a)
|
WO2021219871A2
(en)
|
2020-04-30 |
2021-11-04 |
Aduro Biotech Holdings, Europe B.V. |
Anti-cd103 antibodies
|
WO2021224401A1
(en)
|
2020-05-07 |
2021-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for determining a reference range of β-galactose exposure platelet
|
GB202007312D0
(en)
|
2020-05-18 |
2020-07-01 |
Synthetic Vac Ltd |
Mimotope peptides of the spike protein from the sars-cov-2 virus
|
GB202007404D0
(en)
|
2020-05-19 |
2020-07-01 |
Nasser Syed Muhammad Tahir |
Treatment for viral respiratory infections
|
EP4157881A1
(de)
|
2020-05-27 |
2023-04-05 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antikörper, die spezifisch den nervenwachstumsfaktor erkennen, und deren verwendungen
|
WO2021247591A1
(en)
|
2020-06-02 |
2021-12-09 |
Arcus Biosciences, Inc. |
Antibodies to tigit
|
EP4161650A1
(de)
|
2020-06-04 |
2023-04-12 |
Kenjockety Biotechnology, Inc. |
Anti-abcg2-antikörper und verwendungen davon
|
WO2021247423A1
(en)
|
2020-06-04 |
2021-12-09 |
Kenjockety Biotechnology, Inc. |
Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
|
JP2023527578A
(ja)
|
2020-06-05 |
2023-06-29 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
眼疾患を処置するための方法及び医薬組成物
|
CN116249709A
(zh)
|
2020-06-05 |
2023-06-09 |
皮里斯制药有限公司 |
靶向4-1bb的多聚体免疫调节剂
|
GB202008651D0
(en)
|
2020-06-09 |
2020-07-22 |
Univ Newcastle |
Method of identifying complement modulators
|
KR20230024368A
(ko)
|
2020-06-18 |
2023-02-20 |
제넨테크, 인크. |
항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
|
WO2022008597A1
(en)
|
2020-07-08 |
2022-01-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of infectious diseases
|
WO2022007955A1
(zh)
|
2020-07-09 |
2022-01-13 |
北京凯因科技股份有限公司 |
结合乙型肝炎病毒表面抗原的抗体及其应用
|
TW202216761A
(zh)
|
2020-07-16 |
2022-05-01 |
瑞士商諾華公司 |
抗β細胞素抗體、其片段及多特異性結合分子
|
JP2023535610A
(ja)
|
2020-07-28 |
2023-08-18 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ガンを予防及び処置するための方法及び組成物
|
WO2022029080A1
(en)
|
2020-08-03 |
2022-02-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
JP2023536602A
(ja)
|
2020-08-03 |
2023-08-28 |
ジェネンテック, インコーポレイテッド |
リンパ腫のための診断及び治療方法
|
WO2022031804A1
(en)
|
2020-08-04 |
2022-02-10 |
Abbott Laboratories |
Improved methods and kits for detecting sars-cov-2 protein in a sample
|
CN116419747A
(zh)
|
2020-08-07 |
2023-07-11 |
福蒂斯治疗公司 |
靶向cd46的免疫偶联物及其使用方法
|
MX2023002125A
(es)
|
2020-08-20 |
2023-04-26 |
Amgen Inc |
Proteínas de unión a antígenos con disulfuro no canónico en la región fab.
|
WO2022044010A1
(en)
|
2020-08-26 |
2022-03-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections
|
AU2021336734A1
(en)
|
2020-09-01 |
2023-03-09 |
Merck Patent Gmbh |
NKp30 binders
|
CN116490522A
(zh)
|
2020-09-02 |
2023-07-25 |
肯乔克蒂生物技术股份有限公司 |
抗abcc1抗体及其应用
|
EP3970752A1
(de)
|
2020-09-17 |
2022-03-23 |
Merck Patent GmbH |
Moleküle mit löslichkeitsmarkierung und zugehörige verfahren
|
US20230366884A1
(en)
|
2020-09-18 |
2023-11-16 |
Pieris Pharmaceuticals Gmbh |
Biomarker methods and uses
|
IL301258A
(en)
|
2020-09-21 |
2023-05-01 |
Genentech Inc |
Purification of multispecific antibodies
|
WO2022064049A1
(en)
|
2020-09-28 |
2022-03-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for diagnosing brucella infection
|
JP2023546359A
(ja)
|
2020-10-06 |
2023-11-02 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球療法によるnsclc患者の治療
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
US20230374162A1
(en)
|
2020-10-07 |
2023-11-23 |
Amgen Inc. |
Rational selection of building blocks for the assembly of multispecific antibodies
|
EP3981789A1
(de)
|
2020-10-12 |
2022-04-13 |
Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives |
Anti-lilrb-antikörper und verwendungen davon
|
US20230414700A1
(en)
|
2020-10-15 |
2023-12-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tg2 inhibitors for improving mucociliary clearance in respiratory diseases
|
WO2022081436A1
(en)
|
2020-10-15 |
2022-04-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
WO2022082217A1
(en)
|
2020-10-16 |
2022-04-21 |
Eureka Therapeutics, Inc. |
Compositions for preventing or treating viral and other microbial infections
|
WO2022084300A1
(en)
|
2020-10-20 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosis and monitoring form of coronavirus infection
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
WO2022084531A1
(en)
|
2020-10-23 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating glioma
|
AU2021371309A1
(en)
|
2020-10-30 |
2023-05-18 |
Genentech, Inc. |
Purification platforms for obtaining pharmaceutical compositions having a reduced hydrolytic enzyme activity rate
|
EP4241086A1
(de)
|
2020-11-03 |
2023-09-13 |
Isoplexis Corporation |
Verfahren und vorrichtungen zur multiplexierten proteomischen und genetischen analyse und herstellung von cdna auf einer vorrichtung
|
WO2022096547A1
(en)
|
2020-11-05 |
2022-05-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of il-6 inhibitors for the treatment of acute chest syndrome in patients suffering from sickle cell disease
|
MX2023005234A
(es)
|
2020-11-06 |
2023-05-18 |
Novartis Ag |
Terapia de combinacion de agente anti-cd19 y agente de direccionamiento a celulas b para el tratamiento de neoplasias malignas de celulas b.
|
WO2022097060A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
TW202233251A
(zh)
|
2020-11-09 |
2022-09-01 |
日商武田藥品工業股份有限公司 |
抗體藥物綴合物
|
EP4244246A1
(de)
|
2020-11-10 |
2023-09-20 |
Amgen Inc. |
Neue linker von multispezifischen antigenbindenden domänen
|
EP4244396A1
(de)
|
2020-11-11 |
2023-09-20 |
Gilead Sciences, Inc. |
Verfahren zur identifizierung von auf eine therapie mit gp120-cd4-bindungsstelle gerichteten antikörpern ansprechenden hiv-patienten
|
CA3203652A1
(en)
|
2020-11-13 |
2022-05-19 |
William Robert ARATHOON |
Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
|
WO2022101481A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
AR124123A1
(es)
|
2020-11-20 |
2023-02-15 |
Inst Nat Sante Rech Med |
Anticuerpos anti-cd25
|
JP2024504547A
(ja)
|
2020-11-20 |
2024-02-01 |
インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) |
抗cd25抗体
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
US20220170948A1
(en)
|
2020-12-01 |
2022-06-02 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi
|
GB202019522D0
(en)
|
2020-12-10 |
2021-01-27 |
Oblique Therapeutics Ab |
Epitopes and antibodies
|
TW202241468A
(zh)
|
2020-12-11 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
用腫瘤浸潤性淋巴球療法與braf抑制劑及/或mek抑制劑組合治療癌症患者
|
US20240059766A1
(en)
|
2020-12-16 |
2024-02-22 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
EP4262827A1
(de)
|
2020-12-17 |
2023-10-25 |
Iovance Biotherapeutics, Inc. |
Behandlung von krebs mit tumorinfiltrierenden lymphozyten
|
JP2023554395A
(ja)
|
2020-12-17 |
2023-12-27 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Ctla-4及びpd-1阻害剤と併用した腫瘍浸潤リンパ球療法による治療
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
TW202241441A
(zh)
|
2020-12-29 |
2022-11-01 |
美商英塞特公司 |
包含a2a/a2b抑制劑、pd-1/pd-l1抑制劑及抗cd73抗體之組合療法
|
EP4271998A1
(de)
|
2020-12-30 |
2023-11-08 |
Abbott Laboratories |
Verfahren zur bestimmung des sars-cov-2-antigens und anti-sars-cov-2-antikörpers in einer probe
|
JP2024501845A
(ja)
|
2020-12-31 |
2024-01-16 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の自動化された産生のためのデバイス及びプロセス
|
EP4271482A2
(de)
|
2020-12-31 |
2023-11-08 |
Alamar Biosciences, Inc. |
Bindemoleküle mit hoher affinität und/oder spezifität sowie verfahren zur herstellung und verwendung davon
|
EP4284919A1
(de)
|
2021-01-29 |
2023-12-06 |
Iovance Biotherapeutics, Inc. |
Verfahren zur herstellung von modifizierten tumorinfiltrierenden lymphozyten und deren verwendung in der adoptiven zelltherapie
|
AU2022214006A1
(en)
|
2021-02-01 |
2023-09-21 |
St Phi Therapeutics Co., Ltd. |
Targeted protein degradation system and use thereof
|
WO2022172267A1
(en)
|
2021-02-11 |
2022-08-18 |
Nectin Therapeutics Ltd. |
Antibodies against cd112r and uses thereof
|
WO2022178255A2
(en)
|
2021-02-19 |
2022-08-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies that neutralize sars-cov-2
|
WO2022178253A1
(en)
|
2021-02-19 |
2022-08-25 |
IsoPlexis Corporation |
Methods and devices for spatially resolved analysis of proteomic and genetic information
|
WO2022184910A1
(en)
|
2021-03-04 |
2022-09-09 |
Centre National De La Recherche Scientifique (Cnrs) |
Use of a periostin antibody for treating inflammation, fibrosis and lung diseases
|
CA3210755A1
(en)
|
2021-03-05 |
2022-09-09 |
Kenneth ONIMUS |
Tumor storage and cell culture compositions
|
EP4294927A2
(de)
|
2021-03-10 |
2023-12-27 |
Immunowake Inc. |
Immunmodulatorische moleküle und verwendungen davon
|
WO2022198192A1
(en)
|
2021-03-15 |
2022-09-22 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
WO2022194908A1
(en)
|
2021-03-17 |
2022-09-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2022198141A1
(en)
|
2021-03-19 |
2022-09-22 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
|
EP4313099A2
(de)
|
2021-03-23 |
2024-02-07 |
Pieris Pharmaceuticals GmbH |
Her2/4-1bb bispezifische fusionsproteine zur behandlung von krebs
|
EP4313122A1
(de)
|
2021-03-23 |
2024-02-07 |
Iovance Biotherapeutics, Inc. |
Cish-geneditierung von tumorinfiltrierenden lymphozyten und verwendungen davon in der immuntherapie
|
EP4313317A1
(de)
|
2021-03-23 |
2024-02-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur diagnose und behandlung von t-zelllymphomen
|
WO2022200478A1
(en)
|
2021-03-24 |
2022-09-29 |
Pieris Pharmaceuticals Gmbh |
Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor
|
EP4314253A2
(de)
|
2021-03-25 |
2024-02-07 |
Iovance Biotherapeutics, Inc. |
Verfahren und zusammensetzungen für t-zell-kokulturpotenztests und verwendung mit zelltherapieprodukten
|
EP4320141A1
(de)
|
2021-04-08 |
2024-02-14 |
Pieris Pharmaceuticals GmbH |
Neue für den bindegewebewachstumsfaktor (ctgf) spezifische lipocalinmuteine
|
WO2022214664A1
(en)
|
2021-04-09 |
2022-10-13 |
Philogen S.P.A. |
Improved interferon-gamma mutant
|
WO2022214681A1
(en)
|
2021-04-09 |
2022-10-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of anaplastic large cell lymphoma
|
WO2022219152A1
(en)
|
2021-04-16 |
2022-10-20 |
Oblique Therapeutics Ab |
Kras antibodies
|
BR112023021665A2
(pt)
|
2021-04-19 |
2023-12-19 |
Iovance Biotherapeutics Inc |
Método para tratar um câncer, e, composição
|
EP4326871A1
(de)
|
2021-04-19 |
2024-02-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verwendung von splice-switching-oligonukleotiden zum exon-skipping-vermittelten knockdown von pim2
|
AU2022263406A1
(en)
|
2021-04-20 |
2023-10-19 |
Amgen Inc. |
Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
|
WO2022223791A1
(en)
|
2021-04-23 |
2022-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cell senescence accumulation related disease
|
EP4326779A1
(de)
|
2021-04-23 |
2024-02-28 |
Philogen S.p.A. |
Antikörper gegen fibroblastenaktivierungsprotein
|
WO2022245754A1
(en)
|
2021-05-17 |
2022-11-24 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
WO2022243341A1
(en)
|
2021-05-18 |
2022-11-24 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding affinity for ox40
|
AU2022279156A1
(en)
|
2021-05-18 |
2023-11-02 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
EP4342913A1
(de)
|
2021-05-19 |
2024-03-27 |
Shanghai Escugen Biotechnology Co., Ltd. |
Chimäres antigenrezeptormolekül zur spezifischen erkennung von baff-r und anwendung eines chimären antigenrezeptormoleküls
|
EP4348263A1
(de)
|
2021-05-28 |
2024-04-10 |
Alexion Pharmaceuticals, Inc. |
Verfahren zum nachweis von cm-tma-biomarkern
|
CA3222291A1
(en)
|
2021-06-14 |
2022-12-22 |
Jaime MARINO |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
WO2022261846A1
(zh)
|
2021-06-16 |
2022-12-22 |
上海鑫湾生物科技有限公司 |
靶向axl蛋白的抗体及其抗原结合片段、其制备方法和应用
|
AU2022299282A1
(en)
|
2021-06-22 |
2024-02-01 |
Merck Patent Gmbh |
Vhh-based nkp30 binders
|
WO2023278377A1
(en)
|
2021-06-29 |
2023-01-05 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
IL309780A
(en)
|
2021-07-02 |
2024-02-01 |
Merck Patent Gmbh |
Antibodies and antiprotec complexes
|
WO2023283345A1
(en)
|
2021-07-07 |
2023-01-12 |
Incyte Corporation |
Anti-b7-h4 antibodies and uses thereof
|
TW202317633A
(zh)
|
2021-07-08 |
2023-05-01 |
美商舒泰神(加州)生物科技有限公司 |
特異性識別tnfr2的抗體及其用途
|
WO2023285362A1
(en)
|
2021-07-12 |
2023-01-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of il-36 inhibitors for the treatment of netherton syndrome
|
WO2023284714A1
(zh)
|
2021-07-14 |
2023-01-19 |
舒泰神(北京)生物制药股份有限公司 |
特异性识别cd40的抗体及其应用
|
WO2023287707A1
(en)
|
2021-07-15 |
2023-01-19 |
Just-Evotec Biologics, Inc. |
Bidirectional tangential flow filtration (tff) perfusion system
|
WO2023004074A2
(en)
|
2021-07-22 |
2023-01-26 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
CA3226942A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
WO2023006975A2
(en)
|
2021-07-30 |
2023-02-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Chimeric proteins and methods of immunotherapy
|
WO2023017149A1
(en)
|
2021-08-13 |
2023-02-16 |
Oblique Therapeutics Ab |
Thioredoxin 1 antibodies
|
WO2023019239A1
(en)
|
2021-08-13 |
2023-02-16 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
WO2023028186A1
(en)
|
2021-08-27 |
2023-03-02 |
Abbott Laboratories |
Methods for detecting immunoglobulin g, subclass 4 (igg4) in a biological sample
|
CA3230038A1
(en)
|
2021-08-31 |
2023-03-09 |
Hongwei Zhang |
Methods and systems of diagnosing brain injury
|
WO2023039488A1
(en)
|
2021-09-09 |
2023-03-16 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1 talen knockdown
|
CA3231944A1
(en)
|
2021-09-16 |
2023-03-23 |
Carole GUILLONNEAU |
Anti-human cd45rc binding domains and uses thereof
|
CA3232700A1
(en)
|
2021-09-24 |
2023-03-30 |
Rafael CUBAS |
Expansion processes and agents for tumor infiltrating lymphocytes
|
CA3232176A1
(en)
|
2021-09-30 |
2023-04-06 |
Beth MCQUISTON |
Methods and systems of diagnosing brain injury
|
US20230192843A1
(en)
|
2021-10-14 |
2023-06-22 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
WO2023067348A1
(en)
|
2021-10-21 |
2023-04-27 |
Biosirius Ltd |
Treatment for virally-induced pneumonia
|
WO2023072958A1
(en)
|
2021-10-25 |
2023-05-04 |
Fabmid |
Methods for circularizing linear double stranded nucleic acids and the products thereof
|
TW202331735A
(zh)
|
2021-10-27 |
2023-08-01 |
美商艾歐凡斯生物治療公司 |
協調用於患者特異性免疫療法之細胞之製造的系統及方法
|
WO2023078900A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
WO2023081898A1
(en)
|
2021-11-08 |
2023-05-11 |
Alector Llc |
Soluble cd33 as a biomarker for anti-cd33 efficacy
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
WO2023086803A1
(en)
|
2021-11-10 |
2023-05-19 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
WO2023089131A1
(en)
|
2021-11-19 |
2023-05-25 |
Lykera Biomed, S.A. |
Treatment and diagnosis of diseases associated to pathogenic fibrosis
|
TW202334203A
(zh)
|
2021-11-19 |
2023-09-01 |
德商皮里斯製藥有限公司 |
新穎的ox40及pd-l1特異性融合蛋白
|
TW202330623A
(zh)
|
2021-12-08 |
2023-08-01 |
美商英塞特公司 |
抗突變鈣網伴護蛋(calr))抗體及其用途
|
WO2023105528A1
(en)
|
2021-12-12 |
2023-06-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to ceacam1
|
WO2023114658A1
(en)
|
2021-12-13 |
2023-06-22 |
Kenjockety Biotechnology, Inc. |
Anti-abcb1 antibodies
|
WO2023110937A1
(en)
|
2021-12-14 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
WO2023114884A2
(en)
|
2021-12-15 |
2023-06-22 |
Interius Biotherapeutics, Inc. |
Pseudotyped viral particles, compositions comprising the same, and uses thereof
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
WO2023118165A1
(en)
|
2021-12-21 |
2023-06-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2023118497A1
(en)
|
2021-12-22 |
2023-06-29 |
Pieris Pharmaceuticals Gmbh |
Novel il-18 variants
|
WO2023122796A1
(en)
|
2021-12-23 |
2023-06-29 |
The Broad Institute, Inc. |
Parallel antibody engineering compositions and methods
|
US20230213536A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023144235A1
(en)
|
2022-01-27 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for monitoring and treating warburg effect in patients with pi3k-related disorders
|
WO2023147486A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023144303A1
(en)
|
2022-01-31 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023148707A1
(en)
|
2022-02-07 |
2023-08-10 |
Yeda Research And Development Co. Ltd. |
Humanized anti quiescin suefhydrye oxidase 1 (qsox1) antibodies and uses thereof
|
WO2023159220A1
(en)
|
2022-02-18 |
2023-08-24 |
Kenjockety Biotechnology, Inc. |
Anti-cd47 antibodies
|
WO2023156683A1
(en)
|
2022-02-21 |
2023-08-24 |
Acticor Biotech |
Treatment of cardiovascular diseases using anti-human gpvi antibodies
|
WO2023164516A1
(en)
|
2022-02-23 |
2023-08-31 |
Alector Llc |
Methods of use of anti-trem2 antibodies
|
GB202202569D0
(en)
|
2022-02-24 |
2022-04-13 |
Amlo Biosciences Ltd |
Biomarkers for disease progression and/or recurrence in squamous cell carcinoma
|
WO2023170207A1
(en)
|
2022-03-09 |
2023-09-14 |
Alderaan Biotechnology |
Anti-cd160 transmembrane isoform antibodies
|
WO2023180523A1
(en)
|
2022-03-24 |
2023-09-28 |
Pieris Pharmaceuticals Gmbh |
Process for purifying fusion proteins
|
WO2023192622A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides
|
WO2023196877A1
(en)
|
2022-04-06 |
2023-10-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
EP4257609A1
(de)
|
2022-04-08 |
2023-10-11 |
iOmx Therapeutics AG |
Kombinationstherapien basierend auf pd-1-inhibitoren und sik3-inhibitoren
|
WO2023198648A1
(en)
|
2022-04-11 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t-cell malignancies
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
WO2023215719A1
(en)
|
2022-05-02 |
2023-11-09 |
Arcus Biosciences, Inc. |
Anti-tigit antibodies and uses of the same
|
WO2023220608A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
WO2023222886A1
(en)
|
2022-05-20 |
2023-11-23 |
Depth Charge Ltd |
Antibody-cytokine fusion proteins
|
WO2023237431A1
(en)
|
2022-06-07 |
2023-12-14 |
Esocap Ag |
Drug delivery system comprising an agent effective in the treatment or prevention of an esophageal disease for the application to esophageal mucous membranes
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023237661A1
(en)
|
2022-06-09 |
2023-12-14 |
Institut National de la Santé et de la Recherche Médicale |
Use of endothelin receptor type b agonists for the treatment of aortic valve stenosis
|
WO2023245105A1
(en)
|
2022-06-17 |
2023-12-21 |
Genentech, Inc. |
Use of kosmotropes to enhance yield of an affinity chromatography purification step
|
WO2023250388A1
(en)
|
2022-06-22 |
2023-12-28 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024003380A1
(en)
|
2022-06-30 |
2024-01-04 |
Icm (Institut Du Cerveau Et De La Moelle Épinière) |
Vascular endothelial growth factor receptor-1 (vegfr-1) inhibitors for promoting myelination and neuroprotection
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
WO2024011114A1
(en)
|
2022-07-06 |
2024-01-11 |
Iovance Biotherapeutics, Inc. |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
WO2024008799A1
(en)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of proliferative glomerulonephritis
|
WO2024013234A1
(en)
|
2022-07-13 |
2024-01-18 |
Institut National de la Santé et de la Recherche Médicale |
Methods for diagnosis, prognosis, stratification and treating of myocarditis
|
WO2024016003A2
(en)
|
2022-07-14 |
2024-01-18 |
The Broad Institute, Inc. |
Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor
|
WO2024020407A1
(en)
|
2022-07-19 |
2024-01-25 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
|
WO2024018046A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Garp as a biomarker and biotarget in t-cell malignancies
|
EP4311557A1
(de)
|
2022-07-26 |
2024-01-31 |
Oncomatryx Biopharma, S.L. |
Auf fap abzielende antikörper-arzneimittelkonjugate
|
WO2024026358A1
(en)
|
2022-07-27 |
2024-02-01 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
WO2024030758A1
(en)
|
2022-08-01 |
2024-02-08 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
WO2024028433A1
(en)
|
2022-08-04 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of lymphoproliferative disorders
|
WO2024033399A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sigmar1 ligand for the treatment of pancreatic cancer
|
WO2024033400A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sk2 inhibitor for the treatment of pancreatic cancer
|
WO2024038165A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Ltd |
T cell receptor fusion proteins specific for mage a4
|
WO2024059692A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Hbv diagnostic, prognostic, and therapeutic methods and products
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|
WO2024059739A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2024064714A2
(en)
|
2022-09-21 |
2024-03-28 |
Seagen Inc. |
Antibodies that bind cd228
|
WO2024064713A1
(en)
|
2022-09-21 |
2024-03-28 |
Seagen Inc. |
Novel fusion protein specific for cd137 and cd228
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
WO2024079192A1
(en)
|
2022-10-12 |
2024-04-18 |
Institut National de la Santé et de la Recherche Médicale |
Cd81 as a biomarker and biotarget in t-cell malignancies
|